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Abstract 
Extracellular vesicle (EV) release from tumour cells plays an important role in cancer drug 
resistance. It is essential that chemotherapeutic drugs are retained within target cells for 
increased efficacy in inducing apoptosis and as microvesiculation influences drug retention, this 
study has focused on modulating microvesiculation. Based on EV biogenesis pathways, a range 
of potential inhibitors were tested on PC3, prostate cancer and MCF7, breast cancer cells. Flow 
cytometry (FCM), nanoparticle tracking analysis (NTA) and fluorescent microscopy were used 
for the investigation. All inhibitors tested were shown to inhibit EV release with minimal effect 
on the cell viability. Peptidyl Arginine Deiminase (PAD) inhibitor, Chloramidine (Cl-amidine, 
Cl-am) and Protein Kinase C inhibitor, Bisindolylmaleimide-I (Bis-I) exhibited extensive EV 
inhibition in PC3 and MCF-7 cells. This effect was further tested using an Annexin-V-based 
apoptosis assay and VB-48 vitality assay through image FCM. There was a significant increase 
in 5-fluorouracil (5-FU) activity in the presence of the inhibitors which was more apparent 
when a combination of inhibitors was applied. The hypothesis was further tested using a second, 
chemotherapeutic drug, Doxorubicin (Dox) on PC3 cells. Pre-treatment of PC3 cells with Cl-am 
prior to chemotherapy, exhibited increased activity of Dox and increased drug retention was 
shown by fluorescent microscopy, HPLC, FCM and fluorescence spectrophotometry. Overall 
the findings demonstrated the implication of EV inhibitors in improving chemotherapy while at 
the same time reducing its side effects.   
Cannabidiol (CBD) has been well known for its psychotherapeutic function and has also been 
used in some cancers, including in Glioblastoma multiforme (GBM), although the exact 
pathways that could explain its clear mode of action have not been revealed. This study presents 
CBD as a potent inhibitor of EVs for the first time. Its potential role has here been examined in 
many types of cancer including, prostate, liver, breast and GBM across the study. Successful 
EV inhibition was shown to elicit a favourable response in Temozolomide (TMZ)-mediated 
therapy against GBM cells, which sensitized some GBM cells to TMZ-mediated chemotherapy. . 
Outer membrane vesicles (OMVs) are released by bacterial cells upon activation. Isolation and 
characterisation of these vesicles was carried out using differential centrifugation, ultrafiltration 
and nanoparticle tracking analysis. The presence of an arginine deiminase enzyme, 
corresponding to mammalian Peptidyl Arginine Deiminase (PAD), was confirmed in E. coli 
samples and its deiminating activity on various target proteins was shown in this study for the 
first time. Identification of PAD and PAD-mediated citrullinated/deiminatedproteins was 
identified using immunoprecipitation and Western blotting techniques. The same range of EV 
4 
 
inhibitors as used for cancer cells, along with the PAD inhibitors, was used to investigate the 
effect on OMV biogenesis from Gram-negative, E.coli and Gram-positive S. aureus. EV 
inhibitors Bisindolylmaleimide-I, EGTA, Imipramine, Pantethine and Y27632 inhibited OMV 
release significantly. The role of EV inhibitors on antibiotic therapy was then further explored. 
The disc diffusion method and Minimum Inhibitory Concentration (MIC) was used to determine 
whether OMV inhibition affected antibiotic activity. E. coli samples were treated with OMV 
inhibitors and a range of antibiotics including colistin, erythromycin, rifampicin, kanamycin and 
vancomycin to identify an optimal OMV inhibitor. The OMV inhibitors had a selective 
response to antibiotics which facilitated the choice for the most sensitive antibiotic to use in 
further studies to examine the effect of OMV inhibition in lowering minimum inhibitory 
concentration. .   
These findings, together with previous studies on the association of OMVs with bacteriophage 
particles, prompted an investigation of the role of OMV inhibition on phage therapy. E. coli 
samples were treated with lambda phage with/without pre-treatment of Cl-am.  Bacterial titres 
were calculated after each experiment. Electron microscopy was used to visualise the formation 
of   phage-E.coli-OMVs which confirmed the outcome of the experiments.  
The increase ofcancer cells withresistance to chemotherapy has increased over time which has 
added immense pressure on scientists to discover novel therapies within short periods. EVs play 
a major role in transferring a drug-resistance phenotype to drug-sensitive cells via cellular cargo. 
This also interferes with its negative role of drug efflux which together drive cancer metastasis. 
Increasing the dosage of chemotherapy or introducing novel therapeutic agents has hitherto not 
minimised this effect successfully. Therefore, EV inhibition, as introduced in this study, may 
have a positive influence in developing novel effective anti-cancer therapies. 
The use of OMV inhibition to sensitize bacterial cells to antibiotics is a novel idea which may 
become an effective solution to combat antibiotic resistance and permit the treatment of such 
diseases through effective phage therapy. Overall, the research ideas presented in the current 
study will benefit the implementation of new therapeutic strategies for cancer metastasis and 
bacterial colonisation, minimising multi drug resistance.
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1.0 Introduction 
1.1 Emerging Role of Extracellular Vesicles in Malignancy 
1.1.1 Extracellular Vesicles (EVs) as Mediators of Signal Transduction 
Intercellular signalling is an intricate process of ligand-receptor interaction which may or not 
involve cell contact. It involves the uptake and transfer of secretory molecules such as growth 
factors (Okoye et al., 2009, Antebi et al., 2017). Of the many pathways of cellular-cross talking, 
the short-range paracrine is common. Much intercellular signaling stimulates biochemical 
changes within the cell which results in proliferation, differentiation and ultimately apoptosis.  
There is a particular interest in how cells and their respective signaling pathways (whose 
molecular interactions have largely been deciphered) perceive and process extracellular signals 
(Antebi et al., 2017).  
These cell surface interactions triggering signal transduction and ultimately changes in gene 
expression impose stresses at every stage (Tanase et al., 2012). One of the more recent 
challenges to emerge in cell biology is  communication which also does not require the direct 
contact of cells but is organised through the release of particular  signalling factors embedded in 
membranous structures, namely, extracellular vesicles (EVs) (Plotnikov et al., 2017). 
Extracellular vehicles (EVs) are plasma membrane bound structures that are released 
ubiquitously by all types of cells and are considered to be key mediators of cell-to-cell 
communication (Balaj et al., 2011).Generally known as the ‘secretome’ (Inal et al., 2013), these 
small vesicles that are formed  as a consequence of external stimuli such as stress, have come to 
the fore in recent years in helping us to further understand signal transduction. The capacity of 
these vesicles to package an assortment of macromolecules, including various nucleic acids, 
lipid and proteins, facilitates the compound shuttling between cells.  This has logically led to 
research into the EV-mediated transmission of pathological stimuli to healthy cells and it has 
now become clear that EVs are directly involved in disease progression (Kalra et al., 2016). The 
EV field has grown extensively in recent years, with research focusing on the mechanism of EV 
modulated inter-cellular shuttling. Many research findings are evident of its crucial role of 
enhancing the pathology of various diseases.   
EVs comprise exosomes (EXOs) that range in size from 40 nm to 100 nm, released through 
exocytosis and microvesicles (MVs) larger in size (100 nm to 1000 nm) that bud off directly 
from the plasma membrane.  These shed particles collectively known as EVs in this study  carry 
lipid and protein characteristic of their parental cells and are vehicles for membrane and 
cytoplasmic components (Gangoda et al., 2015). The composition of EVs depends on the cell of 
origin and once released these vesicles mediate intercellular communication between 
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neighbouring and distant cells. They are responsible for conferring new properties on recipient 
cells after the acquisition of new receptors, enzymes or even genetic material from the vesicles 
(Thery et al., 2009). This is evident in the lateral trafficking and vertical transfer of cellular 
cargo to distant cells via EVs.  
1.1.2 EVs are Key Drivers of Tumorigenesis and Metastasis 
EVs from cancer cells, stem cells and blood cells have been used in vital research with a 
diagnostic approach in different pathologies. They have been mainly used as target therapy 
against many cancers and cardiovascular disease (Dörsam et al., 2018, Danielson and Das, 
2014). Tumour cell-released EVs have been shown to promote a tumour-supporting 
environment in non-malignant tissue and, thus, benefit metastasis. Cancer cells excessively 
secrete EVs as a response to high intracellular stress levels, making the EVs a target to develop 
novel chemotherapies. However, dendritic cell-derived EVs (Dex) (Segura et al., 2005) are 
involved in the host immune response to the tumour whilst also  increasing the proliferation and 
cytolytic activity of natural killer (NK cells) (Viaud et al., 2009). Cancer cells continually 
undergo stress due to hypoxia, starvation and chemotherapy and this result in a massive release 
of EVs.  It is well known that tumours shape their microenvironment by EV-driven intercellular 
messaging that leads to increased proliferation, angiogenesis, suppression of the host's immune 
defence and initiation of pre-metastatic niches (Szczepanski et al., 2011, Miller and Grunewald, 
2015). EVs can also carry so-called tumour-associated antigens (TAAs), costimulatory 
molecules and major histocompatibility complexes (MHC) components mediating a stimulatory 
effect on immune cells (Altevogt et al., 2014). It is also apparent that tumour-derived EVs are 
directly involved in immunomodulation that alters between immunoactivation and 
immunosuppression during metastasis (Barros et al., 2018).   
A recent phase II clinical trial applying IFN-γ-Dex loaded with MHC class I- and class II-
restricted cancer antigens as immunotherapy of NSCLC patients after chemotherapy showed 
that the expression of MHC class II on Dex correlated with the expression of the NK cell 
activating NKp30 ligand BCL2-associated athanogene 6 (BAG6) (Binici et al., 2013). The 
chaperone BAG6 plays a role in a multitude of cellular processes and was identified as ligand of 
the activating NK cell receptor NKp30 (Pogge von Strandmann et al., 2007). NK cells are 
required for the interaction of DCs and HSP70 to induce a CTL response and anti-metastatic 
effect in vivo(Granucci et al., 2004, Ciocca and Calderwood, 2005). This double-edged sword 
effect of EVs has made it more concerning to develop novel therapeutic strategies to overcome 
its negative effects but use its special attributes in preventing disease progression.  
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1.2 Mechanism of Secretion of Microvesicles 
1.2.1 Physiological and Exogenous Stimulation of Microvesiculation 
Cellular modifications directly affect the membrane asymmetry that drives vesiculation. In the 
resting stage, Phosphatidylserine (PS) and Phosphatidylethanolamine (PE) are expressed in the 
inner membrane leaflet while Phosphatidylcholine (PC) and sphingomylein are enriched in the 
outer membrane leaflet (Zargarian et al., 2017). Furthermore, scramblase and floppase, ATP-
dependent enzymes remain inactive. By contrast, flippase, an ATP-dependent translocase 
actively catalyses the internalisation of PS and PE (Birge et al., 2016, Hankins et al., 2015). 
Therefore, aminophospholipids are expressed in the outer membrane. Increased levels of 
intracellular calcium up-regulate scramblase and floppase activity and concomitantly inactivate 
flippase activity leading to the PS exposure on the outer leaflet of the lipid bilayer. This 
transverse migration of anionic phospholipids promotes MV release (Beer and Wehman, 2017, 
Muthusamy et al., 2009, Takeda et al., 2014). 
During programmed cell death, apoptotic bodies are formed as a result of Rho-kinase enzyme 
dependent cytoskeletal reorganisation (Street and Bryan, 2011, Povea-Cabello et al., 2017). This 
facilitates calcium influx which results in PS exposure on the outer membrane. Similarly, 
Angiotensin II, homocysteine, thrombin, collagen, cholesterol, pro-inflammatory cytokines, 
sublytic concentrations of complement membrane attack complex (C5b-9) and sheer stress are 
known to stimulate MV biogenesis and release (Antwi-Baffour et al., 2015). Following on with 
the theme of pore formation and increases in intracellular calcium a larger portion of the vWf-
adherent platelet membranes (approximately 21%) was released as MVs subsequent to platelet 
stimulation with the non-physiological agonist calcium ionophore A23187 (Harrison P., 2014). 
Peptidylarginine Deiminases (PADs) have been closely associated with many pathologies, 
including neurodegeneration(Lange et al., 2017b, Tu et al., 2016, Moscarello et al., 2013b, 
Muth A. and Thompson P.R. Development of the Protein Arginine Deiminase (PAD) Inhibitors. 
In: Nicholas A., 2017), rheumatoid arthritis (Damgaard et al., 2016, Basu et al., 2011, Auger et 
al., 2010) and recently cancer(Funayama et al., 2017, Horibata et al., 2017, Lange et al., 2017b, 
Cedervall et al., 2017, Mohanan et al., 2012, Kholia et al., 2015). Many studies have been 
performed on the clinical relevance of PAD inhibition in preventing carcinogenesis. Our 
laboratory at CMIRC first showed that inhibition of PAD expression through chloramidine (Cl-
amidine) decreased EV release which suggested that PADscan directlyinfluence 
EVbiogenesis(Kholia et al., 2015). Adding to these previous findings, our recent research from 
the same group who reported the therapeutic significance of Cl-am- mediated inhibition of EV 
release in prostate cancer (Kosgodage et al., 2017)thus is encouraging the use of EV inhibition 
as a novel therapeutic approach against cancer. 
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1.2.2 Enzymes that catalyse EV biogenesis and release 
1.2.2.1 Acid Sphingomyelinase (A-SMase) 
Membrane blebbing is initiated by the activation of ATP receptor-P2X7 preceded by the 
externalisation of PS, loss of lipid asymmetry and formation of membrane protrusions. 
Sphingomyelin (SM), a phospholipid abundant in the outer leaflet of the PM has a high affinity 
for cholesterol (Ayers et al., 2015). A-SMase and other sphingomyelinases catalyse the 
hydrolysis of SM which in turn increases the efflux of cholesterol and increased membrane 
fluidity. This destabilises the plasma membrane asymmetry and facilitates microvesiculation 
(Bianco et al., 2009). 
1.2.2.2 Rho- Kinase 
The Rho-GTPase-dependent signalling pathway triggers the activation of its downstream targets, 
Rho Kinase ROCK-I and ROCK-II. ROCK-I and ROCK-II are responsible for actin 
cytoskeletal remodelling and actomyosin contraction respectively. Activated ROCK 
phosphorylates Lim-Kinase (LIMK), its downstream target stimulates its kinase activity 
enabling it to phosphorylate Ser3 on cofilin, which prevents cofilin from severing actin 
filaments and prolongs the extension of actin fibres (Li et al., 2012).  This hyper 
phosphorylation of cofilin is essential for EV formation together with ROCK and LIMK 
activation. Moreover Rho-Kinase plays a major role in targeting other signalling pathways in 
addition to ROCK that lead to EV biogenesis and release.   
1.2.2.3 Flippase and Floppase 
These enzymes are ATP-dependent lipid transporters that help maintain the lipid asymmetry of 
the plasma membrane. They require the energy input to transfer phospholipids against a 
concentration gradient. When the cell is at rest flippase actively translocates PE and PS from the 
outer leaflet to the inner leaflet while floppase is inactive. Oxidative stress usually leads to an 
influx of calcium increasing the intracellular concentration. This in turn inactivates flippase and 
concomitantly activates floppase. This flip-flop transition ultimately leads to the release of EVs 
(Bianco et al., 2009).   
1.2.2.4 Scramblase 
Scramblase is a calcium dependent enzyme that is activated in the presence of high 
concentration of cytosolic Ca2+ due to physiological changes in the cells such as platelet 
activation and neurotransmitter release (Suzuki et al., 2013). This allows PS externalisation 
resulting in the release of EVs. The PS exposure on the outer leaflet is a classic characteristic of 
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an apoptotic cell which acts as an ‘eat me’ signal allowing phagocytosis of post-apoptotic 
bodies. 
1.2.2.5 Peptidylarginine Deiminases(PADs) and Tumorigenesis 
PADs are a family of 5 calcium-dependent enzymes designated as PADs 1-4 and PAD 6. They 
catalyse the citrullination/deimination of arginine residues to citrulline in proteins. Post-
translational modifications of proteins, includin citrullination/deimination have become novel 
therapeutic targets in cancer. Autoantibodies that are generated by deimination due to PAD2, 
PAD3 and PAD4 activation have also been shown to play an important roles in autoimmune 
diseases, including in joint damage in rheumatoid arthritis patients (Seaman et al., 2016) and are 
also implicated in Multiple sclerosis (Moscarello et al., 2013a). Furthermore, pan-PAD 
inhibition was shown to prevent neuronal damage following spinal cord injury (Lange et al., 
2011) following hypoxic ischemic insult (HI) (Lange et al., 2014) which further emphasises its 
relevance as a novel therapeutic agent in neuro-inflammation and also highlights deiminated 
proteins as potential biomarkers. The role for PAD-inhibition to sensitise cancer cells to 
chemotherapy has been shown by our group (Kosgodage et al., 2017, Kholia et al., 2015). In 
humans, the PAD genes are localised to a well-organized gene cluster at 1p36.13, which is also 
the cluster region for the tumour suppressor gene RUNX3 (Ellsworth et al., 2008). PAD4 is a 
well characterised isozyme that is widely expressed in immune cells as well as tumour cells, 
localising to cytoplasmic granules and the nucleus(Kholia et al., 2015) .  PAD4 acts as a 
transcriptional co-regulator for tumour suppressor gene, p53. It is also known as a co-mediator 
of gene transcription and epigenetic transfer with histone deacetylase 2 (HDAC2) (Li et al., 
2010) to regulate the p53 activity during apoptosis. PAD4 co-localises with cytokeratins 
deimination of which makes them more resistant to caspase-mediated cleavage therefore 
inhibiting apoptosis of tumour cells. Similarly, its association with epidermal growth factor 
(EGF) mediated gene activity activates the proto-oncogene c-fos promoting carcinogenesis 
(Wang et al., 2012). As both PAD activation and EV biogenesis are calcium-dependent 
processes their synergistic effect in oncogenesis and cancer metastasis are of great interest. 
1.3 Apoptosis 
Programmed cell death occurs via an energy-dependent proteolytic cascade that results in 
morphological and biochemical changes in a cell in preparation for lysis. Our understanding of 
the process has led to a specific targeting of apoptosis with a view to developing effective 
treatment. Apoptosis comprises three mechanisms, intrinsic, extrinsic and the perforin-
granzyme pathway (Elmore, 2007). Involvement of death receptors of the tumour necrosis 
factor (TNF) family initiates this pathway resulting in the activation of caspases- 3 and 8 which 
as a consequence undergo DNA degradation and rapid cell death. Mitochondrial depolarisation 
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releases cytochrome C that activates the intrinsic pathway leading to the activation of Apaf-1 as 
well as procaspase-9, forming an “apoptosome” (Hill et al., 2004). Bcl-2 proteins control the 
intrinsic pathway eventually resulting in nuclear fragmentation and cell shrinkage. Some of the 
members of the Bcl-2 family, Bax, Bad and Bak are pro-apoptotic while other members such as 
Bcl-XL, Mcl-1 and Bcl-2 act as anti-apoptotic proteins. Bcl-2 may also play a role in non-
haematological tumours, and inappropriate expression has been observed in solid tumours such 
as prostate, breast, and small cell and non-small cell lung cancers (Das, 2015, Anagnostou et al., 
2010). This pathway has been the target for chemotherapy over the years. Overall disruption in 
pro-/anti-apoptotic stability directly regulates the cell survival during chemotherapy which in 
turn determines its effectivity as a powerful onco-therapeutic agent. Furthermore, DNA has 
been a more suitable target for chemotherapy and its methylation is associated with 
transcriptional inhibition.  Caspase-8 (CASP8) is silenced owing to gene deletion or promoter 
methylation, especially in paediatric tumours and their cell lines (Teitz et al., 2000, Olsson and 
Zhivotovsky, 2011). The loss of this expression is associated with the amplification of the 
MYCN oncogene facilitating carcinogenesis.  
A hall mark for oncogenesis is to evade this major barrier against cancer which is vital for 
tumour development. P53 mutations act as the main anti-apoptotic mechanism driven by cancer 
cells. This is regulated by inhibition of p53 activation. This is more apparent in viral infections 
in which onco-proteins, E6 and E7 (Indran et al., 2011) produced by Human papilloma Virus 
(HPV) binds and inactivates p53 causing cell death arrest. Also, the excessive secretion of anti-
apoptotic proteins such as Bcl-XL allows rapid cell division aiding carcinogenesis. Likewise 
some rapidly developing tumour cells are programmed to secrete low levels of pro-apoptotic 
proteins to minimise cell death contributing to its aggressiveness in the system (Pistritto et al., 
2016). Classical and novel cancer immunotherapy targets these evading mechanisms adopted by 
cancer cells during their infection.  
1.4 EVs and Cancer 
1.4.1 The release of EVs 
Exosomes and Microvesicles (EVs) are released by cells upon physiological and pathological 
stimulation and play a distinctive role in all cellular activities. These ubiquitously released 
particles serve as bioactive effectors in maintaining many cellular processes including 
homeostasis, thrombosis, inflammation, angiogenesis and pathogenesis. 
1.4.1.1 EVs are conveyors of intercellular communication 
EVs carry cellular cargo within them that is specific to the cell of origin. This can be transferred 
to and induce phenotypic changes in recipient cells. Koppler and co-workers described  
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neutrophil-derived EVs that can mediate inflammation while the release of matrix 
metalloproeases (MMPs) through tumour-derived EVs promotes metastasis (Kim et al., 2007). 
They are also involved in signal transduction pathways where fusion or endocytosis of EVs with 
neighbouring cells can directly alter cellular properties (Andre et al., 2004, Jorfi et al., 2015) . 
EVs harbour membrane proteins and other nuclear matter such as microRNAs and long 
ncRNAs, and are involved in non-selective transfer between cells via fusion or that are ligand-
receptor mediated. The phagocytosis of EVs by antigen presenting cells increases the 
internalisation of molecular information that can be used to trigger signalling cascades (Kovar et 
al., 2006) . EV- cellular interaction can occur locally, regionally or systemically and can result 
in the emission of chemoattractants, growth factors, chemkoines and cytokines that may 
modulate cancer metastasis, inflammation or be involved in the development of infectious 
diseases. 
1.4.1.2 Vesicular Mediated Unconventional Protein Export 
Conventional protein secretion involves the signal-peptide dependent protein translocation from 
ER to the Golgi apparatus which is mediated by intracellular transport vesicles. However, the 
proteins that lack a signal peptide can still be secreted via self-sustained protein translocation 
between membranes, via ABC transporters, vesicular pathways and Golgi bypass for trafficking 
to the plasma membrane. Cytoplasmic proteins such as interleukin 1β (IL1β)(Kovar et al., 2006) 
are transported across membranes via autophagosome-like vesicles(Andreola et al., 2002). 
Golgi bypass involves the release of proteins to the extracellular space through the shedding of 
EVs which is adopted by proteins of the galectin family. Vesiculation is an important 
mechanism for non-conventional protein secretion (Malhotra, 2013, Nickel, 2005). 
1.4.2 EVs in Malignancy and Tumour Metastasis 
Microvesiculation modulates tumour formation and metastasis. The activation of mutant 
oncogenes such as KRAS, EGFR and loss of tumor suppressor genes stimulate EV biogenesis 
and release (van Doormaal et al., 2009). Elevated production of EVs has been associated with 
prostate cancer cultures that have been correlated to the increased oncogenic activity of protein 
kinase B. It has also been shown that inhibition of diaphanous related formin 3 (DRF3) (Di 
Vizio et al., 2009), an actin regulating protein resulted in increased membrane shedding which 
is suggestive that DRF3 acting as an EV inhibitor. DRF3 expression is lost during metastasis 
which suggests alink betweenEV biogenesis, oncogenesis and metastasis.  Similarly, EVs have 
been shown to play a dynamic role in tumorigenesis. Transfer of oncogenes from tumour cells 
to adjacent cells initiates cancer progression. Pro-angiogenic properties of EVs further increases 
the malignancy. EVs safeguard the cancer cells from immuno- hijackers such as Natural Killer 
T-cells therefore facilitating metastasis (Griffioen, 2008). Microvesiculation in the event of drug 
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treatment reduces its intracellular concentration thus making the tumour cells more resistant to 
various chemotherapeutics. 
1.4.2.1 Angiogenesis 
Tumour growth and survival depends on angiogenesis. EVs carry pro-angiogenic factors such as 
VEGF, FGF-2 and proteases that can be transferred to neighbouring cells inducing metastatic 
potential in them (Pluchino et al., 2012). EV-associated EGFR activates the VEGF-VEGFR 
pathway in endothelial cells that in turn promotes angiogenesis. EVs are enriched in 
sphingomyelins which is known to be a primary factor regulating angiogenesis. Furthermore, 
Tissue factor (TF) (Valenti et al., 2006) expressing EVs lead to fibrin deposition and formation 
of niches for tumour cell proliferation that contributes to metastasis.  
1.4.2.2 Immune surveillance Evasion 
Microvesiculation enhances the cancer cell’s ability to protect itself from the immune system 
and to promote carcinogenesis accordingly. 
1.4.2.2.1 EVs and evasion from the Immune System 
Secretions of complement-enriched EVs prevent complement mediated lysis of cancer cells. 
Van Doormaal and colleagues (van Doormaal et al., 2009) discussed ‘complement resistance’ as 
a mechanism to escape from C5b-9, MAC (membrane attack complex) induced lysis. It has also 
been shown that EVs can liberate complement inhibitor CD46 promoting the inactivation of 
C4b and C3b. Microvesicles bearing PS also have the capacity to inhibit complement by 
binding protein S in plasma which has a high affinity for the soluble complement inhibitory 
protein, C4 binding protein (C4bp)(Stratton et al., 2015). Microvesicles also aid the release of 
immune-modulatory molecules which safeguard the cancer cells from any immune complex 
attacks. EVs bearing Fas ligand (Andreola et al., 2002) CD95L induce T-cell apoptosis and 
weaken the immune system. Similarly, the exposure of latent membrane protein-1 (LMP-1) 
inhibits the leucocyte proliferation that further attenuates the immune system mediated tumour 
cell lysis. Incorporation of EVs into monocyte membranes impairs differentiation to antigen 
presenting cells (Andre et al., 2004) which in turn increases tumour survival.  Cancer cells can 
fuse with non-cancer cells through integrin rich EVs. Therefore, transfer of lipids and 
membrane proteins can expedite the chance of survival through immune cell editing.  
1.4.2.3 EVs induce Multi-drug Resistance 
Multidrug resistance (MDR) is a major obstacle for effective chemotherapy. Microvesicles 
enhance the anti-tumoural drug resistance by active efflux of the anti-cancer drug via 
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vesiculation that decreases the intracellular viable concentration needed for apoptosis. In the 
presence of calpeptin (calpain inhibitor) the EV release was inhibited which in turn increased 
the effect of docetaxel and methotrexate in inducing apoptosis of prostate cancer cells, 
PC3(Jorfi et al., 2015)  . It is also clear that drug resistance is transferred from drug-resistant 
tumour cells to drug-sensitive tumour cells via vesicles. Microvesicle surface molecules 
(adhesion molecules) are proposed to be associated with tissue selectivity in the transfer of P-gp 
in malignant breast cells (Pokharel et al., 2014). P-glycoprotein (P-gp) and MRP1 are members 
of the ATP Binding Cassette (ABC) superfamily of transporting molecules and have shown 
detrimental effects on MDR allowing cancer cell survival. In the presence of inhibitors of P-gp 
and MRP-1, the effect was reversed which suggests that such mechanisms are essential to 
prevent cancer recurrence (Gong et al., 2012) .  
As a consequence of their detrimental effect on cancer metastasis, EVs have become a target for 
cancer therapeutics. In particular, the inhibition of EV release has been considered to increase 
the effectivity of chemotherapy with minimum side effects (Moore et al., 2017, Kosgodage et 
al., 2017).  
1.4.2.3.1 Role of p53 and P-glycoprotein (P-gp) in Cancer drug Resistance 
Tumour suppressor gene, p53 is either mutated or inactivated in cancer and has shown a marked 
involvement in drug resistance. Alkylating agents used in oncotherapy operate through DNA 
damage so the sensitivity of p53 affects the sensitivity of tumours for such therapy if p53-
mediated apoptosis occurs readily in these cells (Hientz et al., 2017). Chemoresistance with p53 
is most commonly reported in studies related to ovarian cancers (Brachova et al., 2013). Its also 
been shown that p53+ tumours have an increased survival rate compared to p53- tumours which 
suggests that increases in genomic instability due to p53 abnormalities tends to evolve 
resistance to anti-cancer drugs (Darrah et al., 2012). This coupled with high expression of bcl-2 
diminishes the susceptibility to apoptosis leading to a systemic accumulation of cancer cells.  
Wild type p53 suppresses the expression of drug resistance genes, MDR-1 and MRP-1 and it 
has been shown that mutant p53 upregulates the expression of MDR-1 (the gene product is P-gp) 
but not MRP-1(multi-drug resistant associated protein-I) which are both drug efflux pumps in 
cancer (Breen et al., 2007, Sampath et al., 2001). It is just as likely that these genes could be up-
regulated by the “gain-of-function” activity of mutant p53 (Sigal and Rotter, 2000). The 
deletion analysis in a human colon carcinoma cell line revealed the involvement of only mutant 
p53 with promoter, Ets-1 site that was essential for its activation in MDR-1 but not the wildtype 
p53(Sampath et al., 2001). Interestingly it is shown that loss of p53-mediated repression 
increases the expression of both MDR-1 and MRP-1 which would be problematic for successful 
oncotherapy.  
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Similar studies elicit the correlation between MYCN activation and the upregulation of the 
MDR-1 gene that affects curability with chemotherapy in human neuroblastomas. This 
concomitantly increases MYCN and MDR1 transcripts levels, consistent with chemoresistance 
phenotype and active P-gp (Blanc et al., 2003).  IGR-N-91 neuroblastoma cells enriched with 
the MYCN transcription factor bind to two E-box motifs localized within the MDR1 promoter 
(Blanc et al., 2003). This data is comparable to the above study in terms that both mutant p53 
and MYCN genes do not affect the upregulation of MRP-1. 
P-gp acts as a transmembrane drive which eliminates drugs from the cell membrane and 
cytoplasm. It has further been proposed that P-gp acts like a hydrophobic vacuum cleaner or 
"floppase," transporting drugs from the inner leaflet of the plasma membrane lipid bilayer to the 
outer leaflet or to the external medium (Homolya et al., 2011). Lysosomal fractionation has 
been used to demonstrate the role of P-gp in MDR. P-gp substrate doxorubicin (DOX) was used 
in this study of the mechanism used by the tumour cells to provoke resistance. It was shown that 
p-gp substrates that are ionizable at lysosomal pH (pH 5) (Yamagishi et al., 2013) were 
sequestered and trapped in lysosomes affecting their ability to target apoptosis in cells and thus 
increasing the survival span of circulating tumour cells.  
These research findings reveal the consequence of p53 mutation and P-gp activation through 
MDR-1 translation in developing MDR. This has led to further investigations in using 
alternative therapeutic agents either individual or in combination to combat cancer cell survival.  
1.5 EV Inhibition and Cancer Immunotherapy 
EVs have been identified as potent cancer biomarkers and different therapeutic approaches have 
been used to target the adverse effect of these vesicles on oncogenesis. EVs have also become a 
major topic of interest with regard drug delivery.  They have been used widely in targeted 
therapy for many diseases such as cancer (Tian et al., 2014), cerebral occlusions (Armstrong et 
al., 2017) and neurodegenerative diseases (Croese and Furlan, 2018, Ciregia et al., 2017). 
Conventional chemotherapy targets the DNA damage of the cancer cells that leads to apoptosis. 
This approach has been widely used though not without adverse effects on healthy cells. Also 
the increases in MDR through mutations have allowed the chemotherapeutic agents to fail 
successively, irrespective of their mode of action (Alfarouk et al., 2015). This has alarmed the 
need of complimentary therapy to combat this issue and halt the cancer cell survival. The 
majority of cancer researchers focus on successful cancer drug delivery. In the past decade the 
use of nanocarriers to drive target therapy have pioneered the research field. Using   EVs 
provides multiple advantages including their biocompatibility, stability, low immunogenicity 
and target delivery (Shen et al., 2018).  
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Nevertheless, therapeutic applications of EVs as drug delivery systems have not been without 
challenges. This has limited the use of this strategy due to a lack of methods for scalable EV 
isolation and efficient drug loading (Saari et al., 2015). Furthermore, in order to achieve targeted 
drug delivery, their intrinsic cell targeting properties should be tuned through EV engineering 
(Barkalina et al., 2015). Expulsion of chemotherapeutic drug due to EV release can decrease its 
intact time with the cancer cells making them less susceptible to chemotherapy. In the same way, 
anti-cancer drugs delivered to cells via biological nano-carriers such as stem-cell-derived 
vesicles can also be expelled from the cells during this release (Qi et al., 2017). This in return 
leaves the cells with a non-effective dose of chemotherapy, insufficient for cell cytotoxicity but 
that induces MDR in cancer cells (Singh et al., 2017).  There have been previous studies 
bringing together ideas on improvement of chemotherapy through EV inhibition using different 
types of cancers (Roseblade et al., 2015, Menck et al., 2017, Kholia et al., 2015, Jorfi et al., 
2015). A recent review has discussed pharmacological inhibitors that are connected with 
different pathways of inhibition of EV release and uptake in renal diseases (Karpman et al., 
2017). However, there is no such study related to EV- driven chemotherapy. This was a great 
driver for part of the research presented in this thesis. It has not only resulted in studying most 
of the pathways of EVbiogenesis and release using multiple cancer cell-lines of different origin 
but has also worked through into introducing novel inhibitors.  
1.5.1 Pharmacological Mitotic Inhibitors 
1.5.1.1 Taxanes 
The taxanes are a class of chemotherapeutic agent that increase microtubule polymerisation and 
maintain its stability (by inhibiting its depolymerisation through binding to the β-tubulin); as a 
result they inhibit cell division.Paclitaxel and Docetaxel are abundantly used taxanes against 
tumours which are reported to be well tolerated with minimum side effects in breast cancer 
patients (Crown et al., 2004).  Microtubule stabilisation is ensured by centrosomal impairment, 
induction of abnormal spindles and suppression of spindle microtubule dynamics (Xie et al., 
2016). Taxanes are known to be more effective against prostate cancer. Taxane binding to 
microtubules halts the movement of androgen receptors therefore inhibiting their activity. This 
has been shown to be more active against androgen dependent prostate cancer (Martin and 
Kyprianou, 2015).  
1.5.1.2 Anti-metabolites 
An antimetabolite is any agent that interferes with the normal cell metabolism. 5-Fluorouracil 
(5-FU) has been known to be effective against a wide range of solid tumours including 
gastrointestinal related carcinomas. In vivo, 5-FU is converted to the active metabolite 5-
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fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and 
inhibits RNA processing, thereby inhibiting cell growth (Jacob et al., 2001). Another active 
metabolite irreversibly inhibits thymidylate synthase, resulting in the depletion of thymidine 
triphosphate (TTP) preventing in vivo DNA synthesis (Gottesman, 2002). Previous studies have 
shown that 5-FU can be used in conjunction with radiotherapy merely to enhance its 
cytotoxicity, effectively abrogating metastasis (Swanson et al., 2006). Additionally a novel 
antimetabolite, zebularine has shown promise inducing apoptosis and arresting cellular growth 
in various pancreatic cancer cell lines (Valenzuela et al., 2014). However, resistance to these 
anti-metabolites remains a problem, emphasising the absolute need of either discovering new 
antimetabolites or of developing alternative therapies that will improve a patient’s overall 
survival. This increased resistance to 5-FU has been reported extensively in the field in relation 
to prostate, colorectal and breast cancers. Similar to most cytotoxic anticancer agents, anti-
metabolites are toxic to normal cells, especially those in the bone marrow and gastrointestinal 
tract (Scholar, 2007). Therefore, it is crucial that only a minimal dose of the drug is used to treat 
cancers in order to prevent undesirable toxicity to healthy cells. This research has opened up 
novel ideas to achieve this through coupling of anti-cancer drugs with EV inhibition. 
1.5.1.3 Anthracyclines 
Anthracyclines are a class of drugs that are produced by certain types of Streptomyces bacteria 
such as Streptomyces peucetius var. caesius. They are used in chemotherapy, and therefore 
termed antitumour antibiotics which include daunorubicin, doxorubicin, epirubicin, aclarubicin 
and mitoxantrone (Rabbani et al., 2005). The use of anthracyclines in combination has proven to 
be more effective in chemotherapy than as single agents and appears to have improved 
therapeutic efficacy and to reduce toxicities (Bachur, 2002). The types of malignancies that are 
treated with the various anthracyclines range from acute myelogenous leukemia to lymphoma to 
solid tumors of the breast, lung, gastrointestinal tract, and genitourinary system (Vejpongsa and 
Yeh, 2014).  These anticancer agents work by damaging DNA and by generation of free radicals.  
The anthracyclines are believed to exert their cytotoxic effects through a variety of mechanisms; 
Topoisomerase II (Top II) plays a key role during DNA synthesis, nicking and resealing the 
DNA helix so that it does not become tangled during replication (Liu et al., 2009). The 
anthracyclines prevent the resealing step from occurring by intercalating into and inhibiting the 
DNA–topoisomerase II complex after the nicking phase. This results in a large number of DNA 
fragments, eventually prompting the cancer cell to undergo apoptosis (Bardal et al., 2011). 
As a secondary mechanism, anthracyclines produce free radicals, and these free radicals in turn 
damage cell membranes, proteins, and lipids (Bhattacharyya et al., 2014). The generation of free 
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radicals is also believed to mediate an important toxicity associated with this class which can 
lead to cardiomyopathy (Bardal et al., 2011).  
Cancer cells are known to build up resistance to anthracyclines due to drug efflux through P-
glycoprotein (Pgp-170) or multidrug-resistant (MDR) gene (Pasquier et al., 2011), altered 
topoisomerase II levels, mutations in topoisomerase II (Wang et al., 2014), increased 
glutathione (a free radical scavenger) (Rivera and Gomez, 2010), increased glutathione 
peroxidase activity and decreased concentration of glucose-6-phosphate (G6P) dehydrogenase 
(Wagner et al., 2005).  It is thus crucial to develop a mechanism to combat the resistance and 
make the tumour cells more susceptible to the cytotoxicity of these drugs. 
This study has used DOX to examine the effect of EV inhibition. Also known as Adriamycin, it 
is a prodrug with an active metabolite (Zhao et al., 2015). The anthracyclines are eliminated 
through hepatic metabolism, through a variety of routes. Its widespread use in cancer treatment 
is not without side effects, especially cardiotoxicity(Volkova and Russell, 2011). Dose 
adjustments should be considered in patients with significant hepatic impairment and cardiac 
instabilities and it is vital that the cancer patients are treated with the minimum, yet effective 
dose of the drug. This study will look at how EV inhibition will allow the use of a minimum 
operative dose of doxorubicin in an attempt to reduce drug resistance.  
1.6 Bacterial Outer-membrane Vesicles (OMVs) 
Outer membrane vesicles (OMVs) are predominantly produced by Gram-negative bacteria by 
direct budding of the outer membrane under stress conditions (Kulp and Kuehn, 2010). 
Bacterial OMVs were first reported with respect to E. coli in the 1960s (Pérez-Cruz et al., 2015). 
However recent studies have emphasised the production of OMVs by Gram-positive bacteria 
such as Staphylococcus aureus (Brown et al., 2015). OMV release is a conserved phenomenon, 
but there are considerable differences in composition and activity of OMVs between species, 
between strains, and even between the same strains under different external pressures 
(O'Donoghue and Krachler, 2016). Different mechanisms of OMV biogenesis have been 
discussed in the literature. Initial publications have mentioned that bacterial membrane blebbing 
has occurred as a consequence of cell lysis where the OMVs contain cellular debris (McCaig et 
al., 2013). However latter publications have strongly suggested that OMV biogenesis rather than 
being a byproduct of cell lysis is a deliberate process which gives rise to vesicles following 
dissociation of the bacterial outer-membrane from the peptidoglycan cell wall in the absence of 
anchoring (Schwechheimer and Kuehn, 2015, Kulp and Kuehn, 2010). Therefore, the vesicles 
contain functional bacterial cargo and not ‘cellular debris’ as previously suggested. Nevertheless, 
the mechanism of OMV biogenesis through the peptidoglycan cell wall in such bacteria is still 
not well known. OMVs from these microorganisms range from 20 nm to 400 nm in diameter 
23 
 
(Schrempf et al., 2011). This variability in the size of vesicles suggests that although 
vesiculogenesis may be a universal phenomenon, different bacteria utilise different regulatory 
mechanisms to synthesise these vesicles (Toyofuku et al., 2017). Bacterial OMVs contain 
enzymes and other biologically active proteins which get transferred to neighbouring cells 
bringing about many changes in the recipient cells. OMVs can deliver virulence factors and 
control the host immune system during pathogenesis (Katsir and Bahar, 2017)They may also aid 
in nutrient acquisition (Schwechheimer and Kuehn, 2015), be involved in ecological niche 
protection (Jain and Pillai, 2017) and provide structural support in biofilm formation (Jain and 
Pillai, 2017). Recently, OMVs have been discovered to have therapeutic potential through 
vaccines, adjuvants or as drug delivery vehicles (Jain and Pillai, 2017) not only in the presence 
of bacterial infections but against viral replication (Acevedo et al., 2014).  Therefore, as with 
extracellular vesicles (EVs) in eukaryotes, bacterial OMVs are useful as mediators in 
intercellular communication. The discovery of this broad spectrum of usability has allowed 
OMVs to continue their  transition from ‘cellular rubbish’ (akin to an early description platelet 
MVs as ‘platelet dust’(Wolf, 1967)) to an important means of intercellular communication 
between bacteria and eukaryotic cells  (Olsen and Amano, 2015) 
There are many studies that have discussed the involvement of OMVs in directing antibiotic 
resistance (AR) and reduced phage titre directing phage therapy. A recent comparative 
proteomic analysis on OMVs by Park and colleagues resulted in more drug-binding proteins 
(efflux proteins) in the biofilm compared to planktonic growth of Pseudomonas aeruginosa 
(Park et al., 2014).  Similarly, Fulsundar reported that OMVs act as carriers of AR genes which 
are laterally transferred to recipient cells causing phenotypic transformation leading to 
insensitivity to treatment in Acinetobacter baylyi (Fulsundar et al., 2014b). Likewise, β-
Lactamase-harbouring OMVs from Bacteroides thetaiotaomicron protected Salmonella 
Typhimurium and Bifidobacterium breve from an otherwise lethal dose of cefotaxime(Stentz et 
al., 2015). This was an insight into how enteric and commensal bacteria in the colon are 
protected by β-lactam antibiotics. Furthermore, bacterial defence mechanism was conserved, if 
not augmented through hypervesiculation.  This was examined in a wild-type E.coli treated with 
antimicrobial-peptides. Vesicle-mediated protection was also observed for a human pathogen, 
enterotoxigenic E. coli (ETEC), challenged with polymyxin B (Manning and Kuehn, 2011). 
1.6.1 Bacterial OMVs and Bacteriophage Infection 
Efficacious adsorption of virus particles to a bacterial surface receptor initiates a successful 
phage invasion. These receptors are typically protein or polysaccharide (lipopolysaccharide) and 
must be in a permissive spatial distribution which makes it readily accessible. Interestingly, it 
has been shown that OMVs interfere with phage invasion in many ways. The culprit mostly 
affects the adsorption phase as highlighted by Manning and co-workers (Manning and Kuehn, 
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2011). The T4 phage is obstructed by E.coli-OMVs in this instance which acts as a decoy to 
prevent infection.  
However original research carried out recently has highlighted the beneficial role of OMVs in 
phage attack. Bacteriophage largely impact Horizontal gene transfer (HGT). This work used 
Bacillus subtilis and its lytic phage SPP1 to demonstrate that SPP1 resistant cells regaining the 
sensitivity through co-infection with SPP1-sensitive cells. This acquisition of sensitivity is 
believed to be mediated via OMVs through HGT of the sensitivity gene to the resistant cells 
(Tzipilevich et al., 2017).   
The latter however is possible if the adsorption of phage takes place. Many studies support the 
phenomenon that OMVs obstruct this surface assimilation of phage to initiate the infection. 
Therefore, it is important that this defence mechanism adopted by bacterial cells is overcome to 
provide effective phage therapy. In this research, pharmacological OMV inhibition is reported 
for the first time with an insight into the inhibitory pathways of OMV biogenesis and release. 
This has extended to its beneficial role in preventing antibiotic resistance and ameliorating the 
use of minimum effective antibiotic dose with pronounced changes in both Gram-negative and 
Gram-positive bacterial cells.  
The research presented in this thesis further elaborates into the role of OMVs during 
bacteriophage infection. The implication of OMV inhibition on phage therapy has been 
investigated using E.coli and lambda phage. Also, the putative effect of Cl-amidine has been 
further investigated as a preventative measure of OMV release that can impact phage assembly 
during infection.    
1.7 EVs and Viral Infection 
Numerous studies have also looked into EV association with viruses. Captivatingly it has been 
shown that these vesicles have many characteristics in common with enveloped viruses more 
commonly retroviruses (Meckes and Raab-Traub, 2011). Retaining similar characteristics that 
include biophysical properties, biogenesis and uptake by cells `(Nolte-‘t Hoen et al., 2016) has 
enabled the virus-EV relationship to thrive during infection.  Recent discoveries have further 
explained its mode of action through vesicle-mediated intercellular transfer of functional 
cellular proteins, RNAs, and mRNAs which have revealed additional similarities between 
viruses and EVs. Interestingly, many virally infected cells secrete microvesicles that differ in 
content from their virion counterparts but may contain various viral proteins and RNAs.  
A group has looked into the viral-vesicle relationship in herpes simplex virus-infected HOG- 
cells.  HSV-1 virions were detected from vesicles isolated from these infected cells. 
Furthermore virus-containing vesicles were endocytosed into CHO-K1 cells and were able to 
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actively infect these otherwise nonpermissive cells (Bello-Morales et al., 2018). In conclusion it 
was also revealed that co-infected CHO cells with viral vesicles were not completely neutralised 
by anti-HSV-1 antibodies which excitingly suggested that immune shielding was acquired by 
the virus from its vesicle coating.  A similar study on Epstein-Barr virus further confirmed this 
mechanism of host immune system circumvention. Internalization of fluorescently labelled 
exosomes derived from EBV-uninfected and EBV-infected B cells of type I and type III latency 
into EBV-negative epithelial cells was observed  (Nanbo et al., 2013). This resulted in 
significant phenotypic changes in the recipient cells which suggested that this tumorigenic 
herpesvirus also utilizes exosomes as a mechanism of cell-to-cell communication through the 
transfer of signaling competent proteins and functional microRNAs to uninfected cells (Teow et 
al., 2017, Keryer-Bibens et al., 2006, Ruiss et al., 2011). The vesicle-mediated high virus 
virulence is now central to research and recently interested a group to evaluate the possibility of 
a similar rapport in enteric-viral infections in humans. This has led into the discovery of 
‘vesicle-cloaked virus clusters’ driving the faecal-oral transmission of norovirus and Rotavirus 
enhancing both the multiplicity of infection (MOI) and disease severity between hosts. The 
research was conducted in pigs’ stool samples. There was a significant fraction of vesicle-
containing Rotaviruses in the stool rotavirus pool and it was confirmed that virus coated in 
vesicles are more infectious than free stool Rotaviruses in-vitro (Santiana et al., 2018). It 
suggests that viral-vesicle clusters are considered the optimal agents for spreading infections as 
opposed to freely circulating virus particles. Therefore, target therapy should focus on 
preventing EV-virus cluster formation as a means of controlling inter-organismal viral evasion.   
1.8 Cannabidiol (CBD) and the Biology of EVs 
CBD, a phytocannabinoid derived from Cannabis sativa, is anxiolytic (Blessing et al., 2015) 
and has analgesic, anti-inflammatory, anti-neoplastic and chemo-preventive properties (Pisanti 
et al., 2017, Fernandez-Ruiz et al., 2011). CBD has been shown to have a plethora of molecular 
targets, including the classical endocannabinoid system, while effects that do not involve the 
classical cannabinoid system are also gaining increased attention (Ibeas Bih et al., 2015, Pisanti 
et al., 2017). Recent findings have managed to extend the role of CBD in preventing 
behavioural, electrophysiological, and neuropathological effects in epilepsy. Results conducted 
on an intrahippocampal pilocarpine epilepsy model managed to introduce anticonvulsant and 
neuroprotective characteristic of CBD (Do Val-da Silva et al., 2017, Tang and Fang, 
2017).Known anti-cancerous effects of cannabinoids include inhibition of tumour proliferation, 
angiogenesis and induction of tumour cell death(McAllister et al., 2005, McAllister et al., 2015, 
Velasco et al., 2016, Solinas et al., 2013, Dumitru et al., 2018). 
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Critically, CBD has been shown to be effective in various EV-linked pathologies (Chiurchiù et 
al., 2018), and seems to modulate mitochondrial function, including ATP, ROS and proton leak, 
as well as uptake and release of calcium (Ibeas Bih et al., 2015, Rimmerman et al., 2013, Ryan 
et al., 2009). These observations may be relevant as mitochondria are key in modulating 
calcium signaling (Liu et al., 2001). As described previously, calcium signalling is crucial for 
EV release (Hay, 2007). Furthermore, altered calcium signalling and mitochondrial function are 
hallmarks of many cancers (Chattopadhyay and Roy, 2017, Vyas et al., 2016, Lynam-Lennon et 
al., 2014).  
This study has undoubtedly led to the discovery of a novel role of CBD (Kosgodage et al., 
2018).  Its function as an EV inhibitor has here ben explored in five different cancer cell lines. 
Its inhibitory role has further been confirmed in the presence of the standard anti-cancer drug, 
temozolomide in glioblastoma (Kosgodage et al., 2018)which indicates EV-mediated effects for  
effective cancer therapy. 
1.9 Reagents used as Potential Inhibitors in the Study 
A range of reagents have been used to investigate the potential of inhibiting both the release of 
EV and bacterial OMV release. CBD, AMF30a and GSK199 were not water soluble and were 
dissolved in DMSO to prepare working solutions. Nicotine was a ready to use liquid. The rest of 
the reagents were water soluble including, BB-Cl-amidine and Cl-amidine. The abundance of 
non-polar groups in the chemical structure contributes to the hydrophobicity of some reagents 
while the presence of polar groups makes the reagents hydrophilic as seen with EGTA. The 
chemical structures, hydrophobicity and the net charge of all inhibitiors were taken into account 
during data analysis (Table 1). 
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Potential Inhibitor 
Chemical Structure Hydrophobicity Net 
charge 
EGTA 
(Nowak et.al., 2018) 
 
Less 0 
D-Pantethine 
(PubChem 2019) 
 
More 0 
Bisindolymaleimide-
I 
(PubChem 2019) 
 
Less 0 
Y27632 
(Leonel et.al., 2017) 
 
More 0 
Imipramine 
(Browman & Fox 
2007) 
 
More 0 
Chloramidine 
(Luo et al., 2006) 
 
More 0 
BB-Chloramidine 
(Knight et al., 2014) 
 
More 0 
GSK199 
(Lewis et al., 2015) 
 
More 0 
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AMF30a 
(Muth et al., 2017) 
 
More 0 
Cannabidiol 
(Istvan & Lumir 
2016) 
 
More 0 
Nicotine 
(Pubchem 2019) 
 
More 0 
Table 1. Chemical structures of the potential inhibitors used in the study.These reagents were used in 
different experiments to investigate the effect on EV and OMV inhibiton. Their hydrophobicity and the 
net charge have been taken into considertation during results analysis. 
 
1.10 Gold Standards of Detection and Quantification of EVs 
High throughput analytical platforms have been developed to analyse EVs. Researchers in the 
EV field have utilised various methods to characterise and quantify EVs(Rupert et al., 2017). 
Flow cytometry has been the classic approach (Morales-Kastresana et al., 2017) amongst them, 
but recently more sophisticated techniques such as Nanoparticle Tracking Analysis (NTA), 
based on brownian motion of particles in fluids, have been introduced for high accuracy and 
verification of results. 
1.10.1 Flow Cytometry 
Flow cytometry has been used to analyse the physical and chemical properties of EVs in the 
fluid phase (Akers et al., 2016), especially using high resolution flow cytometers. The forward 
scatter correlates to its particle size while side scatter reflects the granularity. These 
measurements along with fluorescent intensity can be measured as EVs pass through the laser 
beams resulting in the FACS plot. Phosphatidylserinve (PS) exposure on EVs can be detected 
using FITC, PE or alexa fluor conjugates of Annexin-V and using this method it is possible to 
analyse large numbers from a single isolate. The experiments carried out in this study have used 
a Guava EasyCyte flow cytometer (Guava Technologies, UK) which has allowed multiple 
antigen detection using FSC-Hlog and SSC-Hlog settings that allowed, where 
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necessary,accurate quantification of the whole sample. Cytograms consisting of dot plot and 
histograms have been used for data analysis (Reggeti and Bienzle, 2011). 
1.10.2 Nanoparticle Tracking Analysis 
The EV field has shown interest in using a better method than flow cytomtery to quantify EVs 
(Malvern, 2015 News Medical, Wang et al., 2010, Gardiner, 2011). This sophisticated technique 
has become increasingly prevalent among researchers and has allowed accurate analysis of 
particles according to size, based on Brownian motion. The Nanosight LM-10 has mainly been 
used to analyse size distribution and quantify EVs in this study, while the NS300 model was 
also used for analysis of the GBM data. The Nanosight  has allowed the rapid and accurate 
analysis of the data samples utilising the properties of both light scattering and Brownian 
motion in order to obtain the size distribution and concentration measurement of particles in a 
liquid suspension (Malvern, 2015 News Medical). Minimal sample preparation and increased 
sensitivity has made it more viable for EV studies than traditional methods (Dragovic et al., 
2011). 
1.10.3 Fluorescence Microscopy 
High resolution fluorescence microscopy analysis which involves single object studies has 
supported research findings in many studies. Its significance in performing morphology studies 
has encouraged more laboratories to include this identification tool in their investigations. 
Single object studies have the general advantage of uncovering heterogeneity that may be 
hidden during the ensemble averaging which is common in any bulk conventional biochemical 
analysis (Ter-Ovanesyan et al., 2017). The implementation of single object analysis in the study 
of extracellular vesicles (EVs) may therefore be used to characterize specific properties of 
vesicle subsets which would otherwise be undetectable (Carpintero-Fernández et al., 2017, 
Reátegui et al., 2018). 
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1.10 Overall Aim 
Phase I 
The identification of a suitable inhibitor or a combination of inhibitors of EV release from 
cancer cells. Findings from cancer cells were further applied to identify potential strong OMV 
inhibitors using E.coli and S. aureus. 
 
Phase II 
PC3 and MCF-7 cells treatment with anti-cancer drugs, 5-FU in the presence and absence of the 
chosen inhibitors from phase I as well as Peptidyl Arginine Deiminase (PAD) inhibitor and the 
measurement of resulting apoptosis. Additionally, assessment of the effect of EV inhibition in 
DOX-treated PC3 cells. 
Phase III 
Assessments of the effects of OMV inhibitors on Minimum Inhibitory Concentration (MIC) of 
antibiotics. This data was then utilised to conduct further experiments related to antibiotic 
resistance and phage therapy 
 
Phase IV 
Assessment of vesicle-mediated drug delivery using DOX encapsulated in PC3 cell-derived 
EVs. 
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2.0 Materials & Methods 
2.1 Cell lines 
EVs were isolated from PC3 cells (Human prostate cancer cells). PC3, MCF-7 cells (Human 
breast cancer), HEPG2, MDA-MB-231, LN18 and LN229 cell lines were used in EV inhibition 
and apoptosis experiments. 
MCF-7 cells (ECACC; Ref No. 86012803) 
MCF-7 is based on the acronym Michigan Cancer Foundation -7 in Detroit where it was 
established. It is a breast cancer cell line that was first isolated in 1970 from a pleural effusion 
of a 69-year old Caucasian woman following a radical mastectomy of her left breast for 
malignant adenocarcinoma.  
These cells retain mammary epithelial characteristics. They are able to process oestrogen (ER) 
via ER receptors and are sensitive to cytokeratin. The cells are adherent and grow in monolayers 
forming domes. 
PC3 cells (ATCC® CRL-1435™) 
The PC3 cell line was established in 1979 from bone metastasis  (grade IV) of prostate cancer in 
a 62-year-old Caucasian male (Cunningham and You, 2015).The cells do not respond to 
androgens, glucocorticoids or fibroblast growth factors but are influenced by epidermal growth 
factors (Tai et al., 2011). PC3 cells are androgen receptor (AR) and prostate specific antigen 
(PSA) and prostate-specific membrane antigen (PSMA) negative and express characteristics 
similar to Prostatic small cell neuroendocrine carcinoma (SCNC) (Tai et al., 2011).  Electron 
microscopy reveals the similarity between epithelial neoplasms and PC3 cells such as the 
presence of numerous microvilli, junctional complexes, abnormal nuclei and nucleoli, abnormal 
mitochondria, annulated lamellae, and  lipid bodies (Kong et al., 2011). 
HEPG2 cells(Received as a kind gift from Dr K. White, London Metropolitan University) 
Liver cancer cells were first isolated from a 15 year old male Caucasian with a well-
differentiated hepatocellular carcinoma.  These cells are epithelial in morphology and secrete 
plasma proteins such as albumin, transferrin and plasminogen(Mersch-Sundermann et al., 2004). 
These cells have been widely used in research relating to hepatotoxicity and drug metabolism. 
They are able to activate and detoxify xenobiotics and therefore reflect the metabolism of 
xenobiotics in the human body better than other metabolically incompetent cells used in 
conventional in vitro assays (Donato et al., 2015). Cell lines are characterized by their unlimited 
life span, stable phenotype, high availability, and easy handling (Bokhari et al., 2007). However, 
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their major limitation is the lower expression of some metabolic activities compared with 
hepatocytes. 
MDA-MB-231 cells(Received as a kind gift from Dr. T. Kalber, UCL) 
This is a human Caucasian breast adenorcarcinoma cell line established from pleural effusion. It 
has previously been used to study the changes in the morphological pattern and gene expression 
of cells when grown in the presence of sera positive for anti-carbonic anhydrase I (CA I) 
autoantibodies, the effects of normothermic conditioned microwave irradiation on cultured cells 
using an irradiation system and the transendothelial migration rates of the cells under different 
shear stress levels (Chavez et al., 2010). They are of epithelial origin and are adherent cells.  
MDA-MB-231 is a highly aggressive, invasive and poorly differentiated triple-negative breast 
cancer (TNBC) cell line as it lacks oestrogen receptor (ER) and progesterone receptor (PR) 
expression, as well as HER2 (human epidermal growth factor receptor 2) amplification. 
Invasiveness of the cell line is modulated by proteolytic degradation of the extracellular matrix 
(Holliday and Speirs, 2011). 
As a result of lacking ER and PR expression and HER2 amplification, the cell line was initially 
classed as a ‘basal’ breast cancer cell line. However, it is now recognised as belonging to the 
claudin-low molecular subtype as it exhibits down-regulation of claudin-3 and claudin-4, low 
expression of the Ki-67 proliferation marker, enrichment for markers associated with the 
epithelial-mesenchymal transition and the expression of features associated with mammary 
cancer stem cells (CSCs), such as the CD44+CD24-/low phenotype 4(Dai et al., 2017, Subik et 
al., 2010, Sun et al., 2017).  
In 3D culture, the cell line displays endothelial-like morphology and is distinguished by its 
invasive phenotype, having stellate projections that often bridge multiple cell colonies (Syed et 
al., 2017)(Figure 1, D). 
LN18 and LN229 cells (ATCC® CRL-2610™ and ATCC® CRL-2611™)  
Glioblastoma (GBM), the most malignant intrinsic glial brain tumour, hardly colonizes outside 
the central nervous system (CNS). It seems to need the unique composition of the cranial 
microenvironment for growth and invasion as the incidence of extracranial metastasis of GBM 
is as low as 0.5 % (De Vleeschouwer and Bergers, 2017).On the basis of histopathological 
features, GBM are divided in to two major groups, astrocytomas (morphologically resembles 
normal and reactive astrocytes) and  oligodendrogliomas (similar to oligodendrocyte 
lineage)(Zong et al., 2012). GBM is a grade IV and an aggressive tumour and prevailing target 
therapy consists of radiotherapy in conjunction with TMZ-mediated chemotherapy. Two GBM 
cell lines have been used in the present study.  
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The LN-18 cell line was established in 1976 from the cells of the right temporal lobe glioma in 
a 65 year old white male.  The cells are poorly differentiated and negative for glial fibrillary 
acidic proteins and S-100 protein(Wybranska et al., 2013). They exhibit mutated p53 and 
possible homozygous deletions in the p16 and p14ARF tumor suppressor genes, and have a 
wild-type PTEN gene (Sesen et al., 2015).  
Overexpression of Bcl-2 protects these cells from Fas ligand-induced cell death. This cell line is 
frequently used in apoptosis studies and is considered to be TMZ resistant (Happold et al., 
2012).LN-18 cells grow in vitro as bipolar or stellate cells with pleomorphic nuclei, having a 
doubling time of about 72 h and a plating efficiency of 3%(Klein et al., 2012). 
Similarly, LN229 which is also used in apoptosis experiments is used in the current study. They 
were first isolated from brain/right frontal parieto-occipital cortex tissue of a 60 year old white, 
female (Hong et al., 2012). The cells exhibit mutated p53 (TP53) and possible homozygous 
deletions in the p16 and p14ARF tumor suppressor genes. They have a wild-type PTEN gene 
(Ren et al., 2010). LN229 is well known as a TMZ-sensitive cell line as well as to Belinostat 
exposure , a cytostatic agent used in GBM (Kusaczuk et al., 2016).  
 
 
Figure 1:  Microscopic Images of cells used in the study.A, MCF-7 are adherent cells that form domes 
in monolayers. B, PC3 elongated adherent cells.C, MDA-MB-231 cells, spindled-shaped that are 
adherent.D, HEPG2, adherent cells. E-F, gliobastoma cell lines, LN18 (TMZ-resistant) and LN229 
(TMZ-sensitive). The cells are morphologically epithelialand are adherent. 
1µM 
1µM 1µM 
1µM 
1µM 
1µM 1µM 
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2.2 Cell Growth Medium (CGM) 
To make complete growth medium, RPMI 1640 medium with phenol red, containing 2.05mM 
glutamine and sodium pyruvate was supplemented with 10% FBS (v/v) and 1% Penicillin / 
Streptomycin in 500 ml volumes and stored at 4 °C. 
2.3 Methods 
2.3.1 Maintaining cell lines 
Adherent cell lines, PC3, MCF-7, HEPG2, MDA-MB-231, LN18 and LN229 were maintained 
at 37 ºC with 5% CO2, in suitable growth media. Both PC3 and MDA-MB-231 cell lines were 
grown using RPMI supplemented with 10% FBS while MCF-7, HEPG2, LN18 and LN229 
were grown in DMEM supplemented with 10% FBS. These cells were split depending on 
confluence every 3 to 5 days. Cells were washed twice by changing GM with DPBS and 0.25% 
(v/v) trypsin/EDTA was added.  After 10-15min incubation at 37°C with 5% CO2, the flask was 
observed under the microscope and if the cells were detached and floating, growth medium was 
added to inactivate the trypsin. The trypsin solution was removed by centrifugation at 200 g for 
5 min followed by one wash in DPBS for PC3 and centrifuged at 120 g for 5 min followed by 
one wash in DPBS for all other cell lines. Cell pellets were resuspended in the appropriate GM 
volume and seeded in the desired dilution into new culture flasks. Exponentially growing cells 
with a viability of 95% or higher were used in every experiment. The number of cells and 
viability was determined before the start of every experiment using the haemocytometer and 
viability assays on Guava viacount (Guava Technologies, UK) and NucleoCounter® NC-
3000™ (Chemometec) at different occasions. 
2.3.2 Cryopreservation of cells 
To prepare frozen stocks for long term storage, cells grown to almost 100% confluency were 
detached using trypsin/EDTA, washed twice (200 g, 5 min for PC3 and 120g, 5min for all other 
cell lines) with DPBS and cell number determined using Guava Viacount and NucleoCounter® 
NC-3000™ as mentioned in section 3.10. Cells were carefully resuspended in freezing mix 
(growth medium + 10% DMSO), transferred into cryo-vials (Greiner) at 1x107 cells/ml in 1 ml 
volumes and immediately placed on ice. The cryo-vials were frozen at -80 °C in polystyrene 
boxes, which ensure a temperature decrease of 1 °C per minute. For long-term storage the deep 
frozen cryo-vials were kept in liquid nitrogen. 
2.3.3 Defrosting of cryopreserved cells 
To defrost cells, cryo-vials were removed from liquid nitrogen and immediately thawed in a 
water-bath at 37°C. After cleaning the lid with 70% ethanol the contents were transferred to a 
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15 ml centrifuge tube containing 9 ml of complete growth medium, prewarmed to 37°C and 
cells were pelleted by centrifugation at the appropriate speed (200 g, 5 min for PC3 and 120 g, 5 
min for MCF-7). To remove DMSO, the medium was discarded, and the cell pellet resuspended 
in fresh growth medium. The cells were then placed into tissue culture flasks and incubated at 
37 °C with 5% CO2. 
2.4 Biochemical Methods 
2.4.1 Isolation of EVs from conditioned medium 
EVs were isolated from the supernatant of the cell culture medium that consisted of serum-free 
EV-free RPMI which was centrifuged once at 200 g for 5 min (PC3) to remove the cells. The 
supernatant was then centrifuged once at 4,000 g for 60 min at 4°C to remove cell debris. The 
resultant supernatant was centrifuged at 25,000 g for 1h at 4 °C. The isolated EV pellet (which 
also contains exosomes as clumps, were not separated by sonication(Grant et al., 2011)was 
resuspended in sterile-filtered (0.22µM) DPBS and centrifuged again at 25,000 g for 1h at 4 °C 
to remove proteins such as albumin possibly bound to the EV membrane surface. The EV pellet 
was resuspended in sterile-filtered (0.22 µm pore size) DPBS and quantified on a Guava 
EasyCyte flow cytometer using ExpressPlus software (Guava Technologies), Nanosight LM10 
or else a BCA protein quantification was performed. Isolated EVs were then used immediately 
or stored at -80 °C for experiments. For EV associated experiments serum free medium (RPMI) 
was used after ultracentrifugation at 75000 g for 24 h to obtain a medium of minimal 
contamination with vesicles. 
2.4.2 Detection of PS-Positive EVs 
Twenty microlitres of EVs (2 × 106EVs/ml) were resuspended in 5µl Annexin V-FITC and 50 
µl Annexin V binding buffer (FITC was added or not (control)). The sample was then incubated 
at room temperature (RT) for 1.5h with shaking. Fifty microlitres of Ann V binding buffer was 
added and centrifuged at 13,000 g for 1h to pellet EVs. Samples were analysed immediately as 
directed by the manufacturer using the flow cytometer (Guava EasyCyte, GuavaTechnologies). 
2.4.3 Immunostaining of Cells 
PC3 cells were labelled with FITC-labelled anti-CD9, anti-CD29, anti-CD58 and anti-CD71. 
FITC- IgG1 was used as the control for specific binding. Cells were washed three times (200 g 
for 5 min) with serum-free RPMI prior to experiments and once in DPBS for 5 min at 200 g. 
Cell count was determined using the Guava Viacount assay. Cells were fixed with 4% 
paraformaldehyde for 1 0min at RT. Fixed cells were washed 2x with PBS at 400 g for 5 min. 
Cells were equally distributed into 1.5 ml microfuge tubes and pre-incubated with 3% BSA/PBS 
for 45 min at RT. The cell mixture was then treated with 5 µl of the FITC-conjugated antibody 
37 
 
for 1h at 4 °C. Stained cells were washed 3 times with PBS and observed using a 
NucleoCounter® NC-3000™ (Chemometec). 
2.4.4 PKH labelling of PC3 cells and PC3-derived EVs 
PC3 cells were detached with trypsin and washed twice with DPBS at 200 g and a cell pellet 
obtained. 100 µl of diluent was added to the cell pellet. PKH dye + diluent mixture was made by 
adding 40 µl of the dye to 200 µl of the diluent. The cell suspension and dye solutions were 
mixed and incubated at RT for 15 min in the dark. 100 µl of BSA solution was added to the 
reaction mixture and washed thrice at 200 g with DPBS. The washed cells were mounted on a 
glass slide and analysed by fluorescent microscopy.  
The same protocol was used to label isolated EVs but the incubation time was extended to 30 
min in dark and the washing centrifugation was carried out at 25,000 g.  
2.4.5 Protein Quantification 
The concentration of a protein solution was determined using the BCA Protein Assay Kit 
(Pierce, Thermo Scientific, UK). It uses a combination of the biuret reaction (reduction of Cu2+ 
ions to Cu+ ions by proteins in an alkaline medium) and the colorimetric detection of the Cu+ 
cations by a bicinchoninic acid-containing colour reagent. Following the manufacturer’s 
instructions (Pierce BCA Protein Assay Kit, Thermo Scientific) standards were prepared. The 
assay was performed in a 96-well microtitre plate and 25 μl of protein samples were added to 
200 μl of a working solution consisting of a mixture of kit reagent A and reagent B (ratio 50:1 
respectively). The plate was incubated for 30 min at 37°C, followed by 10 min incubation at RT 
to cool the samples. A540 readings were taken on a FLUOstar Omega microplate reader. 
Protein concentrations of the unknown samples were determined by interpolation on a standard 
curve using the Beer Lambert law. 
2.5 Flow Cytometry 
The Guava EasyCyte flow cytometer allows complex biological studies such as cell counting 
and viability testing, cell activation marker analysis and other complex molecular analyses to be 
performed simultaneously. ViaCount assay (counting cells and determining viability) and 
ExpressPlus assay (microvesicle analysis) were used in this study. 
2.5.1 Guava ViaCount Assay 
Cell number and viability were determined using the ViaCount assay, which distinguishes 
between viable and non-viable cells based on the differential permeability of two DNA-binding 
dyes in the Guava ViaCount reagent. The nuclear dye only stains nucleated cells, while the 
viability dye brightly stains necrotic or apoptotic cells. This exclusive combination of dyes 
enables the Guava ViaCount assay to distinguish between viable, apoptotic and dead cells.  
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2.6 Image Flow Cytometry [NucleoCounter® NC-3000™ (Chemometec)] 
2.6.1 Viability Assay 
The Via1-Cassette™ was used to determine the viacount. A sample of the cell suspension was 
drawn directly into the Via1-Cassette™. The live and dead cell count was distinguishable 
through the presence of two different dyes, staining the entire cell population and the non-viable 
cells respectively. The image of the Viability and Cell Count Assay was created through plot 
manager. All cells were stained with Acridine Orange (AO) represented by green cells. 
Nonviable cells are stained with DAPI, represented by blue cells.  
2.6.2 Annexin V apoptosis Assay 
Externalisation of phosphatidylserine (PS) occurs in early apoptosis which is easily detected 
through Annexin V staining. Cells were stained with Hoechst 33342, Propidium Iodide (PI) and 
Annexin V-FITC.  Hoechst 33342 stains the total cell population, while Annexin V stains 
apoptotic and necrotic cells. Scatter plots and histograms created through Plot Manager 
provided the images which were easily analysed. Early apoptotic cells exclude PI, while late 
stage apoptotic and necrotic cells stain positive for both Annexin V and PI.  
2.6.3 Cell Vitality Assay 
Reduced Glutathione (GSH) is involved in many cellular processes such as cell signalling and 
proliferation. The reduction in GSH is a marker for early apoptosis. The vitality assay provides 
easy determination of the level of thiols, such as reduced glutathione (GSH). The VB-48 assay 
was performed according to the manufacturer’s protocol and scatter plots and histograms 
created through Plot Manager. By comparing the VB-48™ intensity of treated cells and control 
cells the fraction of cells with low vitality (e.g. necrotic or apoptotic cells) could be determined. 
Quadrants and polygons were used to define specific areas of apoptosis within the cell 
populations in the samples.   
2.6.4 Mitochondrial Membrane Potential Assay 
Apoptosis leads to many mitochondrial changes in a cell. One of them is loss of membrane 
potential (Ψ). The assay uses tetraethylbenzimidazolylcarbocyanine iodide (JC-1), a cationic, 
lipophilic dye that accumulates in energized mitochondria to measure the mitochondrial 
membrane potential.  JC-1 at low concentrations (normal cells) is predominantly a monomer 
that yields green fluorescence with emission of 530-545 nm (depolarisation). At high 
concentrations the dye aggregates yielding a red to orange coloured emission of 590- 605 nm 
(hyperpolarisation). This is seen in apoptotic and necrotic cells. An optional dead cell dye, 7-
AAD, is also included for discrimination between apoptotic cells and dead cells. Flow 
cytometric analysis of JC-1 fluorescence is best performed using two-dimensional green versus 
red fluorescence plots, where the ratio of green to red fluorescence allows comparative 
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measurements of membrane potential between cell populations which has given a better insight 
into determining the most effective concentration of doxorubicin (DOX) with minimal effect on 
healthy cell viability. 
2.7 Nanoparticle Tracking Analysis 
Samples were diluted 1:50 using sterile-filtered DPBS and the minimum concentration of 
samples was set at 5 ×107 particles/ml. The settings at the capturing stage screen and camera 
gain were 8 and 13 respectively and at the process stage, screen gain and detection threshold 
were set at 9 and 3 respectively. 
2.8 Fluorescent Microscopy 
For fluorescence microscopy analysis, adherent cell samples placed into 12-well plates 
containing 18 mm coverslips were cultured on coverslips at 37 °C with 5% CO2for 24 h. Cells  
were then gently washed twice with PBS and  fixed with 4% paraformaldehyde at 37 °C for 10 
min and mounted on microscope slides with DAPI-VECTASHIELD medium (Vector 
Laboratories Inc. Burlingame, CA) for fixed cells and mounting medium (Agar Scientific, Essex, 
UK) for fixed MVs. Coverslips were mounted on microscope slides and images were collected 
using a fluorescence microscope (1X81 motorized inverted fluorescence microscope, Olympus 
Corporation). The images were processed using Image J software. This technique was used for 
PKH labelling of cells, EVs and to visualise drug transfer via EVs. 
2.9 Western Blot (WB) and Mass Spectrometry Analysis  
2.9.1 Preparation of cell lysates for Western blot analysis 
The bacterial cells were sedimented by centrifugation at 4,000 g for 10 min at RT before lysis. 
OMVs were subjected to a centrifugation of 25,000 g at 4°C prior to lysis. The pellets were 
washed once by careful resuspension in SM buffer by centrifugation. After that, cells were 
counted using a flow cytometer for cells and NTA for vesicles to give a protein concentration 
equivalent to 2 ×105 cells/10 μl.  Bacterial cell and vesicle lysis was performed by resuspension 
of the pellet in B-PER® Bacterial Protein Extraction Reagent from Thermo Scientific 
containing Lysozyme and DNase adhering to manufacturer’s protocol (User Guide: B-PER 
Bacterial Protein Extraction Reagent). The total protein concentration was determined of the 
resultant supernatant (section 2.5.5) and then subjected to sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis. 
2.9.2 Sample preparation for SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Sodium dodecyl sulphate (SDS) sample buffer (2X) was added to samples in a ratio of 1:1 
followed by boiling at 95°C for 4 min.  
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2.9.3 SDS-PAGE Protein Molecular Weight Standards 
As a protein molecular weight standard, pre-stained Protein-marker I (BioRad) was used. 
Prestained markers, ranging from 10 to 250 kDa were used when analysing gels by Western blot 
using the enhanced chemiluminescence (ECL) detection system. Markers were applied by 
loading 7 μl into wells. 
2.9.4 SDS-Polyacrylamide Gel Electrophoresis 
To separate proteins which were denatured by SDS according to their molecular masses, SDS-
PAGE was performed as described (Laemmli, 1970) using the Mini PROTEAN III 
Electrophoresis System (Bio-Rad UK).Ready made TGX gels, 4-20% were used (BioRad UK). 
To perform electrophoresis, the gel was placed into the electrode assembly device inside a 
clamping frame in the tank of the Mini PROTEAN III system. Electrophoresis running buffer 
was added to the inner and outer chambers of the tank and the plastic comb was carefully 
removed. Wells were washed with the running buffer to remove any free unpolymerized 
acrylamide/bisacrylamide. E.coli and E.coli-derived OMV samples (total protein concentration 
added varied according to the sample) were loaded into the wells of the stacking gel using 
loading pipette tips. Electrophoretic separation was performed at 160 V, 3A and 13W for 1h 
until the bromophenol blue front of the SDS sample buffer reached the end of the resolving gel. 
Gels were transferred onto nitrocellulose membrane for Western blotting analysis. 
2.9.5 Western Blotting Analysis 
Proteins separated by SDS-PAGE were transferred to a Hybond C nitrocellulose membrane for 
further analysis using a semidry transfer device (Bio-Rad Sartoblot system). A Hybond C 
nitrocellulose membrane and two pieces of blotting paper (Whatman 3 MM, BioRad) were cut 
to the size of the separating gel. Blotting paper, nitrocellulose membrane and the sandwich- 
blotting cassette were equilibrated in Sartoblot buffer. One piece of blotting paper was placed 
on the cathode plate, and the nitrocellulose membrane was placed on top of the blotting paper. 
The gel was removed from between the sandwich-blotting cassette and placed on top of the 
membrane, and a second blotting paper was also placed on top of the gel. Having removed air 
bubbles, the anode plate, also dampened with the Sartoblot buffer was used to complete the 
sandwich. Electroblotting was carried out at 15V for 1 h. 
2.9.6 Immunochemical Protein Detection using the ECL System 
Western blotting was performed as described above using hybond C nitrocellulose membrane 
(Amersham Biosciences). The membrane was incubated in blocking buffer for 1 h at RT on a 
shaker. Following blocking, the membrane was rinsed with PBS-T (PBS with 1% v/v Tween20) 
and incubated overnight at 4°C on a shaker with the primary antibody at the desired dilution. 
Three 10 min washing steps with PBS-T were performed and the membrane was incubated with 
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isotype matched HRP-conjugated secondary antibody in the desired dilution for 1 h at room 
temperature on a shaker. After three 10 min washes with PBS-T, visualization was performed 
using ECL system (Amersham Pharmacia). The ECL solutions (reagent A and B) were mixed at 
equal volumes and the membrane was incubated with the mixture for 2 min at RT and 
chemiluminescence detected using the UVP ChemiDoc-It system (UVP systems, UK). 
2.10 Liquid Chromatography-Mass Spectrometry (LC-MS/MS) 
Proteomics experiments were performed using mass spectrometry as reported (Rajeeve et al., 
2014, Casado et al., 2013). In brief, E.coli protein complexes were digested into peptides using 
the protease inhibitor trypsin. Peptides were desalted using C18+carbon top tips (Glygen 
Corporation, TT2MC18.96) and eluted with 70% acetonitrile (ACN) in 0.1% formic acid.  
Dried peptides were dissolved in 0.1% TFA and analysed by nanoflow liquid chromatography 
(ultimate 3000 RSL nano instrument) coupled on-line to a tandem mass spectrometer (Q 
Exactive plus, Thermo Fisher Scientific). Gradient elution was from 3% to 35% buffer B in 
120 min at a flow rate 250nL/min with buffer A being used to balance the mobile phase (buffer 
A was 0.1% formic acid in water and B was 0.1% formic acid in ACN) . The mass spectrometer 
was controlled by Xcalibur software (version 4.0) and operated in the positive mode. The spray 
voltage was 1.95 kV and the capillary temperature was set to 255ºC. The Q-Exactive plus was 
operated in data dependent mode with one survey MS scan followed by 15 MS/MS scans. The 
full scans were acquired in the mass analyser at 375- 1500m/z with the resolution of 70 000, and 
the MS/MS scans were obtained with a resolution of 17 500.  
MS raw files were converted into Mascot Generic Format using Mascot Distiller (version 2.5.1) 
and searched against the SwissProt database (release December 2015) restricted to E. coli 
entries using the Mascot search daemon (version 2.5.0). Allowed mass windows were 10 ppm 
and 25 mmu for parent and fragment mass to charge values, respectively. Variable 
modifications included in searches were oxidation of methionine, pyro-glu (N-term) and 
phosphorylation of serine, threonine and tyrosine.  
The mascot result (DAT) files were extracted into excel files for further normalisation and 
statistical analysis. 
2.11 Microbiology Techniques 
2.11.1 Preparation of Agar Plates 
Twenty five grams of Müller Hinton Agar was dissolved in 500 ml of distilled water and shaken 
well. The medium was autoclaved for 15 min at 121 °C, and then allowed to cool. Plates were 
prepared in a laminar flow cabinet.  Initially plates were labelled with the type of medium and 
date. The medium was thoroughly mixed by shaking the bottle prior to pouring and then poured 
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into plates and left to solidify for a maximum of 1h. These were then taped up firmly with 
autoclave tape and incubated overnight.  
After 24 h the plates were checked for any growth. If growth was seen these were autoclaved 
and the rest of the plates placed in the fridge after thorough sealing to use for future experiments.  
2.11.2 Preparation of Müller Hinton Broth 
Eleven grams of Müller Hinton powder was dissolved in 100ml of distilled water and shaken 
well until the contents were fully dissolved. The medium was autoclaved for 15 min at 121 °C 
(15 psi), and then allowed to cool before using in experiments.  
2.12 Transmission Electron Microscopy 
In advance, 400 mesh copper grids with carbon films deposited on them were cleaned via glow 
discharge for 1.5 min on a PELCO easiGlow™ Glow Discharge Cleaning System, Ted Pella. 
Samples were prepared by applying 10 μL to the grid (OMVs, 10-3 lambdaphage and the 
phage-OMV mixture as three different samples) and incubated for 2 min. The grids were then 
washed 5 ×with 50 µl of 1% aqueous uranyl acetate. The last drop was left to incubate on the 
grid for 1.5 min before being wicked off by torn filter paper. Grids were left to dry for 5 min 
before being viewed. Micrographs were taken with a JEOL JEM 1230 transmission electron 
microscope operated at 80 kV at a range of magnification mainly around a magnification of 
80,000 to 100,000. Digital images were recorded on a Morada CCD camera and processed via 
iTEM both from EMSIS. 
2.13 Statistical Data Analysis 
Statistical analysis for all data presented was performed by the unpaired t-test for repeated 
measures using GraphPad Prism version 8.0 for Windows (GraphPad Software, San Diego, 
USA).Statistical correlations between data values were also determined using GraphPad Prism 
software. Differences giving a value of P < 0.05 with confidence interval of 95% were 
considered statistically significant. 
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3.0 Pharmacological Inhibition of Microvesicle Biogenesis and Release 
3.1 Introduction 
The metastatic prostate cancer PC3 cells are adherent cells that grow rapidly in the presence of 
suitable growth conditions. It was essential from the outset to determine the growth rate of these 
cells. Revisiting the EV isolation protocols, many of which had been established at the Cellular 
and Molecular Immunology Research Centre (CMIRC) was essential to adhere to the latest 
advances in the EV field. As a result, experiments to isolate EVs (exosomes and microvesicles) 
from PC3 cells were carried out altering the speed and the duration of centrifugation.  
Much recent research on EVs has focused on taking into account their release from cancer cells 
and the possible influence of their biogenesis on the effectivity of cancer therapy. To optimise 
the effectiveness of chemotherapy, it is essential that the drug is retained within the target cell 
for the optimum duration. This is directly influenced by microvesiculation, so it is important 
that EV release is halted to ensure minimum expulsion of the drug. To this aim it is crucial that 
effective EV inhibitors are used in experiments to investigate the efficiency of anti-cancer drugs. 
Therefore, a set of experiments was designed to study the effect on cells stimulated to release 
EVs with (2'(3')-O-(4-Benzoylbenzoyl) adenosine-5'-triphosphate tri(triethylammonium) salt 
(BzATP). BzATP is an agonist of purinergic receptor P2X7. Triggering of P2X7 by BzATP 
induces phosphatidylserine (PS) externalization and membrane blebbing, increasing EV 
release(MacKenzie et al., 2001).  
Nicotine has previously been used as anEV inhibitor by CMIRC (Grant et al., 2011)  so it was 
interesting to revisit the idea with some modifications. The substance is a naturally occurring 
alkaloid in organic plants such as aubergine and tomatoes. Interestingly high abundance in the 
tobacco plant makes its presence and involvement more apparent in carcinogenesis(Sanner and 
Grimsrud, 2015b). Cigarette smoke promotes cancer cell survival and metastasis in many 
tumours such as breast, lung and colon.  Since nicotine is a naturally occurring product and 
present in vegetables it cannot be harmful when consumed in lower quantities. The detrimental 
effect of cigarette smoke is not only due to nicotine but a contribution of more than 5,000 
chemicals (Talhout et al., 2011). As a result it was interesting to know whether nicotine can play 
a role in cancer immunotherapy if used in minute concentrations.   
3.2 Methods 
3.2.1 Determining the PC3 Growth Rate 
PC3 cells were maintained as described earlier (section 2.4.1). Cells were seeded in triplicateat 
3.8 × 105 /well in a 12-well microtitre plate in the presence of 1.5 ml of complete growth 
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medium/well. The day of setting up the experiment was taken as day 0 and the cell viability was 
checked from day 3 to day 7 using the Guava Viacount assay as described before (section 2.6.1). 
3.2.2 Revisiting EV Isolation Techniques 
PC3 cells were maintatined as described in 2.4.1. 24 h before the experiment, the cells were 
maintained in serum-free RPMI 1640 at 37°C in 5% CO2. Cells were seeded in triplicate at 3.8 
×105 /well in a 12-well microtitre plate in the presence of 1.5 ml of serum-free RPMI/well and 
incubated for 48 h. EVs were isolated as described in 3.5.1 with the exception of centrifuging 
the samples initially at different speeds (5000 g, 10,000 g, 15,000 g, 20,000 g and 25,000g) for 
2 h after the first step of 4,000 g centrifugation for 1h. The experiment was repeated twice and 
the second experiment with a different range of speeds (5,000 g to 15,000 g) was carried out. 
Furthermore, a third experiment was designed to evaluate the optimum duration of 
centrifugation. PC3 cells were maintained as described in 3.4.1. 24 h before the experiment, the 
cells were maintained in serum-free RPMI 1640 at 37°C in 5% CO2. Cells were seeded in 
triplicate at 3.8 ×105 /well in a 12-well microtitre plate in the presence of 1.5 ml of serum-free 
RPMI/well and incubated for 48 h. EVs were isolated as described in 2.5.1 with the exception of 
centrifuging the samples initially at 4,000 g for 1h followed by centrifugation at 13,000g for 
30min, 60min, 90min and 120 min respectively. EV count was determined via Guava 
ExpressPlus. 
3.2.3 EV inhibitors 
3.2.3.1 Optimum concentration of BzATP to stimulate EV release 
The adherent prostate cancer cells, PC3 were maintained in complete growth medium 
containing RPMI and 10% Fetal Bovine Serum. Then 24 h before the experiment the cells were 
maintained in serum-free RPMI 1640 at 37°C in 5% CO2. Cells were washed and resuspended 
in pre-warmed serum-free RPMI and seeded in triplicate at 3.8 ×105 cells/well in a 12-well 
microtitre plate. The cells were treated with 100 µM and 300 µM of BzATP and incubated for 
30 min and 60 min respectively. Cell viability and EV production was determined using Guava 
Viacount and Guava ExpressPlus respectively.  
3.2.3.2 Effect of potential EV inhibitors on Microvesiculation 
Cells were pre-treated as stated before and washed and resuspended in pre-warmed serum-free 
RPMI and seeded in triplicate at 3.8 ×105 cells/well in a 12-well microtitre plate. EGTA 
(1.5mM), Bisindolylmaleimide-I (10 µM), Imipramine (25 µM), Y27632(1 µM), D-pantethine 
(1 mM) and Chloramidine (50 µM) were added separately and incubated for 1 h at 37°C in 5% 
CO2.  At the end of the first incubation, the cells were washed and 300 µM EV stimulator, 
BzATP was added and further incubated for 30 mins at 37°C in 5% CO2. The experiment was 
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repeated thrice and the EV count was determined using the Guava EasyCyte flow cytometer 
(Guava Technologies, UK)   which was further confirmed by using NTA analysis (Nanosight 
LM10). Annexin V staining was performed to confirm the MV release. Guava ViaCount was 
used to investigate the effect of using these reagents on cell viability. 
3.2.4 Nicotine plays a role in EV Inhibition 
Cells were pre-treated as stated before and washed and resuspended in pre-warmed serum-free 
RPMI and seeded in triplicate at 3.8 ×105 cells/well in a 12-well microtitre plate. The cells were 
treated with different concentrations of nicotine. Cell viability and EV concentration was 
determined using Viacount on the NucleoCounter® NC-3000™ (Chemometec) and the BCA 
assay respectively where EV protein concentration was calculated using the Beer- Lambert’s 
law. The results were also confirmed by performing nanosight tracking analysis (NTA). 
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3.3 Results 
3.3.1 Growth rate of PC3 cells 
It was essential to carry out the growth curve to obtain an idea about the doubling time and the 
point where natural death starts occurring in the experimental set-up (Figure 3.1). In this way 
the duration to be used for cytotoxicity experiments was determined. Furthermore, it was 
important to visualise whether EVs derived from PC3 cells carry the parent cells’ characteristics. 
Therefore, immunostaining of PC3 cells was performed using CD markers and visualised on the 
NucleoCounter® NC-3000™ (Chemometec) as shown in (Figure 3.2). Furthermore, PKH 
labelling of PC3 cells and PC3-derived EVs was visualised using fluorescent microscopy 
(Figure 3.3). 
 
 
Figure 3.1 PC3 growth curve.The lag phase was between days 3 to 4 followed by a rapid increase in 
growth. The highest growth was recorded at day 5 which eventually declined by day 7. The doubling time 
was 23.19 h. 
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3.3.2 Immunostaining 
3.3.2.1 Immunostaining of PC3 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Immunostaining of PC3 cells. PC3 cells were stained with FITC-labelled antibodies. A, 
PC3 cells show expression of CD58 and in B of CD29. Nuclei are counter-stained blue using DAPI. 
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3.3.2.2 PKH labelling of PC3-cells and PC3- derived EVs 
 
 
Figure 3.3 PKH labelling of PC3 cells and PC3-derived EVs.A, PKH26- labelled PC3 cells.B, PKH26- 
labelled PC3-EVs. 
 
 
A 
B 
50 
 
3.3.3 EV Isolation 
 
Figure 3.4 25,000 g maximises EV isolation. A, The initial experiment was designed to compare the 
different speeds of centrifugation. The samples were centrifuged at different speeds for 1h and the above 
data was obtained. 25,000 g resulted in the highest EV count (p= 0.0163). B, Centrifugation at lower 
speeds facilitated the isolation of MVs. However as the study focuses on the total EV population 25,000 g 
was used in future experiments. The experiment was repeated three times and the data presented are mean 
± SEM of the results.  
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3.3.3.1 Optimisation of the Centrifugation Speed Resulting in a higher yield of EVs 
Revisiting the isolation techniques was essential to understand the protocols used in the EV 
field. The range of centrifugal force used in (Figure 3.4A) was utilised to match those generally 
used among EV researchers and 25,000 g which was previously used in our lab as well as many 
other labs for isolation. 25,000 g resulted in the highest EV count (43.02% greater compared to 
the lowest EV release at 15,000g, p=0.0163) which suggested that such EV isolations need to be 
carried out at lower speeds.To further investigate the optimum speed for MV isolation the 
experiment was repeated at a broad range of lower centrifugation speeds. Figure 3.4B depicts 
that 13,000 g results in a maximal MV count. However, 25,000 g was used throughout this 
study as it focuses on the total population of EVs.  
EV isolation has been carried out for various durations by researchers and it was evident that 
spinning cell culture supernatants for long periods yielded a lower percentage of vesicles. Since 
spinning for 120 min was the standard in our lab, it was essential to revisit this parameter of our 
protocols as well. Figure 3.5 represents the data from this experiment. 
3.3.3.2 Optimisation of the Duration of Centrifugation Results in a higher yield of 
Microvesicles 
Centrifugation maintained at 13,000 g for 90min resulted in higher EV counts although it was 
even significantly rasied after 60min of centrifugation at 80.84% (p=0.0001) of the maximum 
yield obtained after 90 min. Spinning for 120mins resulted in an EV count 52.41 % (p<0.0001) 
lower than at 60 min and 56.11% (p<0.0001) lower compared to 90min. This further supported 
that centrifugation for prolonged durations lowers the yield obtained.  Therefore, all EV 
isolations in this study were performed at 13,000 g for 60 min (Figure 3.5). 
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Figure 3.5 Centrifugation at 60min was considered to be ideal for EV isolation. The EV count was 
significantly higher at 90 min of centrifugation compared to 60 min (p=0.0131). Standard centrifugation 
duration of 120min resulted in a lower EVcount to that obtained at 60min (p=<0.0001). * = significance 
to control (0 min) and # = significance compared to 60min. Experiments were carried out thrice and the 
data presented are mean ± SEM of the results. 
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3.3.4 EV Inhibitors 
3.3.4.1 Pharmacological Stimulation of EV release 
Using an EV stimulator was deemed important to increase the release of EVs in order to be able 
to observe any inhibition of MV release. However, it was crucial to choose the optimum 
concentration of BzATP that should not directly affect the cell viability as it should not interact 
with the drug treatments in future cytotoxicity assays. It was evident that using 300 µM for 30 
min was ideal. From this work represented in Figure 3.6A it was clear that using 300 µM of 
BzATP did not adversely affect the viability of PC3 cells, even after 1h incubation. Compared 
to untreated PC3 cells, the levels of released EVs increased in a dose-dependent manner. The 
EV count was 68.75% higher upon stimulation for 1h. Treatment with 100 µM for 30 min was 
significantly higher than the untreated control by 74.07% (p<0.0001). However after treating 
with 300 µM BzATP for 30min the EV count was 83.89% higher than the untreated control 
(p<0.0001) which was also 37.88% (p<0.0001) higher than for cells treated  with 100µM 
(Figure 3.6B). 
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Figure 3.6 Stimulation of PC3 cells with300 µM of BzATP for 30min increased microvesiculation. 
A, % Cell viability was reduced when the cells were treated with BzATP for 60 min as opposed to 30 min. 
Therefore 30min was considered to be the standard duration of stimulation. B, EV count was significantly 
higher (**** p<0.0001) in the presence of 300 µM. 
 
 
 
C
on
tr
ol
 
10
0
M
 B
zA
TP
30
0
M
 B
zA
TP
0
10
20
30
40
50
60
70
80
90
100
%
 C
e
ll
 V
ia
b
il
it
y
30mins post Incubation
1hr post Incubation
Effect of BzATP stimulation on PC3 Cell Viability
C
o
n
tr
o
l
1
0
0

M
3
0
0

M
0
51 0 6
11 0 7
1 .51 0 7
21 0 7
                 C o n c e n t r a t io n  o f  B z A T P
N
o
. 
o
f 
E
M
V
s
/m
l
****
****
E ffe c t  o f B z A T P  s t im u la tio n  o n  P C 3 -c e ll d e r iv e d  E M V s
A 
B 
55 
 
 
3.3.4.2 Cl-amidine and Bis-I are more potent inhibitors of EV release 
Before testing pharmacological agents for their capacity to inhibit EV release, it was important 
to ensure that they did not in their own right adversely affect cell viability. To this aim, the 
ViaCount assay (using two DNA-binding dyes, one nuclear the other a viability dye) (Figure 
3.7A) showed that the viability of cells in the presence of each reagent was 80% or above with 
the exception of pantethine which resulted in 25% viability. The presence of 50 µM 
Chloramidine (Cl-am) and 10µM Bisindolylmaleimide-I (Bis-I) resulted in the maximal EV 
inhibition resulting in 95% and 96.2% reduction respectively (Figure 3.7B). However, all the 
reagents used resulted in a clear inhibition. This is suggestive of their involvement in different 
pathways of EV biogenesis that can be used as individually or in combination to develop strong 
EV inhibitors. 
Nanosight results (Figure 3.7 and 3.8) further confirm the flow cytometry (FCM) results. The 
presence of 50 µM Cl-am and 1mM Pantethine resulted in the maximal EV inhibition (98% and 
99.2% respectively). However, all the reagents used resulted in a clear inhibition. This further 
suggests the importance of using them to improve the cytotoxic effect of drug treatment, in the 
case of cancer therapy. 
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Figure 3.7 Bisindolylmaleimide-I and Chloramidine are more potent inhibitors of EVs. A, The viability assay 
clearly demonstrated that the reagents used in this experiment had no detrimental effect on the cell viability. B, The 
flow cytometry values obtained were compared to the control and a significant inhibiton of EV release (*** p<0.001, 
**** p<0.0001) was seen with respect to all the reagents used in the experiment. C, Annexin V staining confirmed 
that the majority of vesicles identified and counted in the study were MVs. 
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3.3.4.3 D-Pantethine and Cl-amidine inhibit EV release most effectively compared to 
other candidate EV inhibitors 
 
 
 
Figure 3.8 D-Pantethine and Cl-amidine are the most potent EVinhibitors.The 
concentration values of EVs released obtained by nanosight tracking analysis for D-Pantethine 
and Chloramidine were compared to the control and a significant inhibition of EV release (*** 
p<0.001) was seen with respect to all the reagents used in the experiment. There was however 
significant reduction in EV concentration in the presence of all other inhibitors used in the 
experiment. EGTA (34%) and Bisindolylmaleimide-I (3%) were lessinhibiting than 
Chloramidine but was more potent compared to Y27632 by 88% (p=0.0009). Y27632 reduced 
the EV concentration by 28% compared to the untreated control. The experiment was repeated 
three times and the data presented are mean ± SEM of the results. 
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Figure 3.9 Nanosight tracking Analysis (NTA) plots of the reagents used.The concentration of the 
particles that ranged in size between 100 nm-500 nm was taken into account. The particles outside this 
size range were not included to avoid misrepresentation of results such as smaller particles corresponding 
to exosomes and larger particles to EV aggregates or apoptotic bodies. 
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3.3.4.4 Nicotine dose-dependently inhibits the release of EVs from PC3 cells 
Previously at CMIRC a small clinical study of 39 volunteers (Grant et al., 2011), showed 
smokers to have significantly lower plasma EV levels than non-smokers. This was confirmed in 
another small study which also looked at changes in miRNA signatures (Badrnya et al., 2014). 
Following on it was found that nicotine could inhibit EV release from THP-1 pro-monocytic 
leukaemic cells significantly at concentrations of 50 and 100 µM.  
Carrying on from the study, it was interesting to see whether the results obtained were 
reproducible. Figures 3.10 and 3.11 summarise the results from the experiment. The EV 
protein concentration with respect to nicotine was calculated using the BCA assay (Figures 
3.10B and 3.10C). EV inhibition was seen throughout the experiment in the presence of 
nicotine. The highest concentration of nicotine used in the study resulted in a 24.21% reduction 
in cell viability. Cells treated with 50 µM nicotine in the presence of BzATP strongly inhibited 
EV release by 63.79% (p=0.0001) compared to the control and 75.45% (p<0.0001) in the 
presence of BzATP alone. Since there was no significance in results between 25 µM and 100 
µM, the lowest concentrations (25 µM and 50 µM) were used to treat the recipient cells in 
future apoptosis studies. 
 
Nanosight Tracking Analysis of the nicotine experiment resulted in similar findings (Figure 
3.11A). 10 µM to 75 µM caused significant EV inhibition when compared to both the untreated 
control and the EV stimulator. The least inhibition was in the presence of 10 µM with only 
29.37 % reduction (p<0.0001) compared to control and 43.89 % (p=0.0236) compared to 
stimulation. Nicotine treatment at 75 µM resulted in the highest significant inhibition being 
79.72 % (p<0.0001) compared to control and 83.89% (p<0.0001) compared to BzATP with no 
detrimental effect on cell viability (Figures 3.11A and  3.11B). 
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Figure 3.10 Nicotine is a strong EV inhibitor. A, Nicotine at lower concentrations doesn’t affect the 
cell viability. B-C, EV stimulation was apparent in the presence of BzATP. 25µM to 100µM of nicotine 
portrayed significant inhibition of EV protein concentration. 100µM reduced the EV protein 
concentration by 78.60% which was significantly higher than using 50µM which only reduced by 54.98% 
(p=0.0046). Cells were at least 78% viable in the presence of all variables of Nicotine. The average of 
three independent experiments carried out in triplicates has been considered. 
A 
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Figure 3.11 Effect of Nicotine on EV release.A, Nicotine demonstrates strong inhibitory 
activity against EV secretion. 10 µM, 25 µM and 75 µM showed significant inhibition 
(p<0.0001). However, 25 µM resulted in the maximum inhibition of 91.6% (p=0.0007). B, 
Nicotine doesn’t seem to affect the healthy cells as it resulted in at least 80% viability. 
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3.4 Discussion 
The doubling time of PC3 cells was shown to be 23.19h (Figure 3.1) which was useful to plan 
subsequent experiments involving apoptosis assays. The standard for EV isolation was 
established as 13,000 g for 1h (Figures 3.4A, 3.4B and 3.5). This resulted in a higher yield of 
less contaminated EVs. PC3 cells upon stimulation with 300 µM of BzATP for 30min generated 
a high EV count which was apparent through flow cytometry and NTA results (Figures 3.7and 
3.8). 
All the reagents used in the later stage of the experiment resulted in clear EV inhibition 
(Figures 3.7, 3.8, and 3.9). EGTA is a calcium chelator that mops up  intracellular Ca2+ (Xiong 
et al., 2012) leading to a decrease in intracellular calcium concentration which prevents EV 
release. Activation of Protein Kinase C (PKC) allows the exposure of phosphatidylserine (PS) 
in the outer membrane driving EV release. Bis-I is a PKC inhibitor which prevents the 
activation and the externalisation of PS (Smith and Hoshi, 2011) thereby inhibiting the EV 
release. On activation of the ATP receptor P2X7, EV shedding is associated with rapid 
activation of A-SMase which moves to the outer leaflet of the plasma membrane. Imipramine is 
an inhibitor of A-SMase thus inhibiting EV release. D-pantethine is a dimer of a pantothenic 
acid linked by a disulphide cystamine. It blocks the translocation of phopatidylserine (El-Assaad 
et al., 2014). This non-externalisation of PS inhibits microvesiculation. It has been shown to 
reduce vesicle formation in mice infected with malaria compared to that of non-pantethine 
treated but interestingly there was no effect on vesicle formation in mice that were not infected 
with malaria (Watanabe et al., 2007). Y27632 inhibits Rho-associated, coiled-coil containing 
protein kinase (ROCK), which influences the redistribution of actin-cytoskeletal changes and 
regulates the apoptosis induced EV release (Li et al., 2012). Inhibition by Y27632 prevents the 
activation of Rho A which in turn abrogates EV biogenesis. PAD2 and PAD4 expression levels 
and the deimination of cytoskeletal actin are increased during microvesiculation(Kholia et al., 
2015). Pharmacological inhibition of PAD enzyme activity using Cl-am significantly reduced 
EV release. 
Cl-amidine, Bisindolylmaleimide-I and D-pantethine resulted in maximum inhibition of EV 
release as determined by flow cytometry and nanosight tracking analysis respectively (Figures 
3.7B and Figure 3.8). However D-pantethine affected the cell viability which was confirmed to 
be 25% suggesting there can be a detrimental effect on neighbouring healthy prostate cells 
(Figure 3.7A). Although pantethine is unknown to have toxic effects (Brunetti et al,. 2014), its 
high lipid solubility compared to other reagents used in the study could explain the low cell 
viability. There is an increased tendency to penetrate healthy cells and create an adverse effect. 
Similarly, the more potent inhibitors showed increased hydrophobic properties meaning that 
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they can easily penetrate the cell membrane compared to hydrophilic reagents (Table 
1) .Therefore the results were suggestive of potential use of both chloramidine and 
bisindolylmaleimide-I either individually or in conjunction to inhibit EV release in recipient 
cells to directlyminimise drug efflux. The minimal effect on cell viability and the high rate of 
inhibition makes it more suitable for these reagents to be used either alongside the classic 
inhibitors or as novel EV inhibitors in future experiments.   
Nicotine has been shown to reduce the EV count previously (Grant et al., 2011) . Experiments 
presented in 3.2.3.4 were designed to establish the optimum concentration of nicotine that can 
be used on recipient cells to inhibit microvesiculation. The presence of 25 µM and 50 µM 
nicotine resulted in maximum inhibition (Figure 3.9B and Figure 3.9C) with minimal effect on 
cell viability (Figure 3.9A).This supports Grant et al. 2011’s findings that 50 µM nicotine 
inhibits EV release(Grant et al., 2011) . Opinions can be raised against this phenomenon as it is 
well known that cigarette smoke is carcinogenic developing lung cancer. Nicotine is known to 
be a promoter of cancer (Sanner and Grimsrud, 2015a) but other elements of tobacco increase 
the tumorigenecity of cigarette smoke. Nicotine content per cigarette on average is 1.2 mg; the 
smoker will absorb around 0.1 mg of nicotine from it which can increase addiction to cigarette 
smoke. The concentrations used in the study (2 5µM = 0.0045mg/ml and 50 µM = 0.0081mg/ml) 
represent smaller quantities compared to the average nicotine content of a cigarette. Therefore it 
is arguable that the effect nicotine has on promoting metastasis under experimental settings is 
minimal compared to the inhalation of a high quantity of nicotine. Nanosight enumeration of 
EVs released further proves that nicotine is a strong EV inhibitor. 
Also, there has been research carried out to understand the effect of nicotine on cell viability. A 
study conducted by Silva and colleagues compared the effect of cigarette smoke condensate and 
nicotine on cell viability in gingival wound healing. Here, the results clearly state that nicotine 
does not alter the cell viability in gingival mesenchymal cells (Silva et al. 2012).  In contrast, 
another group reported that nicotine did affect the cell growth and migration of cementoblasts. It 
further clarified that nicotine induced inflammatory cytokines and ROS by cementoblasts (Chen 
etal. 2015). Therefore, there are mixed thoughts on the effect of cell viability. However, our 
findings have clearly shown that although it is not detrimental, using nicotine can affect the cell 
viability.There was a progressive decrease in cell viability with the use of different 
concentrations of nicotine which plateued around 80%. The nicotine used in the experiment had 
99.7% purity according to the manufacturer’s data sheet. Treatment of recipient cancer cells 
with nicotine at desired concentrations may directly retain the cancer drug within the 
intracellular environment effectively targeting cancer cell apoptosis. Therefore, further research 
on its use is strongly encouraged in prostate cancer apoptosis studies. 
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Chapter 4: Effect of Inhibiting Extracellular Vesicle 
Release on Chemotherapeutic Drug-Induced Apoptosis 
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4.0 Effect of Inhibiting Extracellular Vesicle Release on Chemotherapeutic Drug-
induced Apoptosis 
4.1 Introduction 
Reagents which were analysed and evaluated as potential EV inhibitors in the previous chapter 
were utilised herein to investigate their role in enhancing drug efficacy. Apoptosis studies in the 
presence of a single inhibitor were performed initially, and carrying on, the effect of 
combination therapy with inhibitors was analysed. In both studies, Bis-I, Nictoine and 
Chloramidine were used as the EV inhibitors. The aim of the experiments was to detect the 
influence of EV inhibitors on the activity of the anti-cancer drug, 5-FU and Doxorubicin (Dox) 
in targeting prostate cancer cells and breast cancer. 
Apoptosis was analysed using the NucleoCounter® NC-3000™ (Chemometec) and different 
assays (Annexin V and VB-48 vitality) were utilised. The initial stages of the study were 
performed by direct addition of the 5-FU into cells that were either pre-treated with 
inhibitor/inhibitors or not. However the later phase of the chapter moves away from this direct 
addition of the anti-cancer drug towards the treatment of cells with EVs carrying the drug. This 
was performed again with or without the pre-treatment of cells with Bis-I and the apoptosis was 
determined using an Annexing V and VB-48 vitality assay for externalisation of PS.  
The apoptosis of DOX-treated cells was analysed using Flow cytometry (Annexin V and 
mitochondrial membrane potential assay), fluorescent microscopy, fluorescent 
spectrophotometry and HPLC. Cl-amidine, a pan-PAD inhibitor was used in this study to 
examine its effect of EV inhibition and PC3 sensitisation to DOX. 
4.2 Methods 
4.2.1 Effect of Nicotine on drug Induced Apoptosis in PC3 Cells 
The cells were maintained as before and were seeded in triplicate at 3.8 ×105 cells/well in a 12-
well microtitre plate with pre-warmed RPMI 1640. They were pre-treated with 25 µM and 50 
µM nicotine for 24 h and 1 µM 5-FU then being added or just treated with 1 µM 5-FU as shown 
in (Figure 4.1). The control well was not treated with either nicotine or 5-FU. It was then 
incubated for 72 h at 37ºC in 5% CO2. After 24, 48 and 72 h, upon addition of chemotherapeutic 
drug, a VB48 Vitality assay was performed using the NucleoCounter® NC-3000™ 
(Chemometec). 
4.2.2 Effect of combinatory EV inhibition withNicotine and Cl-amidine on 5-FU treated 
MCF-7 cells 
In order to confirm that nicotine acts as a pan-inhibitor of EVs, a similar experiment was carried 
out on MCF-7 cells.  The adherent cells were maintained as before, seeded in triplicate at 3.8 
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×105 cells/well in a 12-well microtitre plate with pre-warmed RPMI 1640. They were either pre-
treated with 25 µM and 50 µM nicotine and 50 µM chloramidine for 24 h and 1 µM 5-FU then 
added or just treated with 1 µM 5-FU as shown in (Figure 4.3). The control well was not treated 
with either of the inhibitors or 5-FU. It was then incubated for 72 h at 37ºC in 5% CO2. After 24, 
48 and 72 h, upon addition of chemotherapeutic drug, a VB48 Vitality assay was performed 
using the NucleoCounter® NC-3000™ (Chemometec). 
4.2.3 Effect of synergistic EV inhibition with Bisindolylmaleimide-I and Cl-amidine on 
PC3 cell apoptosis 
The synergistic effect of two or more EV inhibitors can increase the anti-cancer drug efficacy. A 
combination of 10 µM Bis-I and 50 µM Chloramidine was used to test the hypothesis. PC3 cells 
were maintained as before and seeded in triplicate at 3.8×105 cells/well in a 12-well microtitre 
plate with pre-warmed RPMI 1640. They were either pre-treated with 10 µM, 50 µM 
chloramidine or the combination of inhibitors for 24 h and 1 µM 5-FU was added (or the cells 
were just treated with 1 µM 5-FU-EVs as shown in Figure 4.5).  The control well was not 
treated with either of the inhibitors or 5-FU. It was then incubated for 72 h at 37ºC in 5% CO2. 
After 24, 48 and 72 h, upon addition of chemotherapeutic drug, a VB48 Vitality assay was 
performed using the NucleoCounter® NC-3000™ (Chemometec). 
4.2.3.1 Apoptosis study using Bisindolylmaleimide-I and 5-FU 
PC3 cells were maintained as described in 2.4.1. Cells were seeded in triplicate at 
3.8×105cells/well in a 12-well microtitre plate in the presence of 1.5 ml of RPMI 1640/well. The 
cells were treated with different concentrations of 5-FU as shown in Figure 4.7A. The 
remaining wells were pre-treated with Bis-I and one set was washed after 24 h of pre-treatment 
and the other set left unwashed. The cells were then treated with 1 µM of 5-FU. EVs were 
isolated after 24 h post treatment as described in section 2.5.1.  EV concentration was 
determined using a BCA assay as described in section2.5.4 to ascertain the EV protein content. 
The control well had cells that were neither pre-treated with Bis-I nor with 5-FU. The 
experiment was repeated thrice and the average of the results was plotted using GraphPadPrism 
7.0 (Figure 4.7A and B). 
4.2.3.2 Preparing 5-FU-EVs 
A T75 flask of PC3 cells was maintained with RPMI 1640 for 24 h. The cells were then washed 
and 1 µM 5-FU added and incubated for a further 24 h. EVs were isolated according to the 
protocol described in section 2.5.1 and EV proteins were quantified using a BCA assay (section 
2.5.4).  
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4.2.3.3 Effect of Bisin-I activity on PC3 Cell Survival 
A second set of cells was maintained as before and seeded in triplicate at 3.8×105cells/well in a 
12-well microtitre plate in the presence of 1.5 ml of RPMI 1640/well. Two of the experiment 
subjects were pre-treated with Bis-I for 24 h and 1 µM 5-FU bearing EVs isolated previously 
were added with/without washing. After 24, 48 and 72 h upon addition of drug EVs, an Annexin 
V apoptosis assay was performed using the NucleoCounter® NC-3000™ (Chemometec). The 
average of two experiments was used to graphically illustrate the results. 
4.2.4 Effect of Chloramidine activity on DOX treated PC3 cells 
4.2.4.1 Identification of the optimum DOX concentration 
A range of DOX concentrations were tested to determine the effect on cell viability. PC3 cells 
were grown at a concentration of 3.8 ×105 cells/well in a 12- well microtitre plate for 24 h. The 
cells were washed twice with PBS and a mitochondrial membrane potential assay was 
performed according to manufacturer’s instructions (JC-1 - Mitochondrial Membrane Potential 
Assay Kit [ab113850]). The cells were subjected to flow cytometry analysis at the end of the 
incubation time and the results recorded as illustrated in Figures 4.10 and 4.11). 
4.2.4.2 Annexin V assay of PC3-EVs and encapsulation of DOX in EVs 
EVs were isolated from PC3 cells as stated (section 2.5.1) and quantified using a nanosight 
LM10 (section 2.8). An Annexin V assay was performed as described earlier (section 2.5.2). 
DOX encapsulation of EVs was performed as previously described (section 4.2.4.2).  EVs were 
treated with 5 µg/ml DOX for 24 h at 37°C and analysed using a Guava flow cytometer. The 
results are summarised in Figure 4.12.  
4.2.4.3 Effect of Cl-amidine on EV release in PC3 cells 
PC3 cells were maintained for 24 h as before and seeded in triplicate at 3.8×105 cells/well in a 
12-well microtitre plate with pre-warmed RPMI 1640. The cells were incubated for 24 h and 
washed with DPBS post-incubation. Cells were treated with either 50 µM Cl-am, 5 µM DOX, 
50 µM Cl-amidine and 5 µM DOX or left untreated (Figure 4.13). The cells were then 
incubated for 1h at 37°C. The EVs were isolated from the supernatant post-incubation according 
to protocl in section 2.5.1 and quantified using the nanosight LM10 (section 2.8). 
4.2.4.4 Fluorescent Microscopy Analysis of DOX transfer via PC3-EVs 
PC3 cells were maintained as mentioned before. The cells were washed and incubated in two 
T25 flasks at a density of 5×106 cells/flask for 24 h at 37°C. Cells were washed with DPBS at 
the end of the incubation period. One flask was treated with 50 µM Cl-am for 1h at 37°C. At the 
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end of the second incubation, equal numbers of pre-prepared DOX-EVs were added to both 
flasks and incubated at 37°C for 4h and 24h respectively. The proportion of DOX stained cells 
were quantified using fluorescent microscopy as described in section 2.9, the data for which is 
presented in Figure 4.14.  
4.2.4.5 HPLC analysis of DOX internalisation in PC3 
PC3 cells were grown in three T75 flasks at a density of 8 x106 cells/flask for24h. The cells 
were washed with DPBS. One flask was pre-treated with Cl-am for 1h. The cells were washed 
at the end of the incubation. This flask together with another was treated with 50 µg/ml DOX, 
while the remaining flask was left untreated. The cells were incubated for 24 h at 37°C. The 
supernatants were collected from all 3 flasks and EVs were isolated as described elsewhere 
(section 2.5.1). Both cell and EV extractions were prepared by treating with 1× RIPA buffer for 
15 min. Proteins were then precipitated with 400 µl of acetonitrile (ACN), followed by 
centrifugation at 3000 rpm using Lab med centrifuge at room temperature for 15 min. The 
supernatant was filtered through a 0.45 μm filter. Proteins were quantified as before (section 
2.5.5). 
Dionex D3 was used as the HPLC system consisting of a pump with a column from Merck C18 
(4.6 mm × 100 mm). A UV-detector with data processor (Chromeleon software) was used to 
produce specific high resolution chromatographs of the drug.  UV detection for Doxorubicin 
was set at 232 nm. The mobile phase of water: acetonitrile (30:70, pH 3.0, adjusted with 85 % 
phosphoric acid) was delivered at a flow rate of 1.0 ml/min and ambient temperature. The 
mobile phase was delivered by gradient method at ACN gradient of 15 % at 0 min, 25 % at 5 
min, 40 % at 10 min, 70 % at 15 min and 100 % at 20 min. Peak identity was confirmed by 
retention time (RT) of DOX at 2.4-2.6 min. 
The standard stock solution of DOX (1.0mg/mL) was prepared in acetonitrile. The working 
standard solution (10 μg/ml) was prepared by diluting the stock solution in the mobile phase (30: 
70, ACN: water) with ph adjusted to 3.0. A serial calibration line of sample concentrations of 1, 
2.5, 5, 12.5, 25, 50 μg/ml of DOX was prepared by diluting definite aliquots of working 
standard mobile phase.  The results obtained were as shown in Figure 4.15 and 4.16.  
 
4.2.4.6 Fluorescence Spectrometry analysis of the effect of EV inhibition on Sensitisation 
to Chemotherapy 
PC3 cells were prepared as described insection 4.2.5.3. One set of cells was pre-treated with 50 
µM Cl-am for 1h at 37°C and the other left untreated.  Both sets of cells were then treated with 
5 µg/ml of DOX for 24 h and EVs were isolated post-incubation. The cells and EVs were 
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subjected to absorption spectrum analysis at 480nm and fluorescence intensity analysis at 485-
590nm. The results are summarised in Figure 4.17 and 4.18.  
4.3 Results 
4.3.1 Bisindolylmaleimide- I Augments 5-FU Efficacy against PC3 Cells 
A range of different concentrations of Bis-I and 5-FU on the cell viability and EV protein 
analysis were tested.  Protein concentration upon pre-treatment with Bis-I was lowered by 62.19% 
(p=0.0093) under washed conditions and by 52.39% (p=0.0052) without washing following 
treatment with Bis-I. This reduction in protein concentration was not only significant compared 
to the control but significant compared to treatment with 1µM 5-FU alone, which was reduced 
by 72.72% (p<0.0001) in washed and by 64.28% (p=0.0018) in unwashed conditions. 5-FU 
treatment was carried out only for 1h.This further justifies that Bis-I abrogates EV release 
(Figure 4.1A).  However, washing cells after pre-treatment with the inhibitor reduced the death 
cell count by 11.43% compared to unwashed conditions (Figure 4.1B). Using high 
concentrationof the drug was not encouraging therefore 1µM was used as the optimum 5-FU 
concentration in future experiments.  
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Figure 4.1 1µM of 5-FU was the optimum concentration for Apoptosis Assays. A, The 
optimum concentration of 5-FU to be used for the experiments was 1µM where protein 
concentration was significantly higher compared to 10µM by 19.42% (p=0.0594), to 50µM 
by 37.19% (p=0.0124) and to 100µM by 26.03% (p=0.0068). 5-FU alone increased the 
protein concentration by 26.8% (p=0.0283) compared to the untreated control. There was a 
prominent reduction of protein concentration in the presence of bisindolylmaelimide-I. 
Although not significant, protein concentration was reduced by 21.43% when cells were 
washed following Bisindolylmaeleimide-I treatment compared to the unwashed condition 
(p=0.0619). Protein concentration after washing was however significantly reduced 
compared to 5-FU treatment alone by 72.72% (p<0.0001) and by 62.71% (p=0.0093) to the 
untreated control. B, There was no detrimental effect on cell viability following treatment 
with 5-FU and Bisinidolymaleimide-I. 
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4.3.2 Nicotine increases Anti-tumour Drug Effectiveness 
The effect of different concentrations of Nicotine was examined. Both 25 µM and 50 µM 
nicotine treated cells indicated that inhibition of EVs increases the drug efficacy compared to 
treatment with anti-cancer drug (even not in combination) (Figure 4.2). There was a reduction 
of viable cells by 37.56% (p=0.0001) on day 1 in the presence of 25 µM which was further 
reduced by 47.31% (p<0.0001) compared to 5-FU treatment by day 3. Similarly, pre-treatment 
with 50 µM reached the maximum apoptosis of 30.13 %(p<0.0001) compared to sole 5-FU 
treatment. The trend in the results was maintained throughout the 72 h duration but the cell 
viability on day 3 was lower even in the control sample by 38.09% (p<0.0001) suggesting that 
natural cell death occurs after few days. 
Presence of 25 µM nicotine with 1 µM 5-FU resulted in the maximum PI (+ve) dead cells 
compared to the untreated both 2 4h and 72 h post incubation. However, pre-treatment of cells 
with both 25 µM and 50 µM showed a significant increase in apoptosis compared to untreated, 
even in the presence of the drug (p<0.0001) (Figure 4.3). 
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Figure 4.2 Pre-treatment with 25µM nicotine increased 5-FU effect on PC3. % Cell viability 
was lowest in the presence of 25 µM nicotine. There was 45% decrease in cell viability between 
day 1 and day 2 in the presence of 25µM (p=0.0302). This was only less than 12% by day 3 
(p=0.0445). However, effect of 50µM treatment was more prominent between day 2 and day 3. 
The apoptosis was increased by 41.6% (p<0.0001) compared to day 1 and day 2 which was only 
16.61% (p=0.0087). These results suggest that 50µM pre-treatment might be more effective in 
apoptosis studies carried out for longer periods. However, both conditions of nicotine pre-
treatment increased the sensitisation of PC3 cells to 5-FU from day 1. This was less sensitive in 
the presence of 50µM by 24.72% compared to the presence of 25µM nicotine even on day 1. 
Data presented are mean ± SEM of three independent experiments performed in triplicate. ***p< 
0.007; **p< 0.01; were considered statistically significant compared to the control. 
 
 
 
 
 
 
 
75 
 
A: Control       
24hpost-treatment    72h post-treatment   
  
 
 
 
 
 
 
 
B: Nicotine 
24h post-treatment                            72h post-treatment 
 
 
 
 
 
 
 
 
C: 5-FU       
       24h post-treatment                                        72h post-treatment  
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D: 25 µM Nicotine + 5-FU 
24h post-treatment                                           72h post-treatment 
 
 
 
 
 
 
 
 
 
 
E: 50 µM Nicotine + 5-FU  
24h post-treatment    72h post-treatment 
 
 
 
 
 
 
 
 
Figure 4.3 Multiplex assays demonstrating VitaBright-48™ staining following Nicotine pre-
treatment.PC3 cells were treated with 25 and 50 µM Nicotine and 1µM 5-FU as shown in A-E. The 
cells were treated with nicotine and 5-FU for 24h Cells were stained with VB-48™, Acridine Orange 
(AO) and Propidium Iodide (PI) and analysed using the Vitality Assay and a NucleoCounter® NC-
3000™. Scatter plots and histograms were obtained from the NucleoView™ NC-3000™ software. 
Polygons and markers in the displayed plots were used to separate the various cell populations. Plots 
show VitaBright-48™ intensity versus PI intensity. Nonviable cells were gated out based on 
propidium iodide uptake. Plots show VitaBright-48™ intensity versus PI intensity. Nonviable cells 
were gated out based on SYTOX green uptake. 25µM was 24.72% more effective resulting in less 
VB-48+ve cells compared to 50µM pre-treatment even on day 1 (p= 0.0013). However, both 25µM 
and 50µM Nicotine treatment increased 5-FU sensitivity of the cells atleast by 20% (p= 0.0001 and 
(p= 0.0023) 
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4.3.3 Synergistic Effect of Inhibitors Promotes Cumulative Apoptosis in MCF7 Cells 
A combined use of inhibitors was deemed the most potent way of enhancing the apoptotic 
potential of 5-FU on MCF7 cells. Both Cl-amidine and nicotine inhibited EV release. Cl-
amidine pretreatment reduced the cell viability by 89.21% (p<0.0001) compared to 5-FU alone. 
However pre-treatment with 50 µM nicotine was less inhibiting than 25 µM by 10.97%, even on 
day 1. Apoptosis with 25 µM was however significantly higher compared to 5-FU alone which 
was 64.71% (p<0.0001) but reduced by 69.43% (p<0.0001) compared to Cl-am pre-treatment 
on day 1. This was however further reduced to 51.08% (p=0.0010) by day 3. Combination pre-
treatment resulted in the maximum apoptosis throughout the study which was 90.11% 
(p<0.0001) on day 1 and 95.83% (p<0.0001) on day 3 compared to 5-FU alone (Figure 4.4 and 
4.5). The results indicate the synergistic effect of the EV inhibitors in minimising the drug 
efflux therefore increasing their bioavailability. EV results suggest that the effect of nicotine is 
not limited to prostate cancer cells but apparent even in other cell lines which together with the 
data presented in Figure 3.10B suggest that it could be used as an EV inhibitor that improves 
chemotherapeutic efficacy. The trend in the results was maintained throughout the 72-h duration. 
With the cell viability on day 3 being lowered by 49.18% (p<0.0001) even in the absence of 
inhibitors and the drug, this suggested that natural cell death occurred after a few days.   
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Figure 4.4 Combination of EVInhibitors causes 5-FU retaining abilityand causes 
cumulative apoptosis in MCF7. % Cell viability was significantly lower in the presence of the 
inhibitors. Pre-treatment with Cl-am and 50µM Nicotine together resulted in the maximum 
apoptosis throughout the study, 90.11% (p<0.0001) on day 1 and 95.83% (p<0.0001) on day 3 
compared to 5-FU alone. The natural cell death occurred by day 3 which was reduced by 49.18% 
in the absence of drug and inhibitiors. Chloramidine alone was more potent than even the most 
sensitive, 25µM nicotine pre-treatment by 69.43% (p<0.0001) even on day 1 suggesting that 
Chloramidine is more potent as an inhibitor compared to nicotine. Data presented are mean ± 
SEM of three independent experiments performed in triplicate. 
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A: 25 µM Nicotine + 5-FU 
24h post-treatment    72h post-treatment 
B: 50uM Nicotine + 5-FU 
    
 
 
 
 
 
B: 50 µM Nicotine + 5-FU 
24h post-treatment    72h post-treatment 
 
 
 
 
 
 
 
 
C: 50 µM Chloramidine + 5-FU  
24h post-treatment    72h post-treatment 
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D: 5-FU + Inhibitors  
24h post-treatment    72h post-treatment 
 
 
 
 
 
 
E: 5-FU        
24h post-treatment    72h post-treatment 
F: Control  
24h post-treatment    72h post-treatment 
Figure 4.5 Multiplex assays demonstrating VitaBright-48™ staining following Cl-amidine-Nicotine pre-
treatment/priming.MCF-7 cells were treated with 25µM and 50 µM Nicotine, 50µM chloramidine and 1µM 5-FU as shown in 
A-F. The cells were treated with for 24h, 48h and 72h.  Cells were stained with VB-48™, Acridine Orange (AO) and Propidium 
Iodide (PI) and analysed using the Vitality Assay and a NucleoCounter® NC-3000™. Scatter plots and histograms were 
obtained from the NucleoView™ NC-3000™ software. Polygons and markers in the displayed plots were used to separate the 
various cell populations. Plots show VitaBright-48™ intensity versus PI intensity. Nonviable cells were gated out based on 
propidium iodide uptake. Plots show VitaBright-48™ intensity versus PI intensity. Nonviable cells were gated out based on 
SYTOX green uptake. Chloramidine treatment was 69.43% more effective resulting in less VB-48+ve, and more PI+ve cells 
compared to even most sensitive , 25µM nicotine pre-treatment  even on day 1 (p<0.0001). However combinatory pre-treatment 
resulted in the maximum % apoptosis by 90.11% (p<0.0001) compared to 5-FU alone. 
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4.3.4 Bis- I and Cl-amidine shed light for Novel Cancer Immunotherapy 
The outcome of the apoptotic study using Bis-I and Cl-amidine justifies the effectiveness of 
using a combination of inhibitors to enhance the anti-neoplastic effect of pharmacological 
reagents. As portrayed in Figure 4.6 and 4.7 there was a significant decrease in live cells in the 
presence of Cl-am by 87.15% (p<0.0001) on day 1 and 81.05% (p<0.0001) on day 3 compared 
to 5-FU alone. The combination treatment was even more effective even on day 3 by 88.18% 
(p<0.0001) compared to 5-FU alone. However, Bis-I was less potent in inhibiting EV release 
compared to to Cl-amidine (52.40%, p=0.0001) and combination (70.32%, p<0.0001) even on 
day 3 (Figure 4.6). The trend in the results was maintained throughout the 72 h duration but the 
cell viability on day 3 was significantly lower even in the absence of inhibitors and the drug by 
18.11% (p=0.0050) suggesting that natural cell death occurs after a few days.  Comparing these 
results with those presented inFigure 4.4 suggest that Cl-amidine can be used as a pan -inhibitor. 
The data presented suggests that the presence of inhibitors may improve the activity of 5-FU by 
inhibiting its elimination from the intracellular space as manifest by the increase of percentage 
of dead cells  even after 24 h compared to the untreated control cells (Figure 4.7). Overall these 
results indicated the importance of having a combination of EV inhibitors which strongly 
increases the efficiency of the chemotherapy compared to the presence of a single EV inhibitor.  
 
 
 
 
 
 
 
82 
 
 
Figure 4.6 Combination of Inhibitors increases PC3 cell apoptosis. % Cell viability was 
lower in the presence of the inhibitors. % Cell viability was significantly lower in the presence of 
the inhibitors. Overall 5-FU alone reduced the cell viability by 38.55% (p=<0.0001). Pre-
treatment with Bisindolylmaleimide-I and Chloramidine together resulted in the maximum 
apoptosis throughout the study, 90.2% (p<0.0001) on day 1 and 88.18% (p<0.0001) on day 3 
compared to 5-FU alone. The natural cell death occurred by day 3 which was reduced by 18% in 
the absence of drug and inhibitiors. Chloramidine alone was more potent than 
Bisindolylmaleimide-Ipre-treatment by 81.9% (p<0.0001) even on day 1 suggesting that 
Chloramidine is more potent as an inhibitor compared to Bisindolylmaleimide-I. Data presented 
are mean ± SEM of three independent experiments performed in triplicate. 
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A: Bisin-I + 5-FU   
    
24h post-treatment    72h post-treatment 
      
 
 
 
 
  
 
B: Chloramidine + 5-FU 
 
24h post-treatment    72h post-treatment 
 
 
 
 
 
 
 
C: 5-FU + (Bis-I + Chlo)     
24h post-treatment    72h post-treatment    
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D: 5-FU 
24h post-treatment     72h post-treatment 
 
 
 
 
 
 
 
E: Control 
24h post-treatment     72h post-treatment 
  
 
 
 
 
 
Figure 4.7 Multiplex assays demonstrating VitaBright-48™ staining following Cl-amidine-
Bisindolylmaleimide-I pre-treatment/priming.PC3 cells were treated with 10 µM 
Bisindolylmaleimide-I, 50µM chloramidine and 1µM 5-FU as shown in A-E. The cells were treated for 
24h, 48h and 72h.  Cells were stained with VB-48™, Acridine Orange (AO) and Propidium Iodide (PI) 
and analysed using the Vitality Assay and a NucleoCounter® NC-3000™. Scatter plots and histograms 
were obtained from the NucleoView™ NC-3000™ software. Polygons and markers in the displayed plots 
were used to separate the various cell populations. Plots show VitaBright-48™ intensity versus PI 
intensity. Nonviable cells were gated out based on propidium iodide uptake. Plots show VitaBright-48™ 
intensity versus PI intensity. Nonviable cells were gated out based on SYTOX green uptake. 
Chloramidine treatment was 52.40% (p=0.0001) more effective than Bisindolymaelimide-I which was 
even increased in the presence of the combination by 70.32% (p<0.0001) resulting in less VB-48+ve,and 
more PI+ve cells even on day 3.  However,Bisindolylmaleimide-I was strong in sensitising PC3 cells to 
5-FU by at least 75% (p<0.0001) compared to 5-FU alone. 
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4.3.5 Pre-treatment with Bis-I abolish EV release Increasing the Cytotoxicity of 
Anti-cancer Drug-EVs 
Bis-I is a strong EVinhibitor, so it became a prime candidate for examining the effect of 
EVinhibition on 5-FU activity. Addition of 5-FU EVs to the Bis-I pre-treated cells increased 
the apoptosis by 15.31% (p=0.0011) on day 1 which was lower but significant on day 3 by 
10% (p=0.0001) compared to the directtreatment with 1 µM 5-FU-EVs (Figure 4.9). The 
apoptosis was lower when cells were washed after Bis-I pre-treatment by 13.69% (p=0.0043) 
even on day 3. The trend in the results was maintained throughout the 72 h period but the 
cell viability was significantly reduced by 19.19% (p=0.0012) even in the absence of 
inhibitor and chemotherapy suggesting that natural cell death occurs after a few days. 
Washing cells after pre-treatment with inhibitor resulted in the apoptotic cells which were 
51% of Annexin- V (+ve) and 10% PI (+ve).(Figure 4.10). This was however less by 14.46% 
(p= 0.0015) compared to cells that were left unwashed after pre-treatment. This close 
synergy of inhibitor-drug interactioncan elicit a favourable response facilitating effective 
chemotherapy as summarised in (Figure 4.8).   
 
 
Figure 4.8 Schematic representation of the synergistic effect of EVinhibitor and chemotherapy. 
Bisindolylmaleimide-I internalisation increased the sensitisation of PC3 cells to 5-FU therapy. 
However pre-treament left ‘unwashed’ increases the sensitisation by at least by 15% compared to 
‘washed’ condition. The natural synergy between EV inhibitor and chemotherapy is more successful 
in cancer cell sensititsation to effective chemotherapy. 
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Figure 4.9 Presence of Bis-I abolishes EVrelease enhancing the Chemotherapeutic 
Cytotoxicity.Cells were treated with 1µM 5-FU-EVs following Bisin-I pre-treatment. Bisin-I 
pretreated cells were then either washed or unwashed before treating with 5-FU-EVs. % cell 
viability was significantly reduced by 10 % on day 1 which was increased to 15% by day 3 
compared to respective untreated controls. However, pre-treatment of cells with 
Bisindolymaelimide-I had a significant effect on lowering total viable cells by less than 9% 
(p=0.2649) in washed condition by 21% (p= 0.0003) in unwashed condition compared to 
untreated control on day 3. Bisindolylmaleimide-I pre-treatment even was more sensititisng than 
direct 5-FU treatment of the cells. Increased sensitisation increased the apoptosis by 10% on day 
1 (p=0.0001). This trend was however conserved throughout the study. Apoptosis was 
significantly affected in cells which were washed after Bisindolylmaleimide-I pre-treatment. 
The % cell viability was higher than direct 5-FU treatment by 12.5% (p= 0.0362) on day 3. Data 
presented are mean ± SEM of three independent experiments performed in triplicate. **p< 0.05 
was considered statistically significant compared to the untreated control. 
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A.Control      B.  1µM 5-FU  
   
 
 
 
 
 
C. 1µM 5-FU+Bisin-I (Unwashed)   D.  1µM 5-FU+ Bisin-I (Washed) 
  
 
 
 
 
 
 
Figure 4.10 Multiplex assays demonstrating Annexin-V staining following Bisindolylmaleimide-I 
pre-treatment/priming.PC3 cells were treated with 10 µM Bisindolylmaleimide-I, and 1µM 5-FU as 
shown in A-D. The cells were treated for 24h, 48h and 72h. Cells were stained with Hoechst-33342, 
Annexin V FITC conjugate and Propidium Iodide (PI) and analysed using the Annexin V Assay and a 
NucleoCounter® NC-3000™. Scatter plots and histograms were obtained from the NucleoView™ NC-
3000™ software. Quadrants and markers in the displayed plots were used to demarcate the various cell 
populations.  Bisindolymaelimide-I treatment increased the sensitisation of PC3 cells to 5-FU-EVs by 
15.31% (p=0.0011) compared to without Bisindloymaleimide-I treatment. However, there is 10% more 
PI+ve cells in unwashed condition (Plot C) compared to washing after treatment with 5-FU-EVs. This 
suggests that there is atleast a 10% increase in late apoptosis when more time is allowed to absorb 5-FU-
EVs (p=0.0001).    
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Figure 4.11 5µg/ml of DOX was the optimum concentration to treat PC3 cells.A, % 
apoptosis increased with increasing concentration of DOX. 59.7% increase in apoptosis was seen 
in the presence of just 1µg/ml which was increased by 28.65% to reach the maximum inhibition 
of 100% when treated with 5 µg/ml. B, there was no detrimental effect on cell viability on using 
5µg/ml which only decreased by 5.1% compared to the untreated.  * < 0.05 was considered 
statistically significant compared to the control, # <0.05 was considered statistically significant 
compared to 5µg/ml. 
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Figure 4.12 Apoptosis of PC3 cells after treating with different concentrations of DOX. PC3 cells were treated 
with 1-50 µg/ml of DOX and a mitochondrial membrane potential assay was performed using the Guava flow 
cytometer to determine levels of apoptosis. JC-1, a fluorescent cationic dye along with dead cell dye, 7-AAD, was 
used to determine the % polarization/depolarization.  90.55% of cells reached apoptosis when treated with 5 µg/ml 
which reached 99% in the presence of 25 µg/ml. However, there was a rapid increase in apoptosis when treated with 
2 µg/ml which increased by 64.8% resulting in a 71% apoptosis. 
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4.3.6 Optimisation of DOX Concentration to be Used in Apoptosis Studies 
A Mitochondrial membrane potential assay was used to determine the effective concentration of 
DOX in this series of experiments.  The JC-1 green fluorescence increased steadily as the DOX 
concentration increased, clearly exhibiting increased percentage of depolarised cells at higher 
concentrations (Figure 4.12). 90.5% of the cells were affected only at 5 µg/ml of DOX with a 
5.1% decrease in cell viability. This was only 10% less than the effect of 50 µg/ml but the cell 
viability in the presence of the highest concentration was reduced by nearly 10% (p=0.0158) 
(Figure 4.11B). This pointed to the use of  5 µg/ml DOX in future experiments.  
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Figure 4.13 Flow cytometry confirmation of drugs encapsulated in EVs.A,Annexin V labelling 
revealed that 99.64% of the vesicles isolated were Annexin V positive which confirms that most are 
MVs.  B, encapsulation of fluorescent labelled-DOX was carried out followed by a 4h incubation of 
EVs with drug at 37°C. Only 64.8% of the vesicles were labelled with the drug. A positive control of 
free-drug (99.04%) and a negative control of just EV-free RPMI were used to confirm the validity of 
the results.  The experiment was repeated thrice, and the average was noted for final values.   
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4.3.7 PC3-cell derived, annexin-V positive EV Drug Encapsulation 
EVs isolated from PC3 cells were 99.64% positive for Annexin V-FITC labelling (Figure 
4.13A). The EVs were processed for DOX loading and analysed by flow cytometry. Less than 
65% of the EVs were DOX positive which was a 40% decrease compared to the free-drug 
(Figure 4.13B). This was however distinguishable from the DOX-untreated, control EVs. 
4.3.8 Cl-amidine significantly inhibits EV release in PC3 cells 
EV release was significantly inhibited by Cl-amidine up to 99.6% (p=0.0004). In contrast, the 
anti-cancer drug DOX pronouncedly increased the EV release by 97.67% compared to the 
untreated control (p<0.0001). However, Cl-amidine pre-treatment managed to reduce the EV 
release up to 69.63% compared to the DOX only treated (p<0.0001). The outcome remarkably 
encourages the use of EV inhibition in order to increase the sensitisation of cancer cells to 
chemotherapy (Figure 4.14).  
4.3.9 Fluorescence Microscopy analysis of Anti-cancer Drug transfer via EVs 
Figure 4.15 summarises the effect of EV inhibition on the sensitisation to chemotherapeutic 
drug, DOX, delivered via EVs. 4h post-incubation only 5.76% of the Cl-amidine untreated cells 
were stained with DOX which still represented a 42.4% reduction compared to those that were 
stained following Cl-amidine pre-treatment. This was increased significantly after 24 h 
incubation. Less than 65% cells exhibited DOX in Cl-amidine pre-treated cells while only 30% 
of the cells were affected following co-incubation with DOX-EVs. This clearly depicts that Cl-
amidine pre-treatment has increased the sensitisation of the PC3 cells to drug-EVs.   
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Figure 4.14 EV release in the presence of DOX and pan-PAD inhibitor, Cl-amidine. EV 
release was at its highest from PC3 cells when treated with DOX (p<0.0001). In contrast where 
the cells were treated with Cl-amidine, this inhibited the EV shedding by 99.6% compared to 
DOX treatment which was also lower than the untreated control by 81.09% (p=0.0004). 
However, Cl-amidine pre-treatment pronouncedly reduced the EV shedding by 69.63% 
(p<0.0001) compared to Dox on its own. The average of three independent experiments was 
considered.   
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Figure 4.15 Fluorescent microscopy analysis of Cl-amidine pre-treatment sensitising PC3 
cells to DOX-EVs. PC3 cells were incubated with DOX-EVs for 4h and 24h at 37 °C. A, only 
30% of the PC3 cells without pre-treatment of Cl-amidine was labelled with DOX after 24h 
incubation. B, this was increased in Cl-amidine pre-treated cells where 64% of the total cell 
population showed the drug transfer via DOX-EVs.  The experiment was repeated thrice, and 
representative images have been presented. 
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Figure 4.16 HPLC chromatograms of the effect of EV inhibition on DOX retention in PC3 cells. PC3 
cells were treated with 50 µg/ml of Doxorubicin, with a retention time of 2.243 min. EVs were isolated 
following DOX treatment and analysed on HPLC. DOX-treated cells resulted in a 129.292 mAU (20.60% 
of the total) while EVs were of 498.265 mAU which comprised 79.39% of the total. In contrast, Cl-am pre-
treatment resulted in higher retention of the drug within cells (72.14%) while only 27.86% was seen in EVs. 
Isolation was carried out at 233 nm. 
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Figure 4.17 Cl-amidine pre-treatment increases sensitisation of PC3 cells to Doxorubicin. 
In the absence of Cl-amidine pre-treatment, 74% of the drug was absorbed by DOX-EVs 
(p=0.0012) as opposed to the cells. While the Cl-am pre-treatment increased the cellular uptake 
of the drug by 50.68% (p=0.0118). The experiment was repeated thrice, and the average 
considered. * = significance compared to its subset and # = significance compared to the control.   
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4.3.10 HPLC analysis confirms the importance of EV inhibition on the increased Effect 
of Anti-cancer Drug 
A variety of chromatographic conditions and sample preparation methods were experimented 
upon before establishing the used method to achieve optimum conditions for reasonable peak 
separation of the analyte. Figure 4.17 summarises the results that represent the chromatographs 
in Figure 4.16. It was quite apparent that the Cl-am pre-treatment decreased the drug expulsion 
by 61.39% (p=0.0129). There was 74% increase in DOX in EVs in the absence of the pre-
treatment (p=0.0012). More than 78% of the drug was expelled within EVs in the absence of the 
Cl-am pre-treatment (p=0.0015). Interestingly EV inhibition increased the drug retainability by 
50.68% in cells (p=0.018). Untreated cells and EVs were used as the negative control to validate 
the results.  
4.3.11 Fluorescence Spectrometry Analysis further confirms that EV inhibition Increases 
the Effectiveness of Anti-tumour Therapy 
The absorbance and fluorescence intensity in DOX-treated cells and EVs was analysed in the 
presence and absence of Cl-am pre-treatment.  Figure 4.18 undoubtedly shows that there was 
very much less DOX absorbance in cells that were not pre-treated with Cl-am which was 
reduced by 18.67% (p=0.0060) compared to that following pre-treatment. In contrast, 
absorbance in EVs under the same condition had a significant increase of 50.58% (p=0.0022) 
compared to that following pre-treatment. Similarly, apoptotic cells had a reduced absorbance, 
35.33%, following Cl-am pre-treatment. Equally, it was very interesting to see that intensity 
results followed the same direction (Figure 4.19). Fluorescence intensity was higher in the 
presence of Cl-am pre-treatment by 53.16% (p=0.0021). A distinct reduction of 61.54% was 
seen in the supernatant of the pre-treated cells (p=0.0257). The outcome has further underlined 
the significance of EV inhibition on operative chemotherapy. 
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Figure 4.18 Absorbance of DOX by PC3 cells and PC3-EVs analysed by fluorescent 
spectroscopy. A, DOX absorption was higher in Cl-am pre-treated cells by 18.67% compared to 
no pre-treatment (p=0.0060). B, DOX absorbance was higher in EVs in the absence of Cl-am 
pre-treatment (p=0.0022). C, Apoptotic cells had a reduced absorbance post-pre-treatment with 
Cl-am by 35.33%. The experiment was repeated thrice and average ±SEM presented. 
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Figure 4.19 Fluorescence intensity of PC3 cells and supernatant analysed by fluorescence 
spectroscopy. A, High fluorescence intensity was recorded in the Cl-am pre-treated cells compared to 
when it was absent (p=0.0021). In contrast, this was reduced in the supernatant by 41.45% (p=0.0257). B, 
Cells solely treated with DOX, however, had a 69.2% reduced fluorescence intensity compared to the 
supernatant (p=<0.0001). 
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4.4 Discussion 
Conducting apoptosis assays further justified the significance of using EV inhibitors in cancer 
therapy in order to minimise the expulsion of anti-cancer drug, therefore increasing its 
effectiveness. Pre-treatment with nicotine repressed the EV release thereby improving the drug 
effectiveness both with respect to PC3 (Figure: 4.2.and 4.3) and MCF7 cells (Figure: 4.4. and 
4.5). Treatment with 25µM nicotine resulted in a relatively high percentage of propidium iodide 
stained (dead) cells compared with 50 µM nicotine. However, there was substantial apoptosis in 
both PC3 and MCF7 in the presence of nicotine in contrast to the untreated controls. This 
further suggests that nicotine at smaller concentrations can be safely used to advance the 
therapeutic potential of anti-cancer drugs minimising chemoresistance.   
It was important to determine the use of EVs as drug delivery vehicles. Therefore, EVs loaded 
directly with 5-FU were used to target the PC3 cells as shown in Figures 4.1, 4.9 and 4.10. 
Washing cells after pre-treatment with Bis-I resulted in low apoptosis compared to unwashed 
condition. This prolonged EV inhibition through Bis-I in the intercellular environment 
preventing the efflux of 5-FU-EVs from cells causing increased apoptosis. Furthermore, it was 
well established that the inhibition of EVs increases the drug efficacy compared to treatment 
solely with the anti-cancer drug. This phenomenon was further explained through apoptosis 
assays where it was found that the % of annexin-V positive cells increased throughout the 72 h 
period with a greater increase in the presence of Bis-I + 5-FU compared to the other subjects. 
There was a natural decline in viable cells by day 3 of the experiment suggesting natural cell 
death.  
It was essential to test the hypothesis using a second anti-cancer drug with a different mode of 
action. Therefore, Doxorubicin was used in the subsequent array of experiments. Interestingly 
results further confirmed that inhibition of EVs is crucial to maintain a constant intracellular 
concentration of chemotherapeutic drug in order to elicit an effective response against the 
cancer cells. Cl-amidine oncemore was found to be an outstanding EV inhibitor that managed to 
remarkably reduce the EV biogenesis and release. HPLC, fluorescence microscopy and 
fluorescence spectrometry data strongly suggested that EV inhibition increased the 
susceptibility of the cancer cells to DOX. Though changes in drug concentration in cells were 
increased upon EV inhibition and drug was detected in released EVs, these changes were small 
as detected by HPLC and fluorescence microscopy (Figures 4.15 and 4.17) but significant 
enough to be noted. Furthermore, there was success in packaging the DOX into EVs compared 
to producing 5-FU-EVs previously. Enhanced susceptibility of PC3 cells to DOX was shown 
through a range of techniques to demonstrate the importance of EV inhibition in increasing anti-
cancer drug effectiveness. These experiments are very promising, and this approach should be 
used to advance the development of future cancer drug therapy. Various studies have 
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concentrated on packaging vesicles and nanoparticles with therapeutic mRNA and various 
synthetic reagents to target cancer cells (Piktel et al., 2016). Nano-drug delivery can be active or 
passive. Passive drug deliver is based on the fact that tumor vasculature is characterized by 
discontinuous epithelium, impaired lymphatic drainage and reduced uptake of the interstitial 
fluid in contrast to normal blood vessels with firmly sealed endothelium. Subsequent 
accumulation of macromolecules provides the environment supporting the passive transport of 
nanotherapeutics to the target site (Bertrand et al., 2014) while active drug delivery involves the 
binding of ligands on the nanoparticles to surface receptors on target cancer cells (Byrne et al., 
2008, Shah et al., 2013).  Similar studies have shown that anti-cancer drugs such as Docetaxel 
(DTX) and Methotrexate (MTX) have been carried in EVs in these particular cases also being 
quantified through HPLC. The inhibition of the release of such drug-EVs was targeted in 
xenograft models of prostate cancer with the result of decreasing the rate of increase of the 
implanted tumour as well as increased apoptosis(Jorfi et al., 2015). Pascucci and co-workers 
have demonstrated that Mesenchymal stromal cells (MSCs) are able to package and deliver drug 
through their EVs. This was shown using a MSC murine cell line, SR4987. The release of 
paclitaxel (PTX) from SR4987 in the conditioned medium (CM) was checked by HPLC and the 
anti-tumor activity of both CM and EVs was tested on the human pancreatic cell line CFPAC-1 
(Pascucci et al., 2014).  A similar study on exosome mediated drug delivery has been reported 
where DOX was packaged into exosomes through electroporation and transferred to αv integrin-
positive breast cancer cells in vitro as demonstrated by confocal imaging and flow cytometry.  
The study also showed that the intravenous application of drug-exosomes increased the 
specificity of the target therapy without overt toxicity (Tian et al., 2014).  
HPLC data can be improved by using alternative methods. The mobile phase can be changed 
accordingly to obtain more clean peaks which can improve the quality of the results. Also, the 
cells can be treated with the inhibitor and the drug for an extended duration which will increase 
the drug retainability in the cells giving rise to distinguishable results. Using high-sensitivity 
HPLC detectors could improve the performance of peak detection and integration for small 
quantities of materials being analysed. Also using a column with a smaller diameter will enable 
the analysis of small quantities of the sample which will be an advantage in such studies. 
Locatelli and peers have suggested other improvements, specifically that ‘the most common 
choice for improving chromatographic performance is the use of columns packed with low-
diameter particles to obtain efficiency improvement, optimal velocity, and mass transfer’ to 
prevent the pressure build up in the column (Locatelli et al., 2012). 
In addition, relative intensities and absorption spectra are hampered by the sensitivity of the 
absorption and fluorescence properties of most chromophores to their microenvironment. Hence 
these give rise to environment-specific results (Resch-Genger et al., 2005) which can result in 
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inaccuracy. Therefore, it is important to standardise the methodology to improve the quality 
control of the procedure and increase the reliability of the results.  
It must be noted that whilst using drug-EVs elicits an apoptotic response it is less compared to 
direct addition of the drug either in the presence or absence of the inhibitor/inhibitors. However, 
this can be overcome by using an EV inhibitor at the same time. This not only increases the 
susceptibility of the cancer cells to the drug but allows the use of very low concentrations of the 
drug to stimulate the same response in the cells. Of course, the additional benefit of 
encapsulating the drug within an EV is the protection afforded by an autologous vesicle. This 
phenomenon can be further tested using different anti-cancer drugs to increase the diversity and 
reproducibility of the results. 
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Chapter 5: Cannabidiol is a Novel Inhibitor of 
Extracellular Vesicle Biogenesis and Release in Cancer 
Cells 
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5.0 Cannabidiol (CBD) is a Novel Inhibitor of Extracellular Vesicle Biogenesis and Release 
in Cancer Cells 
5.1 Introduction 
CBD is generally safe at therapeutic doses, shows biphasic effects on the immune system, and 
has demonstrated anti-cancer activity in vivo(Massi et al., 2013, Velasco et al., 2016, Velasco et 
al., 2017). This study therefore aimed to investigate putative modulatory effects of CBD on EV 
release and to further establish whether CBD had combinatory effects with the recently 
described EV inhibitor Cl-amidine(Kosgodage et al., 2017, Kholia et al., 2015). For proof of 
principle three cancer cell lines, prostate cancer (PC3), hepatocellular carcinoma (HEPG2) and 
breast adenocarcinoma (MDA-MB-231) were used. The effects of CBD on EV release are 
discussed in this chapter. Our findings suggest a new link between the emerging understanding 
of anti-cancer effects of CBD and its modulatory effects onEV biogenesis in cancer cells which 
has been described for the first time by our team (Kosgodage et al., 2018). 
Effect of CBD on two glioblastoma cell lines was also asessed. 5µM CBD was more effective in 
other cancer cell lines on EV release compared to 1µM, therefore 5µM of CBD was used in 
these tests. It was essential to see the combinatory effect of an EV inhibitor and chemotherapy. 
Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) 
and astrocytomas(Lee, 2016). It is an imidazotetrazine derivative of the alkylating agent 
dacarbazine and a prodrug of the anti-cancer drug Temodar. TMZ is known to induce cell cycle 
arrest at G2/M and to eventually lead to apoptosisand has been widely used in concomitantly 
with radiotherapy against melanomas as well(Zhang et al., 2012). However this therapy has not 
always been successful as some glioblastoma cell lines exhibit resistance to TMZ(Perazzoli et 
al., 2015).As a result it was an idea to investigate whether EVs plays a role in driving the 
resistance mechanism and to whether EV inhibition can overcome this issue. As a consequence 
the latter part of this section has focussed on EV inhibition in two glioblastoma cell lines, 
LN229 (TMZ-sensitive) and LN18 (TMZ-resistant). CBD has been used as the EV inhibitor 
along with TMZ as the anti-cancer drug (Kosgodage et al., 2019).  
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5.2 Methods 
 
5.2.1 Cell viability assays 
EasyCyte 8HT flow cytometer and ViaCount assay were used to count and determine viability 
of cells before the start of every experiment and to assess cell viability after treatment with EV 
inhibitors, as previously described (section 2.6.1) 
5.2.3 Effects on EV biogenesis using Cannabidiol (CBD) and Cl-amidine 
For assessment of effects of CBD and Cl-amidine on EV generation, PC3, HEPG2 and MDA-
MB- 231 cells were seeded at a density of 3.8 x 105 cells/well, in triplicate, in 12-well microtitre 
plates, using pre-warmed serum- and EV-free RPMI 164. To ensure that the medium was EV 
free, it was centrifuged at 70,000g / 24 h and filtered through a 0.22 μm pore sizemembrane 
before use. The cells were then incubated with CBD (1 or 5 μM), Cl-amidine (50 μM) or with a 
combination of CBD (5 μM) and Cl-amidine (50 μM), for 60 min at 37°C / 5% CO2, while 
control cells were treated with either DMSO (0.001%) or serum free-RPMI  for CBD and Cl-
amidine respectively. The following concentrationsof CBD were used: 1 μM or 5 μM in 0.001% 
DMSO, based on clinically relevant doses for CBD (Bergamaschi et al., 2011); while Cl-
amidine wasused at 50 μM concentration (in PBS) as previously determined as an optimal dose 
for maximum EV inhibition in several cancer cell lines (Kosgodage et al., 2017). For testing of 
a combinatory effect on EV release, CBD was applied at 5 μM together with Cl-amidine at 50 
μM concentrations. After the 1h incubation period, the supernatants from each well were 
collected from the cell preparations, transferred to sterile 1.5 ml Eppendorf tubes (kept on ice) 
and centrifuged at 200g for 5 min at 4°C to remove the cell debris. The resulting supernatants 
were kept on ice and subsequently treated for isolation of EVs, as described in (section 2.5.1) to 
include both exosomes and MVs based on previously established protocols(Kosgodage et al., 
2017, Kholia et al., 2015). Each experiment was repeated three times and performed in triplicate. 
111 
 
5.2.4 Effect of Temozolomide (TMZ) on Glioblastoma cell lines 
A range of concentration of TMZ was tested on both LN18 and LN229 cells for 1h. EasyCyte 
8HT flow cytometer and ViaCount assay were used to count and determine viability of cells 
after the treatment as described in (section 2.6.1). 
5.2.5 Effect of CBD on TMZ treatment in LN18 and LN229 cells 
LN18 and LN229 cells were seeded at a density of 3.8 x 105 cells/well, in triplicate, in 12-well 
microtitre plates, using pre-warmed serum- and EV-free RPMI 1640. One set of cells were 
incubated with CBD 5 μM for 1h and then treated with TMZ 800µM for 1h.The next two sets of 
cells were either treated with CBD 5µM or TMZ 800µM alone for 1h.  Control cells were 
treated with DMSO (0.001%). CBD 5 μM in 0.001% DMSO was used based on clinically 
relevant doses for CBD(Bergamaschi et al., 2011) and previously established methods in the 
laboratory. The supernatants from each well were collected from the cell preparations, 
transferred to sterile 1.5 ml Eppendorf tubes (kept on ice) and centrifuged at 200g for 5 min at 
4°C to remove the cell debris. The resulting supernatants were kept on ice and subsequently 
treated for isolation of EVs, as described in (section 2.5.1) to include both exosomes and MVs 
based on previously established protocols(Kosgodage et al., 2017). Each experiment was 
repeated three times and performed in triplicate. 
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5.3 Results 
5.3.1 CBD inhibits EV release in PC3 cells 
Figure 5.1 Effect of CBD on PC3-derived EV release. A-C, CBD significantly inhibits total EV, 
exosome and MV release from PC3 EVs represent all vesicles 0-900 nm (A); microvesicles (MV) are 
100-900 nm (B) and exosomes are vesicles <100 nm (C); D, Cancer cell viability was not significantly 
affected by the levels of CBD used in these experiments after 1 h incubation 1 μM CBD resulted in a 5.6% 
decrease in cell viability (p=0.1583), and 5 μM CBD in a 2.2% decrease in cell viability (p=0.7247) 
compared to DMSO. However Cl-amidine resulted in a significant reduction (p=0.0005) compared to the 
treated control cells. The experiments were repeatedthree times and the data presented are mean ± SEM 
of the results (*p ≤0.05; **p ≤0.01; ***p ≤0.001;****p ≤0.0001 vs Control; Differences between CBD 
and Cl-amidine treatment group is furtherindicated as #p ≤0.05; ##p ≤0.01; ###p ≤0.001; ####p ≤0.0001) 
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Pre-treatment of PC3 cells with both 1 μM and 5 μM CBD, for 1h before EV isolation, resulted 
in asignificant reduction of total EV release compared to the DMSO treated control cells (44.5% 
and 44 98.1% reduction of EV release for 1 μM (p=0.0149) and 5 μM (p=0.0008) CBD 
respectively) (Figure 5.1A). The inhibitory effect by 5 μM CBD on total EV release was greater 
thanobserved with Cl-amidine (p=0.0001), while Cl-amidine had a significantly stronger EV 
inhibitory effect than 1μM CBD (p=0.0001).  
When using CBD (5 μM) in combination with Cl-amidine no additional changein total EV 
inhibition was found compared to single inhibitors. Analysis of inhibitory effects on exosome, 
showed that both CBD and Cl-amidine significantly reduced the number of vesicles released 
compared to untreated PC3cells (98.0% versus 66.1%; p=0.0001 and p=0.0001 respectively). 
Asignificantly stronger inhibitory effect was observed for 5 μM CBD than with Cl-amidine 
(p=0.0001), while 1 μM CBD was less effective, inhibiting exosome release by 51.3% 
compared tocontrol (p=0.0002). Combinatory treatment with 5 μM CBD and Cl-amidine gave 
similar results assingle CBD (5 μM) inhibitor treatment (96.6%; p=0.0001 compared to control) 
(Figure 5.1C).CBD mediated MV release was significant for both 1 μM (38.5%; p=0.0009) and 
5 μM (98.1%; p=0.0001) compared to non-treatedcontrol cells, although 5 μM CBD was 
significantly more effective than 1 μM CBD (p=0.0002). Theeffect of 5 μM CBD alone was 
similar in reducing MV release as seen for Cl-amidine compared tocontrol cells (95.6%; 
p=0.0001) while combinatory treatment of CBD (5μM) and Cl-amidine did notexhibit a further 
additive effect on MV release (93.6%; p=0.0001 compared to control) (Figure 5.1B). 
Cell viability was not significantly affected by the levels of CBD used after 1h incubation 
(Figure 5.1 D). 1 μM CBD resulted in a 5.6% decrease in cell viability (p=0.1583), and 5 μM 
CBD in a 2.2% decrease in cell viability (p=0.7247) compared to DMSOtreated control cells. In 
comparison, cell viability was affected to some extent by Cl-amidine (20%; p=0.0005 compared 
to PBS treated control cells).  
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5.3.2 Effect of CBD on EV release in HEPG2 cells 
 
Figure 5.2 Effect of CBD on HEPG2-derived EV release.  A-C, CBD significantly inhibits total EV, 
exosome and MV release from HEPG2 cells. EVs represent all vesicles 0-900 nm (A); microvesicles 
(MV) are 100-900 nm (B); exosomes arevesicles <100 nm (C).D, CBD does not affect cell viability of 
HEPG2 cells after 1h treatment. However, Cl-amidine significantly reduces the cell viability (p=0.0033). 
The experiments were repeated thrice and the data presented are mean ± SEM of the results (*p ≤0.05; 
**p ≤0.01; ***p ≤0.001;****p ≤0.0001 vs Control; Differences between CBD and Cl-amidine treatment 
group is furtherindicated as #p ≤0.05; ##p ≤0.01; ###p ≤0.001; ####p ≤0.0001). 
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Pre-treatment of HEPG2 with both 1 μM and 5 μM CBDresultedin a significant reduction of 
total EV release compared to the DMSO treated control cells (86.7%; p=0.0001 and 97.9%; 
p=0.0002 respectively) and was more potent than for Cl-amidine (61.9%; p=0.0002) compared 
to control(Figure 5.2A). Combinatory treatment with 5µM CBD and Cl-amidine resulted in a 
significantly higher inhibition compared to Cl-amidine alone (p=0.0058). This was 91.9% 
(p=0.0002) compared to untreated control.  
The inhibitory effect of CBD on MVs was significant in HEPG2 cells for both 1 μM (86.1%; 
p=0.0001) and 5 μM (99.6%; p=0.0001) concentrations of CBD compared to control cells, with 
5 μM CBD being significantly more effective (p=0.0001) (Figure 5.2 B). MV inhibitory effects 
of Cl-amidine in comparison were 61.1% compared to control (p=0.0007), while combinatory 
treatment of CBD (5 μM) and Cl-amidine showed a similar effect on total EV release (96.2%; 
p=0.0001) as CBD alone. 
Analysis of inhibitory effects on exosomes showed that both concentrationsof CBD (1 μM and 5 
μM) were more effective (91.6%; p=0.0005 and 84.0%; p=0.0009; respectively) than Cl-
amidine (68.4%; p=0.0026). The lower dose of CBD (1 μM) was the mostpotent inhibitor of 
exosome release in this cancer cell type. Combinatory treatment with 5 μM CBDand Cl-amidine 
resulted in less exosome inhibition (57.9% compared to control; p=0.0039) than anyof the single 
inhibitor treatments (Figure 5.2C). 
Cell viability of HEPG2 cells was not apparent. Both 1 μM and 5 μM CBD caused 1.18% 
decreased cell viability (p=0.1890 and p=0.2746 respectively) compared to DMSO treated 
control cells.  Cl-amidine reduced the cell viability by 11% (p=0.0033) compared to PBS treated 
control cells (Figure 5.2D). 
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5.3.3 Effect of CBD on EV release in MDAMB231 cells 
 
Figure 5.3 Effect of CBD on MDAMB231-derived EV release. A-C, EVs represent all vesicles 0-900 
nm (A); MVs are 100-900 nm (B) and exosomes are vesicles <100 nm (C). D, CBD does not affect cell 
viability of cells after 1h treatment. However, Cl-amidine significantly reduces the cell viability 
(p=0.0353). The experiments were repeated three times and the data presented are mean ± SEM of the 
results (*p ≤0.05; **p ≤0.01; ***p ≤0.001; ****p ≤0.0001 vs Control; Differences between CBD and Cl-
amidine treatment group is further indicated as #p ≤0.05; ##p ≤0.01; ###p ≤0.001; ####p ≤0.0001). 
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Pre-treatment of MDA-MB-231 with CBD resulted in a significant reduction of total EV release 
compared to the untreated control (53.4%; p=0.0001 and 42.9%; p=0.0001, respectively) but 
was a less potent total EV inhibitor than Cl-amidine (75.9%; p=0.0001 compared to control). 
When using CBD (5 μM) in combination with Cl-amidine, a significantly (p=0.0052) higher 
inhibition was observed compared to 5 μM CBD alone, while there was no significant 
difference compared to 1 μM CBD treatment (p=0.2474). Compared to control treated cells the 
combinatory treatment resulted in a 55.1% reduction of total EVs (p=0.0006) (Figure 5.3A).  
The inhibitory effect of CBD on MVs was significant for both concentrations but seemed to be 
less effective than Cl-amidine. CBD showed 34.4% (p=0.0001) inhibition at 1μM, and 56.5% 
(p=0.0001) inhibition at 5 μM, compared to control, with 5 μM CBD being a significantly more 
effective (p=0.0007) total MV inhibitor. In comparison, MV inhibitory effects of Cl-amidine 
were higher, at 77.8% compared to control (p=0.0001), while combinatory treatment of CBD (5 
μM) and Cl-amidine showed a similar effect on total MV release (52.7%; p=0.0001) as 5 μM 
CBD alone (Figure 5.3B) 
Analysis of inhibitory effects on exosomes showed that both concentrations of CBD (1 μM and 
5 μM) were similarly potent. CBD 1µM inhibited the EV release by 97.5% (p=0.0001) and 
CBD 5µM by99%(p=0.0001). This was stronger compared to Cl-amidine which only inhibited 
exosome release by 46.7% (p=0.0001) compared to control treated MDA-MB-231 cells. 
Combinatory treatment with 5 μM CBD and Cl-amidine resulted in similar effects on exosome 
inhibition as CBD alone (99.5%; p=0.0001) (Figure 5.3C). CBD did also not affect MDA-MB-
231 cell viability significantly compared to DMSO treated control cells, with a 3.5% decrease 
observed in 1 μM CBD (p=0.7090) and 5.4% decrease in 5 μM CBD treated cells (p=0.3081) 
and by 5.3% for MDA-MB- 231(p=0.0353) in the presence of 50 μM Cl-amidine compared to 
PBS treated control cells (Figure 5.3D). 
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5.3.4 Optimum concentration of TMZ to treat Glioblastoma cell lines 
 
 
Figure 5.4 GBM cells LN18 and LN229 tolerate similar TMZ concentration.  A range of 
concentrations of TMZ was tested against the GBM cell lines.  A, LN18 was more sensitive to lower 
concentration of TMZ compared to LN229. There was a 15% reduction in cell viability in the presence of 
400 µM (p=0.0023) while the maximum decrease was recorded in the presence of 800µM which was 23 % 
(p=<0.0001). B, In contrast only 5% decrease was recorded with 800 µM in LN229 which was the 
maximum (p=0.0907). The experiments were repeated three times and the data presented are mean ± 
SEM of the results. Therefore, 800µM TMZ was used in subsequent experiments. 
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5.3.5 Effect of CBD and TMZ treatment on the viability of GBM cells 
 
 
Figure 5.5 Glioblastoma cell viability is minimally affected following CBD and TMZ treatment. A, 
LN18 exhibited maximum decrease of 27.37% (p= 0.002) in cell viability following combination therapy. 
B, There was no significant effect on cell viability. Similarly, combination therapy with CBD and TMZ 
resulted in the maximum reduction in viable cells, 12.77% (p=0.0085). The experiments were repeated 
three times and the data presented are mean ± SEM of the results. 
C
o
n
tr
o
l 
D
M
S
O
C
B
D
 5
 
M
T
M
Z
 8
0
0
M
T
M
Z
+
C
B
D
 5

M
0
5 0
1 0 0
V ia b ility  o f L N 2 2 9  c e lls  in  th e  P re s e n c e  o f  C a n n a b id io l
N
o
. 
o
f 
V
ia
b
le
 C
e
ll
s
/m
l
C
o
n
tr
o
l 
D
M
S
O
C
B
D
 5
 
M
T
M
Z
 8
0
0
M
T
M
Z
+
C
B
D
 5

M
0
5 0
1 0 0
V ia b ility  o f  L N 1 8  c e lls  in  th e  P re s e n c e  o f  C a n n ib id io l
N
o
. 
o
f 
V
ia
b
le
 C
e
ll
s
/m
l *
**
***
A 
B 
120 
 
 
5.3.4 Optimum concentration of TMZ to treat Glioblastoma Multiforme (GBM) cell lines 
 
In order to determine the optimal concentration, a range of concentrations of TMZ was tested on 
both LN229 and LN18 cells.  LN18 exhibited minimal effect on cell viability in the presence of 
even the highest TMZ concentration, 800µM (23%; p<0.0001). However, both 200 µM and 400 
µM resulted in 10% and 15% reduction in cell viability respectively (p=0.1018; 0.0023). There 
was no effect on cell viability in the presence of 100µM (Figure 5.4A).  
In contrast the effect of TMZ on LN229 was low. 800 µM of TMZ only resulted in a 5% 
reduction in cell viability (p=0.0907%) compared to the untreated control. This was also evident 
in other concentrations used in the experiment. 200-400 µM only resulted in 2% and 5% 
decrease respectively (p=0.3739; 0.1355). Similar to LN18, cell viability was not affected in the 
presence of 100 µM (Figure 5.4B).  
EV inhibition was modulated via CBD while TMZ was used as the anti-cancer drug. CBD had 
the least effect on cell viability which only reduced by 9.47% (p=0.0173) compared to the 
DMSO treated control in LN18.  However, cell viability was not negatively affected when this 
effect was compared with that of TMZ (9.76%; p=0.0464) and combinatory therapy (15.85%; 
p=0.0027). TMZ significantly reduced the cell viability (18.68%; p=0.0032) and a further 
reduction by 24.18% was seen in the presence of combinatory therapy (p=0.0002).   
LN229 cells were less affected by CBD treatment, the cell viability being reduced by 7.61% 
(p=0.0732). This was however reduced compared to that with TMZ (2.29%; p=0.7290) and 
combination treatment (3.53%;p=0.4081) while TMZ treatment resulted in a less negative effect 
on cell viability which was 5.43% (p=0.2187) (Figure 5.5B). Combinatory therapy only 
reduced the cell viability by 10.87% (p=0.0118). These changes were not significant compared 
to the effect seen on LN18 (Figure 5.5A). 
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5.3.6 Effect of EV inhibition on TMZ-treated LN229 GBMcells 
 
 
 
 
 
Figure 5.6 CBD modulated vesicle release is increased compared to TMZ treatment in LN229. A-D, 
suggest that EV inhibition does not affect TMZ in combinatory treatment. However, TMZ alone increases 
the release of 101-500 nm sized vesicles by 50 % (p= 0.0008) compared to the control. However sole 
TMZ treatment reduced <100nm-sized vesicles as well as the total EVs by at least 45% (p=0.0006). The 
combinatory effect of both treatments increased EVs in all subpopulations by at least 49% (p=0.0316).  
EV subpopulations were determined via size-exclusion nanosight analysis (>100nm-exosomes; 101-200 
nm and 201-500 nm- MVs). The experiments were repeated three times and the data presented are mean 
± SEM of the results. 
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Pre-treatment with CBD increased >100nm-sized vesicles compared to the untreated control by 
64.88% (p=0.0144). It also increased the effect by 15.5% compared to cells treated with TMZ 
alone and combinatory therapy by 22.48% (p=0.0326 and p=0.8772).  Treatment with TMZ 
alone did increase the exosome release by 58.44% compared to the control (p=0.006) but was 
less compared to that of CBD and combination (8.26%; p=0.0115). Combination therapy 
stimulated the exosome release by 54.7% (p=0.0049) (Figure 5.6A). 
TMZ stimulated vesicle release the least in all subpopulations compared to the proposed EV 
inhibitor, CBD. This was also apparent in 101-200nm-sized vesicles which was increased by 
40.19% (p=0.0008) but was lower than CBD by 17.19% (p=0.0653) and combination therapy 
by 22.06% (p=0.046) (Figure 5.6B). CBD stimulated the vesicle release by 50.47% (p=0.0001) 
which was higher than the combination therapy by 5.88% although not significant (p=0.3169). 
The stimulation of vesicles in the presence of both CBD+ TMZ was lower compared to 
exosomes but was increased by 53.38% compared to the untreated control (p=0.0002) 
Figure 5.6C resulted in the highest stimulation of vesicles by sole TMZ treatment which was by 
49% (p=0.0406) but was low compared to CBD (16.67%; p=0.7891) but had no difference 
compared to the combination therapy. CBD was again the highest in stimulating vesicle release. 
It stimulated a 57.5% increase compared to the control and 16.67% compared to the combined 
treatment (p=0.0140 and p=0.7025 respectively). Combination therapy increased the vesicle 
release by 49% which was similar to TMZ alone (p=0.0316).  
Total EVs were further increased by CBD by 60.38% (p=0.0051) compared to the control which 
was higher than TMZ (40.95%; p=0.006). Combination therapy stimulated the total EVs by 
62.18% (p=0.0015). Although not significant, this was higher than CBD by 4.55% (p= 0.7339). 
This was however lower than sole TMZ treatment by 43.64% (p=0.0020). TMZ inhibited the 
stimulated EV release by 32.9% (p=0.0392) compared to the control. Total EVs were stimulated 
in the presence of all treatments (Figure 5.6D). 
5.3.7 Effect of EV inhibition on TMZ-treated LN18 GBM cells 
Pre-treatment with CBD decreased >100nm-sized vesicles significantly compared to the 
untreated control by 28.95% (p=0.0066). It also reduced the effect by 19.8% compared to cells 
treated with TMZ alone and combinatory therapy by 19% (p=0.0255 and p=0.0376).  Treatment 
with TMZ alone did increase the exosome release by 11.4% compared to the control (p=0.4978) 
but was less compared to that of combined treatment (17.69%; p=0.2471). Combination therapy 
stimulated the exosome release by 12.28% (p=0.3827) (Figure 5.7A). 
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CBD was a pan-inhibitor of LN18-derived vesicles. This was also apparent in 101-200nm-sized 
vesicles which was reduced by 23.96% (p<0.0001). The inhibition achieved was also lower than 
sole TMZ treatment by 2.26% (p=0.2378) and combination therapy by 19.35% (p<0.0001) 
(Figure 5.7B). TMZ also inhibited the vesicle release by 20.21% (p=0.0003) which was higher 
than CBD (2.26%; p=0.2378) but lower than the combination therapy by 44.58% which 
stimulated the vesicle release (p=0.0002). The stimulation of vesicles in the presence of both 
CBD+ TMZ was 4.17% compared to the untreated control (p=0.4818) 
Both CBD and combinatory treatment significantly inhibited the vesicle release.TMZ was the 
only vesicle stimulator. Vesicle release was increased by 1.1% (p=0.7160) but was significantly 
higher compared to CBD (55%; p=0.0010) and by 59.44% (p=0.0010) compared to the 
combination therapy. CBD stimulated the vesicle release by 55.56% (p=<0.0001). However, it 
was lower than the inhibitory effect in the presence of both CBD and TMZ treatment by 12.5% 
(p=0.0363) which was 61.11% compared to the DMSO control (p=<0.0001) (Figure 5.7.C).   
Total EVs were further reduced by TMZ treatment alone by 56.17% (p=0.0001) compared to 
the control. This inhibitory effect was however significantly higher than that exerted by CBD 
(24.64%; p=0.0012) and exhibited opposing effects to combination therapy which increased the 
total EVs by 60% compared to sole TMZ (p=<0.0001) and by 10.26% (p=0.0724) compared to 
the untreated control. This was higher than CBD by 46.15% (p<0.0001). CBD also inhibited 
total EVs by 40% (p=0.0002) compared to the control. Total EVs were inhibited in the presence 
of CBD and TMZ on its own but was stimulated in the presence of the reagents in synergy 
(Figure 5.7D). 
5.3.8 Size exclusion analysis of vesicle release in GBMcell lines 
The results suggest that overall vesicle release is significantly higher in TMZ-sensitive LN229 
cells compared to the TMZ-resistant LN18 cells (Figure 5.8). This is apparent in all 
subpopulations. Total EV release was decreased by 11.97% (p= 0.0385). Although not 
significant, the lowest reduction was seen with the MV population in the 101-200 nm range 
which was just 11.03% (p=0.4103). <100nm-sized vesicle release in LN18 was reduced by 
17.38% compared to that released by LN229 (p=0.0005). LN229 had a significant increase in 
201-500nm-sized MV release by 57.59% compared to LN18 (p=0.0006).  
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5.3.7 Effect of EV inhibition on TMZ-treated LN18 GBM cells 
 
Figure 5.7 CBD modulated vesicle release is decreased compared to the TMZ treatment in LN18. 
A-D, CBD significantly inhibited the vesicle release in all subpopulations by 25% with the highest 
recorded in 201-500nm vesicles which was 55.56% (p<0.0001). Total EVs were reduced by 56.17% 
(p=0.0001) following TMZ treatment. Nevertheless, combined effect of CBD and TMZ increased the 
overall EV release by at least 10% with the exception of the 201-500 nm subpopulation which resulted in 
a significant reduction of 61.11% compared to the control (p<0.0001). EV subpopulations were 
determined via size-exclusion nanosight analysis (>100nm-exosomes; 101-200nm and 201-500nm- MVs). 
The experiments were repeated three times and the data presented are mean ± SEM of the results. 
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5.3.8 Comparison of Size Exclusion Vesicle release in GBM cell lines 
 
 
 
Figure 5.8 LN18-derived EV release is significantly lower than TMZ-sensitive LN229. There is an 
overall reduction in the release of all vesicle subpopulations in LN18 compared to LN229. However, 201-
500 nm-sized vesicle release is lowest, at 57.59%, compared to the rest of the groups (p=0.0006). There 
was only 11.03% reduction in 101-200nm-sized vesicle release which was not statistically significant. 
Total EVs were only affected by 11.97% (p=0.0385). EV subpopulations were determined via size-
exclusion nanosight analysis (>100nm-exosomes; 101-200 nm and 201-500 nm- MVs). The experiments 
were repeated three times and the data presented are mean ± SEM of the results. 
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5.4 Discussion 
This chapter discusses a novel and potential inhibitor of EV release in cancer cell lines which is 
also a novel finding for functions of CBD. The different cancer cell lines tested here (prostate 
cancer PC3, hepatocellular carcinoma HEPG2, breast adenocarcinoma MDA-MB-231, GBM 
cell lines, LN18 and LN229) showed that CBD consistently inhibited exosome release and also 
had significant, although more variable, modulating effects on MV release. This study was the 
base for the recently published research findings (Kosgodage et al., 2018, Kosgodage et al., 
2019) that highlights this novel function of CBD on EV release for the first time. This is of high 
relevance for optimised therapeutic application in various EV-mediated pathologies. 
There has been a significant interest in EV inhibition during the past few years as it plays a 
considerable role in metastasis and other EV-associated disease statuses. This has been reported 
throughout this work by comparing the efficacy of different pharmacological agents in 
inhibiting EV biogenesis and release. Published research findings from the previous chapters of 
this study as well as previous work carried out in the same laboratory have outlined the 
importance in using EV inhibition as a novel therapeutic strategy(Kholia et al., 2015, 
Kosgodage et al., 2017) . Here, the impact of PAD inhibition on prostate cancer was highlighted 
using Cl-amidine and 5-FU as well asMTX as anti-cancer drugs. Furthermore, novel EV 
inhibition pathways were introduced to the field which have shown success compared to that 
were previously experimented. Many researches have been conducted to increase sensitisation 
of cancer cells to chemotherapy.  Consequently, the presented study on CBD was an interesting 
approach to develop a novel EV inhibition pathway. 
As shown in the results, CBD has consistently affected the EV profiles of different cancercells 
tested. However its effect was significant in exosome inhibition while MV subpopulations 
varied. This EV modulation was in some instances more potent than Cl-amidine. It was also 
interesting to observe different effects on different EV subpopulations that differed between the 
cancers. In PC3 cells, 5μM of CBD was more effective than 1µM CBD in inhibiting total EVs, 
exosomes and MV subpopulations. In the HEPG2 hepatocellular carcinoma cells 5 μM CBD 
had the main impact on total EV and MV release, while 1 μM CBD most significantly affected 
exosome release. Overall, the potency of CBD to inhibit all subsets of EVs tested here was most 
marked in the HEPG2 cells. In MDA-MB-231 cells the inhibitory effect of CBD was 
particularly marked for exosome release, while total MV release was less inhibited by CBD 
compared to Cl-amidine (Kosgodage et al., 2019).  
Recent studies in this invasive breast cancer cell line have suggested an active role of exosomes 
in increased cell movement and metastasis (Harris et al., 2015). The increase in MVs released in 
response to CBD treatment was specific for the MDA-MB-231 cells. This may indicate a higher 
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sensitivity of this particular cancer cell line to CBD and may also be a sign of pseudoapoptotic 
responses, where increased membrane permeability and leakage of reactive oxygen species 
(ROS) and other apoptotic factors is still low enough for the cell to turn the apoptosome into 
MVs for export of hazardous agents via pseudoapoptosis (Kosgodage et al., 2018, Inal et al., 
2012). Using a combination therapy of CBD and Cl-amidine resulted in different effects on the 
various EV subsets and varied between the three cancer cell lines. In general, Cl-amidine did 
not have additive effects on the inhibitory effect of EV release compared to CBD alone, while 
the combinatory treatment was more effective on some subsets than Cl-amidine alone, as was 
observed on exosome release in PC3 cells and on MV release in HEPG2 cells. Similarly, 
combinatory treatment did not show more effect than CBD or Cl-amidine alone on exosome 
release from HEPG2 cells.  
Interestingly, in MDA-MB-231 cells, Cl-amidine counteracted the increased CBD-mediated 
release observed for the total EVs when used in combination, bringing the amount of vesicles 
release below the level of sole CBD treatment. Overall the results presented here suggest that 
the two EV inhibitors act on different pathways involved in MV and exosome release. While 
previously, Cl-amidine has been shown to act on MV biogenesis via increased cytoskeletal actin 
deimination and nuclear PAD translocation, indicative of changes in histone deimination(Kholia 
et al., 2015) , CBD may act in part through modulation of mitochondrial metabolism as 
described earlier (Kosgodage et.al. 2018).  
The application of CBD in EV inhibition was further tested using GBM cell lines, LN18 and 
LN229. Previously, CBD has been shown to enhance effects of TMZ (Torres et al., 2011). In 
this study we also have used TMZ in conjunction with CBD to study the effect of CBD-
mediated EV inhibition on the GBM treatment. Previously conducted research confirmed that 
the anti-cancer drug itself stimulated the EV release in the presence of DOX and 5-FU(Lange et 
al., 2017b, Aubertin et al., 2016). However, an opposing effect was visualised in TMZ-sensitive 
LN229 cells where EV release was inhibited following TMZ treatment alone. This was true in 
all subsets of EVs. CBD did not act as an inhibitor in this cell line which promoted hyper-
vesiculation in the presence of combined treatment with CBD and TMZ.  In contrast, TMZ 
stimulated the EV release in all EV sumpopulations (exosomes and MVs) but the TMZ-resistant 
cell line, LN18, exhibited the previously demonstrated phenomenon, TMZ stimulating EV 
release in exosomes and MV subpopulations. This also portrayed significant EV inhibition in 
the presence of CBD compared to the control treatment. Nevertheless, only the large MV subset 
(201-500nm) revealed a significant decrease in EVs in the presence of combined therapy which 
was may indicate pseudoapoptotic responses. In addition, both cell lines varied in the 
proportional amounts of total EVs, MVs and exosomes released under standard conditions 
(Figure 5.8). LN229 resulted in a significant release of vesicles in all subpopulations compared 
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to LN18. Further work on miRNA profiling and other cargo profiling of these vesicle subtypes 
will have to be carried out to confirm whether LN229 vesicles contain for example protective 
miRNAs which would further support the observations made so far(Kosgodage et al., 2018b, 
Kosgodage et al., 2019).  
However, from the results observed, the TMZ-resistant LN18 responded to CBD treatment 
favourably. This it suggests that CBD-EV inhibition can certainly overcome the TMZ resistance 
in this cell line and encourages further testing to investigate both in vitro and in vivo.  
The expanded repertoire of EV inhibiting agents, including CBD along with its sensitising 
effects on cancer cells to cisplatin-mediated apoptosis (Kosgodage et.al 2018), indicates a 
therapeutic potential for sensitisation of cancer cells to chemotherapy, as has been demonstrated 
for other promising EV inhibitors (Vader et al., 2014, Nishida-Aoki et al., 2017, Kholia et al., 
2015, Kosgodage et al., 2017). Importantly, such EV-modulating agents could be used to 
circumvent the use of high doses of chemotherapeutic drug minimising its side effects but 
enhancing effective inhibition of tumour growth in vivo. The results in this chapter have shown 
the ability of CBD to inhibit EV release. However further work will have to be carried out to 
fully understand its beneficial EV-mediated effects in cancer therapy. 
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6.0 Isolation of Bacterial Outer Membrane Vesicles 
6.1 Introduction 
The research focus on bacterial outer membrane vesicles (OMVs) has grown rapidly in the 
recent years. Using nanovesicles as drug delivery vehicles has fascinated researchers in the EV 
field. Therefore using OMVs in targeted therapy and in drug delivery has encouraged the 
development of such new therapies .Wang and colleagues have demonstrated its use in vaccine 
development (Wang et al., 2018) while Gujrati and co-workers have demonstrated the 
importance of its use in drug delivery against cancer cells. Bioengineered bacterial OMVs of a 
mutant strain of E.coli with low immunogenicity were used to kill cancer cells (Gujrati et al., 
2014)in a cell-specific manner by delivering small interfering RNA (siRNA) targeting kinesin 
spindle protein (KSP). These vesicles were engineered to generate OMVs displaying a human 
epidermal growth factor receptor 2 (HER2)-specific affibody in the membrane as a targeting 
ligand (Gujrati et al., 2014). The advantages of using OMVs in therapy have been highlighted in 
a recent study by Bitto and Kaparakis-Liaskos (Bitto and Kaparakis-Liaskos, 2017). 
‘Naturalimmunogenicity and self-adjuvanting capability’ (Bitto and Kaparakis-Liaskos, 2017), 
controls cell and antibody-mediated immune responses. These, together with its cost-
effectiveness to produce, temperature-stability, and safety when used in humanmake them more 
potent to be used as vaccines.  
OMVs have been widely used as neoadjuvants.  The recent rise in the incidence of whooping 
cough has resulted in the use of Bordetella pertussis-OMV vaccines compared to the current 
approved whole cell B. pertussis vaccine which showed a rise in humoral response in mice 
(Raeven et al., 2016, Gaillard et al., 2014). Similarly, increasing antibiotic resistance in cases of 
Staphylococcal infections has encouraged S. aureus vaccine studies. It alsoreported that 
vaccination of mice with S. aureusOMV resulted in much stronger cell-mediated and humoral 
responses(Choi et al., 2015). The inclusion of a lipid functional group attachedto the target 
protein that drives membrane tethering or fusion of the target protein directly to a 
transmembrane OM protein has been described as the mechanisms for anchoring desired 
pharmacological reagents (Alves et al., 2016b).  
PAD catalyses the citrullination of arginine residues and has been found in Porphyromonas 
gingivalis (P.gingivalis), a Gram-negative bacteriumthat causes chronic periodontitis (Gully et 
al., 2014a, Maresz et al., 2013). The association of PADs in P.ginigivalis has opened new 
avenues for research by linking different disease statuses such as oral cavity disease to 
rheumatoid arthritis. However no significant data is available to confirm the presence of PAD in 
the E.coli genome, also a Gram-negative bacterial species, although arginine deiminase has 
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been identified.The deiminating activity of arginine deiminase of E.coli has though not been 
shown until in this thesis. Association of PAD inhibitors ofEV release and thus potential effects 
on arginine deiminase inOMV release, led to the current study toevaluate an effect of PAD 
inhibition on OMV release in E.coli.  
Previous research findings demonstrate the effect of EV inhibition on enhanced cancer therapy 
successfully. This together with rapid advancements in the therapeutic use of OMVs has 
encouraged the direction in this chapter to apply OMV inhibition to develop their therapeutic 
potential by minimising multi-drug resistance associated with such treatment. This will also 
increase the sensitisation of the cells to OMV-mediated drug delivery and adjuvant therapy 
which will be an innovative approach for the establishment of an OMV-targeted treatment. This 
section of the study has utilised E.coliand S.aureus to isolate OMVs and identify their 
characteristics. The latter part of the chapter has focussed on pharmacological OMV inhibition 
in both Gram-positive and Gram-negative bacteria with the idea to exploit this in successful 
improvement of antibiotic and phage therapy.  
6.2 Materials &Methods 
6.2.1 Maintenance of E.coli cultures 
E.coli cultures were maintained by plating on Müeller-Hinton agar plates and sub culturing was 
performed each week.S. aureus were maintained in nutrient agar plates and subculturing was 
performed each week.  
6.2.2 Preparation of Outer Membrane Vesicles (OMVs) 
Two different methods were used as suggested in the literature to prepare E.coli- OMVs. 
However subsequent experiments utilised ultracentrifugation method. S.aureus- OMVs were 
prepared using ultracentrifugation method in experiments.  
6.2.2.1 Centrifugation Method 
Bacteria were allowed to grow for 24h at 37°C and 5% CO2 and OMV isolation was carried out. 
OMVs were isolated from the supernatant of the bacterial culture medium which was initially 
centrifuged once at 400 g for 10 min to remove the cells. The resultant supernatant was then 
centrifuged again at 4000g this time for 1h at 4°C to remove cell debris. The resultant 
supernatant was centrifuged at 25,000g for 1h at 4°C. The isolated OMV pellet was resuspended 
in ultracentrifuged and sterile filtered(0.22µm) DPBS and centrifuged again at 25,000g for 1h at 
4°C to remove proteins such as albumin possibly bound to the OMV membrane surface. The 
OMV pellet was resuspended in sterile filtered (0.22µm) PBS and the isolated OMVs then used 
immediately or stored at -80°C for future experiments. For OMV associated experiments the 
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bacterial growth medium and DPBS was used after ultracentrifugation at 75,000 g for 24h to 
obtain a medium minimally contaminated with vesicles. 
 
6.2.2.2 Ultrafiltration Method 
 
Figure 6.1 Ultrafiltration method of OMVisolation.The diagram shows the steps of OMV isolation 
through ultrafiltration. The product of step 6 was assumed to be exosome-like vesicles which were 
quantified as shown in (Figure 6.2.1) and (Figure 6.2.2). Between step 8 and 9, the filtration unit was 
autoclaved to ensure a sterile filtrate of OMVs was obtained. 
Bacterial samples were allowed to grow for 24 h and then centrifuged at (4000 g for 15 min) to 
remove intact bacteria. The resultant supernatant was subject to vacuum suction filtration using 
a vaccum pump method. Concentration of the culture filtrate was performed through pumping 
the filtrate through a viva flow concentrator to ensure the OMV sample was concentrated 
sufficiently and to allow accurate quantification. The filtrate was assumed to contain bacterial 
exosomes and was sterile filtered using a 0.22µm sterile filter. The remaining supernantant was 
subject to a subsequent vacuum suction filtration this time using the autoclaved unit to ensure a 
sterile OMV sample was obtained. Both samples were quantified using the nanosight LM10. 
6.2.3 Immunoprecipitation (IP) 
To determine the proteins that had been citrullinated by the PAD enzymes when stimulated for 
microvesiculation, cell lysates from E.coli and E.coli-derived OMVs were immunoprecipitated 
Bacterial growth 24h
1.
Centrifugation- 4000 g for 15min
Resultant Supernatant 
Vacuum Suction Ultrafiltration
(VSU)
VIVA FLOW 
CONCENTRATOR
Concentrating the OMV sample
? Bacterial Exosomes
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VSU
Autoclaved filtration unit
Sterile filtered OMV sample
2. 3. 4.
5.
6.
7.
8.
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133 
 
(Catch and Release v2.0 IP kit, Millipore) with the pan-citrulline F95, PAD2, PAD3 and PAD4 
antibodies. 
6.2.3.1 Materials and Reagents 
• 1x Wash buffer - Diluted from 10X catch release buffer (provided in kit) 
• Spin columns 
• Capture tubes 
• 1.5 ml microcentrifuge tubes (Eppendorf) 
• Antibody affinity ligand - provided in the kit 
• F95, PAD2, PAD3 and PAD4 antibodies 
• Denaturing elution buffer with β-Mercaptoethanol (5% v/v) added immediately before 
use. 
• Milli-Q water – For dilution of throughout, wash and elution buffers  
 
6.2.3.2 IP Protocol 
Spin columns, capture tubes and 1.5 ml microcentrifuge tubes to be used were labelled. Caps 
and snap-off plugs located at the bottom of the spin columns were removed and stored for later 
use. Individual spin columns were then inserted into individual capture tubes and centrifuged at 
2000 g for 30 s to remove the resin slurry buffer. The columns were then washed twice with 405 
µl of 1x wash buffer (provided in kit) at 2,000 g for 30 s. The snap-off plugs removed earlier 
were then plugged back into the spin columns. 
As per the manufacturer’s directions a volume of combined reagents had to be determined to 
add to the spin columns as follows: 528 µg of E.coli cell lysate and 54.45g of OMV lysate, 5 µl 
of F95, PAD2, PAD3 and PAD4 antibodies, affinity ligand (10 µl - fixed volume) and 1x wash 
buffer (the volume of which was adjusted to 500 µl final volume). After determining the 
volumes required for each of the reagents mentioned above, they were added in the respective 
spin columns in the following order: 1x wash buffer, cell lysate, primary antibodies, and 
antibody capture affinity ligands. The spin columns were then capped and incubated at 4°C on a 
rotator overnight. 
Post incubation, the spin columns were inserted in capture tubes with the snap-off plugs 
removed and centrifuged at 2,000 g for 30s. The flow-through was transferred to 1.5 ml 
microcentrifuge tubes and stored at -20°C for later analysis. The columns were then washed 
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three times with 400 µl of 1x wash buffer spinning at 2,000 g for 30s. Each of the washes were 
collected in one tube and stored at -20°C for later analysis if required. 
The columns were then placed in fresh capture tubes and the protein eluted by adding 250 µl of 
1x denaturing elution buffer containing 5% β-Mercaptoethanol and centrifuging at 2,000 g for 
30 s. For maximum recovery of the protein a successive elution step was carried out with 4x 
denaturing buffer instead. The eluate was then stored at -20°C for Western blot analysis. 
E. coli and E. coli-OMVs were washed three times with cold PBS at 400 g for 5 min and lysed 
with B-PER buffer (as per section 2.2.6). 528 µg of E. coli cell lysate and 54.45g of OMV 
lysate were then immunoprecipitated with antibodies and eluate analysed for deiminated 
proteins by immunoblotting. 
6.2.4 Western blot analysis of citrullinated/deiminated proteins from E. coli and E. coli-
derived OMVs 
In order to compare protein profiles of citrullinated proteins between E. coli and E. coli-OMVs, 
cell and vesicle lysates were subjected to Western blot analysis.Briefly, 50 µg of cell lysates 
were separated by SDS-PAGE using 4–20% Mini-Protean TGX protein gels (BioRad, U.K) and 
transferred to a nitrocellulose membrane as per (section 2.9.1-2.9.4). Western blotting using 
PAD2,PAD3,PAD4, as well as the monoclonal F95 mouse IgM antibody, that was raised 
against a deca-citrullinated peptide and specifically detects protein citrulline (Nicholas and 
Whitaker, 2002), for the detection of putative deiminated/citrullinated sites in E. coli and E. 
coli-OMVs. Approximately 5 μg of protein was loaded per lane, even loadingbeing assessed 
using Ponceau S staining (Sigma, U.K.); membranes were thereafter blocked in 5% bovine 
serum albumin (BSA) in Tris buffered saline with 0.01% Tween20 (TBS-T) for 1 h, followed by 
incubation at 4 °C overnight with the primary antibodies (F95 [1:2000], PAD2[1:1000], 
PAD3[1:1000], PAD4 [1:1000] (BioRad, U.K). Membranes were then washed three times in 
TBS-T, incubated at room temperature for 1 h with HRP-conjugated secondary antibodies (anti-
mouse IgM –F95 and anti-rabbit IgM-PAD4 1:4000 (BioRad, U.K.), followed by six washes in 
TBS-T before visualisation with ECL (Amersham, U.K.). Membranes were imaged using the 
UVP transilluminator (UVP BioDoc-IT™ System, U.K.). 
6.2.5 Mass Spectrometry analysis of citrullinated/deiminated proteins from E. coli and E. 
coli-derived OMVs 
In order to identify proteins that were citrullinated during OMVrelease, 54.45 µg of E.coli cell 
lysate and OMV lysate were immunoprecipitated with F95 and PAD4 antibody and eluted with 
250 µl of non-denaturing buffer four times successively for maximum recovery of protein. The 
eluate was then subjected to mass spectrometry analysis as per (section 2.10.7). 
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6.2.6 Effect of pharmacological EV Inhibitors on E. coli-OMV Release 
E. coli was cultivated using EV-free Müeller-Hinton brothfor 24h. The cells were washed at 
4,000g for 10min and seeded in triplicate in micro centrifuge tubes. EGTA (1.5mM), 
Bisindolylmaleimide-I (10µM), Imipramine (25µM), Y27632(1µM) and D-pantethine(1mM) 
were added in triplicate and incubated for 1h at 37°C in 5% CO2. OMV isolation was carried out 
according as described earlier(section5.2.1.1).The experiment was repeated thrice and the 
OMVs were quantified using NTA analysis (Nanosight LM10).  
6.2.7 Effect of pharmacological PAD inhibitors on E. coli-OMV Release 
E. coli cultures were prepared as mentioned before(section 6.2.2). PAD2 inhibitor AMF30a 
(5µM), PAD4 inhibitor, GSK199 (10µM) and pan PAD inhibitor, Cl-am(50µM) were addedin 
triplicate and incubated for 1h at 37°C in 5% CO2. OMV isolation was carried out according to 
section 6.2.2.1.The experiment was repeated thrice and the OMVs were quantified using NTA 
analysis (Nanosight LM10). 
6.2.8 Effect of pharmacological EV and PAD inhibitors on S. aureus- OMV Release 
S. aureus cultures were prepared as mentioned above(section 6.2.2). Both pharmacological 
EVand PAD inhibitors were added in triplicate and incubated for 1h at 37°C in 5% CO2. OMV 
isolation was carried out according to section 6.2.2.1.The experiment was repeated thrice and 
the OMVs were quantified using NTA analysis (Nanosight LM10). 
6.3 Results 
6.3.1 Isolation of Bacterial OMVs 
Ultrafiltration and ultracentrifugation have widely been used in OMV isolation. The data 
presented both in (Figure 6.2.1) and (Figure 6.2.2) suggests that ultrafiltration is efficient in the 
isolation of differently sized particles. However, using the centrifugation method has 
appreciated the abundance of both exosome-like vesicles (OEXos) and OMVs in samples. 
Nevertheless, ultrafiltration has resulted in a higher yield of vesicles compared to centrifugation.  
The experiments described henceforth haveutilised the centrifugation method as it was 
important to see the effect on vesicles as a general population.   
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Figure 6.2.1 Size distribution of vesicles using ultrafiltration. A, OMV vesicles are larger than the B, 
OEXo vesicles which suggest that adopting the ultrafiltration method as described in Fig 5.1 clearly 
distinguishes between the two types, exosomes and microvesicles. C, demonstrates that the yield of 
OMVs are higher than OExo by atleast 85% (p<0.001). The experiment was repeated three times and the 
data presented are mean ± SEM of the results. 
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Figure 6.2.2: Size distribution of vesicles using centrifugation. A, Both OMV and OEXo are visible 
on this plot. B, still suggests that the yield of OMV is still higher atleast by 30% (p=0.018) compared to 
OExo. Experiment was repeated twice and the data presented are mean ± SEM of the results. 
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6.3.2 Phylogenetic reconstruction of E.coli-PAD sequences 
Two well supported clades were formed within the Neighbour-joining phylogeny (Fig. 6.3), 
which suggests that E. coli PAD is closely associated with human PAD2 but that it carries 
similarities to PAD3 and PAD4. This is supported by the multiple sequence alignment which 
was generated through clustal omega(Sievers and Higgins, 2018),  a method of progressive 
alignment construction. PAD E. coli has 220 amino acids (aa) while PAD2, 3 and 4 have 
665,663,664 aa respectively. There are many positions that have a single, fully conserved 
residue in all 3 proteins while some conservation of similarity between E. coli, PAD2 and PAD3 
is visible that scores > 0.5 in the Gonner PAM matrix. Very few weakly similar properties are 
detected between the two species. This clearly demonstrates that E. coli PAD and human PAD 
are evolutionary related. 
 
6.3.3 Detection of PAD enzymes and citrullinated/deiminated proteins in E. coli via 
Western blot Analysis 
E. coli and E. coli-OMV samples were analysed by Western blotting fortotal deiminated 
proteins (F95), deiminated PAD2, PAD3 and PAD4.Bands in the size range of 100, 75, 37–50 
and 20 kDawererevealed for total deiminated proteins (F95) in both E. coli and OMVs.The 
presences of PADs were verified by detection of anexpected band at 75/76 kDa which was 
stronger in PAD4 but faint in PAD3 and PAD2 (Figure 6.4). These results correlated with those 
observed in OMVs suggesting that the deiminated proteins, as detected by F95 positive proteins, 
have been transferred to the OMVs from E. coli.  
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E.coli-      ---------------------------mmgkiitva------------------------ 9 
PAD2         dvdadrdgvve--knnpkkaswtwgpegqgaillvncdretpwlpkedcrdekvyskedl 178 
PAD3         dcdlncegr--qdrnfvdkrqwvwgpsgyggillvncdrddpscdvqdncdqhvhclqdl 177 
PAD4         caditrtgkvkptravkdqrtwtwgpcgqgaillvncdrdnlessamdceddevldsedl 177 
                                          * *: *                          
E.coli-      ------------------------------------------------------------ 9 
PAD2         kdmsqmilrtkgpdrlpagyeivlyismsdsdkvgvfyvenpff-gqryihilgrrklyh 237 
PAD3         edmsvmvlrtqgpaalfddhklvlhtssydakraqvfhicgpedvceayrhvlgqdkv-s 236 
PAD4         qdmslmtlstktpkdfftnhtlvlhvarsemdkvrvfqatrgkl-sskcsvvlgpkwpsh 236 
 
E.coli-      -----------------------ghkgg-------------------------------- 14 
PAD2         vvkytggsaellffveglcfpdegfsglvsihvslleymaqdipltpiftdtvifriapw 297 
PAD3         yevprlhgdeerffveglsfpdagftglisfhvtllddsnedfsaspiftdtvvfrvapw 296 
PAD4         ylmvpggkhnmdfyvealafpdtdfpglitltislldtsnlelpeavvfqdsvvfrvapw 296 
                                    .. *                                  
E.coli-      i----------------------------gkstvlcslcvcvirkgktacfletdsq-gs 45 
PAD2         imtpnilppvsvfvccmkdnylflkevknlvektncelkvcfqylnrgdrwiqdeiefgy 357 
PAD3         imtpstlpplevyvcrvrnntcfvdavaelarkagcklticpqaenrndrwiqdemelgy 356 
PAD4         imtpntqppqevyacsifenedflksvttlamkakcklticpeeenmddqwmqdemeigy 356 
             *                               .. *.* :*    .    ::: : : *  
E.coli-      ik------dfieerktnarlseipyfecytdipamvqklaarfdyvfvdtpgmkspafvk 99 
PAD2         ieaphkgfpvvldsprdgnlkdfpvke----------llgpdfgyvtrepl-fesvtsld 406 
PAD3         vqaphktlpvvfdsprngelqdfpykr----------ilgpdfgyvtrepr-drsvsgld 405 
PAD4         iqaphktlpvvfdsprnrglkefpikr----------vmgpdfgyvtrgpq-tggisgld 405 
             ::       .: :   :  *.::*  .           :.  *.**        . : :. 
E.coli-      alscadilftfvepgsgieintlgrlvfdiktaqagvnpsmkawivlnkcstnpsdseas 159 
PAD2         sfgnlevsppvtvng---ktyplgriligss-fplsggrrmtk--vvr------dflkaq 454 
PAD3         sfgnlevsppvvang---keyplgriliggn-lpgssgrrvtq--vvr------dflhaq 453 
PAD4         sfgnlevsppvtvrg---keyplgrilfgdscypsndsrqmhq--alq------dflsaq 454 
             ::.  ::   ..  *   :   ***:::. .    . .  :    .:.      .   *. 
E.coli-      elrkqlnddpdwlpvprqriymrtah---------------------kkayncgmgvhey 198 
A 
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PAD2         qvqapvelysdwltvghvdefmsfvpipgtkkflllmastsacyklfrekqkdghgeaim 514 
PAD3         kvqppvelfvdwlavghvdeflsfvpapdgkgfrmllaspgacfklfqekqkcghgrall 513 
PAD4         qvqapvklysdwlsvghvdeflsfvpapdrkgfrlllasprscyklfqeqqneghgeall 514 
             :::  ::   *** * :   ::  .                      ::  : * *     
E.coli-      ddkrgnk--------------------------------argevelllketdii------ 220 
PAD2         fkglggms-skritinkilsneslvqenlyfqrcldwnrdilkkelglteqdiidlpalf 573 
PAD3         fqgvvddeqvktisinqvlsnkdlinynkfvqscidwnrevlkrelglaecdiidipqlf 573 
PAD4         fegikkkkqq---kiknilsnktlrehnsfvercidwnrellkrelglaesdiidipqlf 571 
              .                                        : ** * * ***       
E.coli-      ------------------------------------------------------------ 220 
PAD2         kmdedhraraffpnmvnmivldkdlgipkpfgpqveeecclemhvrglleplglectfid 633 
PAD3         kte-rkkataffpdlvnmlvlgkhlgipkpfgpiingcccleekvrslleplglhctfid 632 
PAD4         klkefskaeaffpnmvnmlvlgkhlgipkpfgpvingrccleekvcslleplglqctfin 631 
 
E.coli-      -------------------------------- 220 
PAD2         disayhkflgevhcgtnvrrkpftfkwwhmvp 665 
PAD3         dftpyhmlhgevhcgtnvcrkpfsfkwwnmvp 664 
PAD4         dfftyhirhgevhcgtnvrrkpfsfkwwnmvp 663 
 
Figure 6.3 Neighbour joining tree and Multiple Sequence Alignment (MAP) showing phylogenetic 
clustering of E.coli- PAD. The evolutionary analysis was inferred using the Neighbour-Joining method 
under the conditions of the Poisson distance correction model in MEGA6. Bootstrap values > 50 based on 
1,000 replicates are shown as nodal support. Where Clade 1, contains E. coli sequence and Clade 2 
contains human PAD2, PAD3 and PAD4 sequences. B, MAP indicates the evolutionary relationship 
between the two species; (*) indicates positions which have a single, fully conserved residue,(:) indicates 
conservation between groups of strongly similar properties - scoring > 0.5 in the Gonnet PAM 250 
matrix;(.) indicates conservation between groups of weakly similar properties - scoring =< 0.5 in the 
Gonnet PAM 250 matrix. 
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6.3.3Detection of PAD enzymes and citrullinated/deiminated proteins in E.coli and 
observation of transfer in E.coli-OMVs 
 
 
 
 
 
Figure 6.4 Western blotting of deiminated proteins in E.coli and OMVs. A, E. coli and E. coli-OMVs 
were analysed for total deiminated proteins (F95), PAD2, PAD3 and PAD4. Bands in the size range of 
37-50 and 75-76 and 20 kDa wererevealed for pan-deimination antibody (F95). PAD was detected as an 
expectedband of 75-76 kDa with PAD4 being very prominent. PAD2 and PAD3 were less expressed. B, 
Ponceau S staining (PoncS) is shown to confirm that even loading was carried out. Lane 1contains 
Precision Plus Protein Standard (161–0376, BioRad, U.K.), F95, lanes 2-3contain two E. colisamples, 
lanes 4-5 contains 2 OMV samples; PAD2 and PAD3, lane 2 contains E. coli sample and lane 3 contains 
OMV sample; PAD4, lanes 2-3 contains E. coli sample while lane 4 contains the OMV sample.  
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6.3.4 Immunoprecipitation and Protein Identification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 Immunoprecipitated deiminated proteins (F95) and PAD4 from E.coli and OMVs. IP 
was performed on E. coli-F95 and OMV-F95 as well as E. coli-PAD4. F95 blot,Lanes 8-10 has a band at 
37kDa corresponding to F95. However, the band in lane 8 is faint compared to lanes 9-10. E. coli PAD4 
blot has a significant band at 49kDa which corresponds to E. coli-PAD.  Bands are detected in the size 
range of 100, 75, 37–50 and 20 kDa and were identified by proteomic analysis. Lane 1 contains Precision 
Plus Protein Standard (161–0376, BioRad, U.K.) 
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6.3.5LC-MS/MS analysis of citrullinated proteins in E.coli and E.coli-OMVs 
6.3.5.1Common deiminated proteins identified in E.coli–F95, E.coli-PAD4 and OMVs-F95 
  MS2 intensities   
UniProt ID Protein name  E.coli F95 E.coli 
PAD4 
OMV F95 Score 
(p<0.05) 
 
Q1R6H3 30S ribosomal protein S15  128707 61762 67181 585.62 
P04949 Flagellin  704599 1E+06 9488.7 653.24 
P0A906 Outer membrane lipoprotein 
SlyB  
289574 555800 10565 632.79 
Q1R636 30S ribosomal protein S4  22719 44378 3554.4 289.35 
Table 2: Deiminated proteins identified in E.coli and E.coli-OMVs.Deiminatedproteins were isolated 
by immunoprecipitation using the pan-deimination F95 and PAD4 antibodies, analysed by LC-MS/MS. 
Ions score is −10*Log(P), where p is the probability that the observedmatch is a random event. Individual 
ions scores > 16 indicated identity orextensive homology (p< 0.05). Protein scores were derived from 
ions scoresas a non-probabilistic basis for ranking protein hits. Cut-off was set at Ions score20.Values 
with 2 or more peptides per protein and a score of >50 were considered. 
6.3.5.2 Unique deiminated proteins identified in E.coli –F95 
  MS2 Intensity 
UniProt ID  Protein name  E.coli -F95  Score (p<0.05) 
B7MQF2 Trigger factor  81193 192.72 
B7NKH1 UPF0227 protein YcfP  11941 166.86 
B7MSJ0 RNA-binding protein Hfq  256917 132.47 
Q1R638 50S ribosomal protein L17  126430 128.85 
Q1R602 50S ribosomal protein L3  69461 254.77 
Q1R619 50S ribosomal protein L24  6484.4 75.48 
B7N255 Protein-export protein SecB  136512 77.044 
P14407 Fumarate hydratase class I, anaerobic  15233 78.27 
P0A9S6 Glycerol dehydrogenase  220449 441.19 
P69799 PTS system mannose-specific EIIAB 
component  
94232 56.71 
B7MRV6 Serine--tRNA ligase  16845 55.11 
Table 3: Deiminated proteins identified in E.coli-F95 sample.Deiminated proteins were isolated by immunoprecipitation using 
the pan-deimination F95antibody, analysed by LC-MS/MS. Ions score is −10*Log(P), where p is the probability that the observed 
match is a random event. Individual ions scores > 16 indicated identity or extensive homology (p< 0.05). Protein scores were 
derived from ions scores as a non-probabilistic basis for ranking protein hits. Cut-off was set at Ions score 20. Values with 2 or more 
peptides per protein and a score of >50 were considered. 
144 
 
6.3.5.3 Unique deiminated proteins identified in E.coli –PAD4 
  MS2 
Intensity 
UniProt 
ID 
 Protein name  E. coli
PAD4 
 Score 
(p<0.05) 
P0A8N5 Lysine--tRNA ligase, heat inducible  321997 300.12 
Q8X9L0 ATP-dependent zinc metalloprotease FtsH  1E+06 151.09 
B7MRC1 Regulator of sigma D  23402 247.53 
P0ABC5 Modulator of FtsH protease HflC  66850 189.23 
Q1R5V0 50S ribosomal protein L10  478659 218.99 
Q8X4S5 Arabinose 5-phosphate isomerase GutQ  486219 120.37 
Q1R6A9 50S ribosomal protein L13  99365 135.62 
P0AA45 Ribosomal small subunit pseudouridine 
synthase A  
50727 162.27 
A7ZML6 Succinylornithine transaminase  232079 73.58 
B7MPT2 Curved DNA binding protein 6123.2 90.68 
P69911 Glutamate decarboxylase beta  387378 72.46 
A7ZY39 Cyclic pyranopterin monophosphate 
synthase accessory protein  
17232 67.03 
Q1R613 50S ribosomal protein L16  475140 95.53 
Q1R358 30S ribosomal protein S18  312269 103.87 
P07014 Succinate dehydrogenase iron-sulfur 
subunit  
48651 157.85 
P42632 PFL-like enzyme TdcE  29499 66.01 
P0AGL3 Putative reactive intermediate deaminase 
TdcF  
161746 80.57 
Q8X7I0 UPF0339 protein YegP  6121.7 87.63 
Q0TFD0 Acetyl-coenzyme A carboxylase carboxyl 
transferase subunit beta  
156916 99.12 
P0A6A5 Acetate kinase  79146 70.42 
P0A9Q3 Aerobic respiration control protein ArcA  19035 60.23 
A8A0U0 Succinylornithine transaminase  28022 73.51 
P0A9H4 Inducible lysine decarboxylase 716567 78.26 
Q8FJM0 DNA protection during starvation protein  51562 65.43 
B7N1L1 Glycine--tRNA ligase beta subunit  23006 87.76 
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B7N2S2 ATP-dependent protease ATPase subunit 
HslU  
398703 52.01 
B7N2Q7 ATP-dependent 6-phosphofructokinase 
isozyme 1  
57552 62.75 
B7UJ59 Polyribonucleotide nucleotidyltransferase  5914.7 70.94 
B7MZ76 CTP synthase  17163 59.39 
B6I184 50S ribosomal protein L25  56618 57.85 
Q0TA78 DNA-directed RNA polymerase subunit 
beta  
102175 72.91 
B6HZE3 30S ribosomal protein S2  226035 68.17 
B7NGD4 30S ribosomal protein S6  151007 61.19 
C4ZUJ7 30S ribosomal protein S12  396281 110.55 
Q8XBT3 Universal stress protein G  36115 159.67 
P0AF94 2-iminobutanoate/2-iminopropanoate 
deaminase  
22468 105.18 
 
Table 4: Deiminated proteins identified in E.coli-PAD4 sample.Deiminated proteins were isolated by 
immunoprecipitation using the PAD4 antibody, analysed by LC-MS/MS. Ions score is −10*Log(P), 
where p is the probability that the observed match is a random event. Individual ions scores > 16 
indicated identity or extensive homology (p< 0.05). Protein scores were derived from ions scores as a 
non-probabilistic basis for ranking protein hits. Cut-off was set at Ions score 20. Values with 2 or more 
peptides per protein and a score of >50 were considered. 
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6.3.5.4 Deiminated proteins identified in OMV-F95 
      MS2 
Intensity  
  
UniProt ID  Protein name 
(short) 
Gene 
name 
OMV 
F95 
Score (p<0.05) 
Q1R6H3 30S ribosomal protein 
S15  
rpsO 67181.14 585.62 
P04949 Flagellin  fliC 9488.724 653.24 
P0A906 Outer membrane 
lipoprotein SlyB  
slyB 10565.21 632.79 
Q1R636 30S ribosomal protein 
S4  
rpsD 3554.363 289.35 
B7L6J2 Threonine--tRNA 
ligase  
thrS 8718.552 371.78 
P21513 Ribonuclease E  rne 8574.855 369.58 
P02925 D-ribose-binding 
periplasmic protein  
rbsB 6973.666 270.86 
P63285 Chaperone protein 
ClpB  
clpB 30537.26 227.63 
B5YWX8 
  
  
50S ribosomal protein 
L25   
rplY 4326.5 51.12 
 
 
 
 
 
 
 
 
Figure 6.6 Deiminated proteins identified inE.coli-OMV-F95 sample. Deiminated proteins were 
isolated by immunoprecipitation using the F95 antibody, analysed by LC-MS/MS. A, all deiminated 
proteins identified in OMV sample. These contain all proteins which had a score of >50. B, String 
analysis of OMV-F95 proteins revealed nine proteins. Only 5 out of 9 proteins were associated with each 
other at least through text mining. Ions score is −10*Log (P), where p is the probability that the observed 
match is a random event. Individual ions scores > 16 indicated identity or extensive homology (p< 0.05). 
Protein scores were derived from ions scores as a non-probabilistic basis for ranking protein hits. Cut-off 
was set at Ions score 20. Values with 2 or more peptides per protein and a score of >50 were considered 
for A. 
A 
B 
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6.3.5. Identification of deiminated proteins from E. coli and E. coli-OMVs by 
Immunoprecipitation 
Proteins from E. coli and OMVs were immunoprecipitated using the pan-deimination F95 
antibody (both E. coli and OMVs) and PAD4 antibody (E. coli only) (Figure 6.5). Bands were 
significant at 37, 75 and 100kDa in E. coli samples that corresponds to F95. Similar bands were 
observed with respect to the OMV sample with the exception of the 37kDa band being very 
weak. Although the PAD4 corresponds to a band at 70-75kDa (Magnadottir et al., 2018), there 
are occasions that it has reacted with lower bands as well. Thisconfirms our findings which had 
a very strong band at around 50kDa that corresponds to PAD4 but non-specific bands were also 
present at low molecular weights and may also represent proteins binding to E.coli PAD. The 
OMV sample did not react to the PAD antibody which suggests that the bands seen in E. coli 
samples correlate to the PAD immunoprecipitation.  
6.3.6 Massspectrophotometry analysis of immune-precipitated proteins from E. coli and E. 
coli-OMVs 
Immunoprecipitated proteins from E.coli and OMV samples were analysed by LC-MS/MS. 
Deiminatedprotein candidates included immunogenic, cytoskeletal, nuclear andmetabolic 
proteins, and are listed in Tables 2-4and figure 6.6.Table 1, summarise the common proteins in 
all samples that had 2 or more peptides and a protein score of >50. There were more proteins 
identified in E. coli samples that were unique to both F95 (Table 3) and PAD4 (Table 4). Nine 
proteins were identified from the E. coli OMV protein sample (Figure 5.3.6 A) after 
citrullinated protein enrichment using an F95 antibody immunoprecipitation method. Only 30s 
ribosomal protein S15 was unique to OMVs (Figure 5.3.6 C). Threonine—tRNA ligase (thrS), 
has not yet been reported in E. coli OMVs. However, peptides are only present in the E. coli 
F95 and E. coli PAD4 samples. There is however the potential that this maybe a novel 
identification in OMVs and that it is thus connected with the other proteins identified in the 
OMV fraction. 
STRING analysis was carried out to assess if Threonine—tRNA ligase is interconnected with 
the other proteins in the OMV associated proteins (Figure 6.6 B). This shows that 5 of the 9 
proteins are associated with each other at least through text mining. The novel E.coli OMV 
protein Threonine—tRNA ligase is co-expressed with 30s ribosomal protein S15 (rpsO), 30s 
ribosomal protein S4 (rpsD) and 50S ribosomal protein L22 (rplV) as well as being 
experimentally determined to interact with rplV. 
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6.3.7 Effect of EV inhibitors on OMV Inhibition 
To observe effect of EV inhibitors on OMV release was encouraging (Figure 6.7). 
Thisrepresents the effect of the inhibitors previously used for EV experiments in human cancer 
cells. It is evident that these inhibitors have a significant effect also on OMV release which 
suggests that they can be used further in investigations similar to apoptosis experiments as 
described in previous sections. Imipramine is the most potent OMV inhibitor, but all reagents 
have shown marked reduction in OMVs.  Imipramine resulted in the strongest inhibition of 
72.38% (p<0.0001) with a reduction of only 4.12% in cell viability. This was higher than EGTA 
(1.04%) which least affected the cells with only an inhibition of 21.56% (p=0.0048). Bis-I was 
the second strongest inhibitor, 67.95% (p<0.0001) which only reduced the cell viability by 
6.25%. Both pantethine and Y27632 resulted in less than 50% inhibition, 21.09 %( p=0.0027) 
and 43.03% (p=0.0004) respectively with greater effect on cell viability with pantethine 
reducing it by 25% and Y27632 by 12.5%.  
6.3.8 Effect of PAD inhibitors on OMV Biogenesis and Release 
 
Figure 6.8 represents the effect of the PAD inhibitors on OMV release. Only Cl-amidine had 
previously been used in EV experiments in human cancer cells. GSK199, a PAD4 inhibitor, is 
more potent with 66.36% inhibition (p=0.0001) but all reagents showeda noticeable reduction in 
OMVs. However, GSK199 had the highest effect on viability with a 23.86% reduction.  BBCl-
am, is the second bestinhibitor with 53.79% inhibition (p<0.0001) and a reduction of 19.32% of 
viable cells. Cl-amidine resulted in a 42.42% inhibition (p=0.0001) with 18.18% decrease in cell 
viability while AMF30a, a PAD2 inhibitor, only resulted in 28.18% (p=0.0116) with a 14.73% 
viability.  Cl-amidine has been widely used as a pan-PAD inhibitor so it was interesting to 
appreciate the effectiveness compared to other specific inhibitors. BBCl-am reduced the number 
of OMVs by 19.7% (p=0.0014) and GSK199 by 41.58 %( p=0.0024). Interestingly AMF30a 
stimulated OMVs compared to Cl-amidine by 19.8% (p=0.0742). 
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Figure 6.7 Effect of inhibitors on OMV inhibition. A, All reagents used in the experiment have shown clear inhibition. However, 
Imipramine and Bisindolylmaleimide-I were more potent inhibitors of OMV release by 73.4% and 63.19% respectively (p<0.0001). 
However, Imipramine-mediated inhibition was more significant to Bisindolylmaleimide-I by 27.5% (p=0.3630). Y27632 resulted in 
a 38.45% inhibition which was better compared to the latter. EGTA and Pantethine reduced the OMVs by 14.97% (p=0.0048, 
p=0.0027). B, except for pantethine (35.5% viability), there is no detrimental effect on healthy cells which suggests that using these 
reagents in future experiments is advisable. The experiment was repeated twice and the data presented are mean ± SEM of the 
results. 
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Figure 6.8 Effect of PAD inhibitors on OMV biogenesis and release in E. coli. A, All reagents used in 
the experiment have shown clear inhibition. However, GSK199 and BB-Cl-amidine inhibit OMV release 
significantly by 59.07% and 51.23% respectively (p=<0.0001). Pan PAD inhibitor, Cl-amidine affected 
the inhibition less compared to BB-Cl-amidine by 20% (p=0.0014) and GSK199 by 42% (p=0.0024). 
However, it was more potent than PAD2 inhibitor, AMF30a by 19.19% (p=0.0742)   *= significance 
compared to the control; *= significance compared to Cl-amidine. B, There is no detrimental effect on 
healthy cells which suggests that using these reagents in future experiments is advisable. The experiment 
was repeated three times and the data presented are mean ± SEM of the results. 
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Figure 6.9 Effect of inhibitors on S.aureus OMV biogenesis and release. A, All reagents used in the experiment except for 
AMF30a and BB-Clamidinehave shown clear inhibition. However, EGTA (36.63%) and Bisindolylmaleimide-I(35.79%) inhibits 
OMV release significantly (*p= 0.0002 and p<0.0001 respectively). BB-Clamidine has a significant effect compared to Cl-amidine 
(*p=0.0412). B, There is no detrimental effect on healthy cells with only EGTA resulting in 18.48% reduction in cell viability which 
suggests that using these reagents in future experiments is advisable. The experiment was repeated three times and the data 
presented are mean ± SEM of the results. 
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6.3.9 Effect of inhibitors on S. aureus-OMV Biogenesis and Release 
 
A selected range of OMV inhibitors was used to examine the effect as shown in (Figure 6.9). 
Both Bisin-I and EGTA showed significant inhibition with Bisin-I having less effect on cell 
viability, 8.69% compared to EGTA which was 18.48%. PAD inhibitors were less effective but 
still had significant effects (p=<0.0001) compared the control treatment. GSK199 resulted in the 
highest inhibition of 22.49% (p=0.0018) PAD2 inhibitor showed only 3.39 %( p=0.0606) and 
BB-Clamidine (p=0.0061) being only 7.64% OMV inhibition and were thus significantly lower 
in their capacity for OMV inhibition compared to that in E. coli. However, Cl-amidine resulted 
in a 12.5% inhibition with the lowest effect on cell viability, 3.26% which was 5.36% more 
effective compared to its modified reagent, BB-Clamidine (p=0.0412). Overall the OMV 
inhibition was less than 40% in the presence of inhibitors which suggests that they are less 
effective in Gram-positive species compared to that of Gram-negative.  
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6.4 Discussion 
 
Vesicles released from E. coli were isolated utilising both ultrafiltration and ultracentrifugation. 
Ultrafiltration resulted in a pure population of both OMVs and OExos. However, 
ultracentrifugation was chosen as the preferred method in order to examine the effect on 
vesicles as a general population as the yield was higher in both OExo and OMVs which has 
been considered collectively in future experiments. Other researchers have taken similar 
approaches during OMV preparation in Gram-negative bacteria (Klimentova and Stulik, 2015, 
McCaig et al., 2013) which suggests that there are different methods to ensure a pure isolate is 
obtained. The OMVs were quantified using ananosight LM10 which has also recently been used 
by other researchers (Roier et al., 2016a). Other detection methods include flow cytometry 
(Wieser et al., 2014) and direct labelling of OMVs with lypophilic dyes such as 
PKH(O'Donoghue and Krachler,  
2016).  
 
OMVs have been reported in different contexts by many researchers to fall in the size range of 
10-300nm (Huang et al., 2016, Kulkarni et al., 2015). However, in the main the literature cites 
the OMVs to be 20-250nm in size. Our Nanosight Tracking Analysis (NTA) plots inFigures 
6.3.1 and 6.3.2 suggest that OMVs can be larger in size. Nevertheless, work carried out in this 
study has considered vesicles in the 20-250nm range as OMVs to enable standardisation.  
PAD has been reported as a protein that is solely expressed in P. gingivalis(Bielecka et al., 2014, 
Mangat et al., 2010), and the citrullinome of gingivalis has been published (Stobernack et al., 
2016) while arginine deiminases have been reported in various bacteria, but hitherto not with 
deiminating activity. Our findings in this chapter firmly corroborate the presence of citrullinated 
proteins in E. coli through immunoprecipitation and Mass spectrometry analysis. Though PAD 
association with P. gingivalis has been looked at previously, our study was the first to 
investigate the possibility of PAD-like activity in E. coli species. Western blot analysis gave rise 
to strong bands in the presence of F95 (a pan-deiminationantibody detecting deiminated 
proteins, Nicholas and Whitaker, 2002) and also detected a PAD-like protein as assessed by 
cross-reactivity with PAD-antibodies. Identification of PAD-positive bands with low molecular 
weight correlates with previous research carried out on P.gingivalis with band sizes ranging 
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between 43to 49kDa(Bielecka et al., 2014, Gabarrini et al., 2015).However, evolutionary 
relationship analysis by the means of the phylogenetic tree and the multiple sequence alignment 
strongly suggested that E. coli PAD is closely connected to human PAD2 (Figure 6.3). 
Nevertheless, PAD in P. gingivalis, also a Gram-negative bacterium is believed to be 
evolutionarily unrelated to mammalian PAD despite the fact that both catalyze the same 
chemical reaction(Rodriguez et al., 2009).E.coli PAD has shown to be evolutionary connected 
with human PAD2(Figure 6.3 A)(Magnadóttir et al., 2018). However,inhibition assays 
clearlydemonstrated that PAD4 inhibitor, GSK199 has been effective in both Gram-positive and 
Gram-negative bacteria compared to PAD2 inhibitior, AMF30a. Figure 6.8 and 6.9 which 
prompted the investigation to its presence primarily in E. coli. It may nevertheless also be 
possible that the confirmation of the E.coli PAD may be more similar to the human PAD4, 
although the sequence is more PAD2 related, and thus the PAD4 specific GSK199 inhibitor 
may be more effective than the other PAD-inhibitors. This will require further investigation. 
Immunoprecipitation results suggest that E. coli deiminated proteins as seen in the F95 
immunoprecipitation data.  Interestingly, total deiminated proteins were captured by anti-F95 in 
both E. coli and OMV samples and although fewer deiminated proteins were identified in the 
OMVs, it still confirms that lateral transferof deiminated proteins occurs via OMVs.OMV-
mediated genetic predisposition has been confirmed in other studies. Bielecka and colleagues 
observed a total citrullination of C5a post-treatment with P. gingivalis-OMVs as opposed to in 
vitro treatment of C5a with PAD. This vastly contributes to immune evasion decreasing the 
chemotactic ability of neutrophils (Bielecka et al., 2014).   Identification of threonine-tRNA 
ligase for the first time in OMVs was particularly interesting. Presence of only a single peptide 
is concerning but interaction with other proteins is shown by string analysis (Figure 6.6 B). 
Threonine-tRNA ligase also known as threonine-tRNA synthetase is a 642 aa long protein 
present inE. coli belonging to the family of aminoacyl-tRNA synthetases. This is present in all 
IP samples. They link amino acids to their cognate transfer RNAs (tRNA) in aminoacylation 
reactions that establish the connection between a specific aminoacid and 
a nucleotidetriplet anticodon embedded in the tRNA(Schimmel, 2008). Its involvement in RNA 
splicingandtranscriptional and translational regulation might playan important role in protein 
deimination. 
30S ribosomal protein is one of the primary rRNA binding proteins that bind directly to 16S 
rRNA where it helps nucleate assembly of the platform of the 30S subunit by binding and 
bridging several RNA helices of the 16S rRNA (Gao et al., 2003). 30S ribosomal protein 
S4(rpsD) and S15(rpsO)were present in all deiminated samples including the OMVs. This has 
been previously reported as a substrate of PAD4 mediated citrullination in HEK 293T(Guo et al., 
2011). This confirms its presence in both F95 and PAD4 E. coli IP samples. All commonly 
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expressed proteins including chaperone protein, ribonuclease, outer membrane lipoprotein, 50S 
ribosomal protein L22 and flagellin are believed to be either substrates or products of protein 
deimination(Claushuis et al., 2018). Figure 5.3.7 depicts the clear inhibition of OMV release in 
the presence of previously used EV inhibitors.Imipraminewas the most potent (72.38% 
reduction) in inhibiting OMV release compared to other reagents. The least effective was 
pantethine (21.09%) which also resulted in a 25% reduction in cell viability compared to the 
untreated control. Overall all reagents used in this study have demonstrated OMV inhibition in 
E.coli which suggests they can be used in antibiotic sensitivity assays and phage-mediated 
cytotoxicity in subsequent experiments. Also Figure 6.8 clearly demonstrates that inhibition of 
vesicle release via PAD inhibition is successful. PAD4 inhibitor, GSK199 was significantly 
effective compared to other reagents used. Although the extent of inhibition was less than with 
other OMV inhibitors as shown in (Figure 6.7), PAD reagents can still be used in future 
experiments for bacterial OMV inhibition with minimal effect on cell viability. Neutrophil 
extracellular trap (NET) formation is a well known mechanism of the immune system for 
bacterial killing. It has been found that PAD4-mediated chromatin decondensation is essential to 
form NETs and is a main player in histone-mediated bacterial killing (Bicker and Thompson, 
2013). PAD4 association with NETosis therefore increases innate immunity. Here, PAD-
inhibition in E.coli showed a different anti-bacterial mechanism by inhibiting OMV release 
from the bacteria, which may further sensitize them to killing and also prevent them from 
carrying out immune evasive strategies, including via the relase of OMVs. Many studies on 
OMVs have been based on Gram-negative bacterial species (Bonnington and Kuehn, 2014, 
Roier et al., 2016b, Perez-Cruz et al., 2013). OMV release in S. aureus has been previously 
shown by different groups in the field (Olsen and Amano, 2015, Gurung et al., 
2011).Interestingly our study has demonstrated that inhibition of biogenesis and release of 
OMVs is seen in Gram-positive bacterial species as well. Nonetheless the OMV inhibition in 
the presence of the same inhibitors was seem to be lower compared to E. coli. However, Bisin-I 
and EGTA were more potent than PAD inhibitors (Figure 6.9).  
My results suggest that EV inhibitors used previously on eukaryotic cells (Kosgodage et al., 
2017) are successful inhibitors of OMV release from bacteria, which prompts further 
investigation.The increased hydrophobicity of the reagents (Table 1) is an attribute likely to 
lead to increased cell penetration, which is visible in the results. Both EGTA and Bisin-I are less 
hydrophobic compared to the PAD inhibitors which are more successful in OMV inhibition in 
both Gram-positive and Gram-negative bacteria. Nevertheless, this type of study has not 
previously been conducted on bacterial OMVs, according to the literature, which makes it more 
interesting to express the results and steer its use in combatting antibiotic resistance and 
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possibly increasing the bacterial cell’s susceptibility to bacteriophage therapy as highlighted in 
Figure 6.10. 
 
Both CBD and nicotine have shown to effectively inhibit EV release in previous chapters. CBD 
is also well known to possess anti-bacterial properties (Appendino et.al. 2008, Hernández-
Cervantes et.al. 2017). Previous research has looked into the anti-bacterial effect of nicotine. 
According to a study by Pavia and colleagues this revealed that nicotine is effective against both 
Gram-positve and Gram- negative bacteria and fungal pathogens (Pavia et.al. 2000). Later in the 
field, agroup lead by Zaidi also clearly portrayed the anti-bacterial effect of nicotine against 
both groups of bacteria, E.coli and P. aeroginosa being Gram-negative and S. faecalis being the 
only Gram-positive bacterial species that were used in the study. It had no effect on S. aureus 
(Zaidi et.al. 2012)).However, no studies have been performed in relation to their capacity in 
OMV inhibition. Therefore,it will be very interesting to investigate the potency of CBD and 
Nicotine in OMV inhibition in the future. 
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Figure 6.10 Formulaic representation of the effect OMV inhibition could have on antibiotic and 
phage therapy. Synthesis of OMVs from bacterial cells mimics the attack by hosts’ innate and adaptive 
immune system increasing its virulence in disease.Therefore, OMV inhibition increases the susceptibility 
of bacterial cells to anti-bacterial therapy. 
 
Better OMV isolation techniques such as optiprep and a combination of density gradient 
centrifugation and ultrafiltration needs to be used to purify the vesicles and improve the quality 
of results as suggested by experts in the field (Rompikuntal et al., 2015, Elluri et al., 2014, 
Alves et al., 2016b). Also it is crucial that the size range of OMVs to isstandardised in the field 
to enable accurate quantification of vesicles that significantly affect the development of accurate 
detection methods and therapeutic strategies.Better OMV isolation techniques such as optiprep 
and a combination of density gradient centrifugation and ultrafiltration needs to be used to 
purify the vesicles and improve the quality of results as recently suggested (Rompikuntal et al., 
2015, Elluri et al., 2014, Alves et al., 2016b). 
 
It will certainly be interesting to conduct IP and Western blotting on S. aureus samples to 
identify deiminated proteins which can directly correlate with inhibition of OMV release data 
obtained in this study. 
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Chapter 7: Effect of Inhibiting OMVrelease on 
Antibiotic Activity and Phage Therapy 
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7.0 Effect of Inhibiting OMV Release on Antibiotic Activity and Phage Therapy 
7.1 Introduction 
This chapter investigates the potential of using OMV inhibitors to enhance antibiotic activity 
against E. coli and follows on from the previous work that I conducted (Chapter 6) and that 
other colleagues conducted in CMIRC (Kholia et al., 2015, Jorfi et al., 2015) investigating the 
effect of inhibiting the release of vesicles from cancer cells to enhance, by sensitizing cells, their 
response to chemotherapeutic treatment. The same reagents used in the previous chapter will be 
followed to determine their effect on the antibiotic activity via the disc diffusion method and 
Minimum Inhibitory Concentration (MIC) followed by Minimum Bactericidal Concentration 
(MBC). A range of antibiotics was used to determine the effect of these OMV inhibitors and the 
MIC experiment was performed using just Colistin. The Disc Diffusion method uses antibiotic-
impregnated discs to determine the antibiotic sensitivity of bacteria. MIC is a measure of the 
concentration of the antibiotic needed to eliminate the visible bacterial growth. MBC is the 
minimum concentration of antibiotic needed to kill the bacteria.  
7.1.1Colistin 
Colistin (Polymyxin E) is a non-ribosomal peptide with a molecular weight of approximately 
1200Da, (Figure 7.1), and is synthesized by Paenibacillus polymyxa, a Gram-positive 
bacterium. This antibiotic is seen as the ‘antibiotic of the 21st century’ (Yu et al., 2017). It acts 
on the lipoglycans and endotoxins of the Gram-negative bacterial cell membrane.  Colistin also 
known as polymyxin E, belongs to the group of Polymyxinantibiotics that was first isolated in 
Japan and used to treat Gram- negative bacterial infections (Livermore et al., 2011). These 
together with Polymyxin B are the only Polymyxins used clinically.  
Its mechanism of action is widely described by microbiologists, and essentially it  is a 
bactericidal drug that directly binds to lipopolysaccharides(LPS) and phospholipids in the outer 
cell membrane of Gram-negative bacteria and competitively displaces divalent cations from the 
phosphate groups of lipids(Falagas et al., 2005).  This disruption to the cell membrane integrity 
causes leakage of intracellular contents leading to bacterial death. 
It is also known to bind and neutralise LPS and avert pathophysiological effects of endotoxin in 
the circulation (Yahav et al., 2012, Falagas et al., 2005).MIC values for Colistin ranged between 
2-16µg/ml in the literature (Moskowitz et al., 2010, Rojas et al., 2017). Therefore, the current 
study extended this range from 0.015µg/ml to 64µg/ml. 
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Figure 7.1. The molecular structure of Colistin.  Colistin is a combination of the cyclic polypeptides 
colistin A and B with a molecular weight of 1155.455g/mol . 
7.1.2 Vancomycin 
Vancomycin is effective against Gram-positive bacterial species including Staphylococcus, 
Streptococcus and Listeria. It is recommended to be administered intravenously and is 
prescribed for serious skin, blood-borne and joint infections and meningitis caused by 
methicillin-resistant S. aureus (MRSA). It is a unique glycopeptide that is structurally unrelated 
to any other antibiotic (Ng et al., 2014). There is sufficient evidence that vancomycin alters the 
permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis. Induction 
of bacterial L-phase variants from susceptible organisms with vancomycin is extremely difficult, 
and such variants are unstable. Stable L-phase variants induced by other agents are susceptible 
to vancomycin (Watanakunakorn, 1984). Abundant usage of vancomycin in studies(Goldstein et 
al., 2018)related to Staphlococcus spp. was the main reason to use it in the current study against 
S.aureus. The majority of MIC values for vancomycin have been recorded in the range of 1.5-
2µg/ml(Maclayton et al., 2006, Kshetry et al., 2016) but there are some studies where a MIC 
value of 8µg/ml and higher have been reported(Jiang et al., 2017, Lepe et al., 2014).Therefore, a 
MIC confirmation test starting from a concentration of 8µg/ml was carried out and the MIC was 
considered accordingly.  
7.1.3 OMV inhibition and Phage Therapy 
My earlier description of pharmacological inhibition of OMV release as a means of enhancing 
antibiotic therapy, also has a potential to promote the effectivitiy of bacteriophage (phage) 
therapy, where phage are used to lyse bacteria (Inal, J. AITE 2004) especially if OMV play a 
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role as a decoy to phage infection.  Lambda phage was the virus chosen againstE.coli. The Pan-
PAD inhibitor, Cl-amidinewas to be used as described in the previous chapter.  In this study, the 
effect of OMVs and the inhibitor have been analysed in terms of phage titre (plaque forming 
units) and the results illustrate the effect. 
7.1.4 Phage Therapy 
Phage therapy describes the therapeutic use of viruses that have a lytic life cycle after infecting 
their host bacteria. This has been widely used to treat pathogenic bacterial 
infections(Sulakvelidze et al., 2001).  It is important that the specific phage is used that targets 
the particular bacteria. The specificity of this treatment is likely to be much narrower than 
available antibiotic therapies. The limited host range is an advantage as phage therapy is thus 
lessadverse to side-effects and off-target effects, compared to the use of antibiotics which can 
destroy the normal gut flora resulting in adverse side-effects. Phage resistance is also possible 
just as with antibiotic resistance but the rate of appearance is lower and it is comparatively much 
easier to develop new phage strains than developing a novel antibiotic. As bacteria evolve 
resistance, the relevant phages naturally evolve alongside(Lin et al., 2017). When‘superbugs’ 
(resistant bacteria) appear, the super phage already attacks it. The phage will have to be isolated 
from the same environment.  
Phages are ideal for localised use as they penetrate deeper as long as the infection is present 
unlike antibiotics which are surface treatments. Also phage stop reproducing once the targeting 
host has been destroyed(Abedon et al., 2011). Therefore, it has no detrimental effect on the 
surrounding healthy tissue. Furthermore, phages do not build up secondary resistance as seen 
with antibiotics. Phage therapy should be improved as a solution to multi-drug resistance. 
7.1.5 Lambda Phage 
Lambda phage (λ) is an enterobacteriaceae infecting virus which was discovered by Esther 
Lederberg in 1949 (Rajagopala et al., 2011). It consists of an Icosahedral head, measuring 
around 50-60 nm in diameter, containing double-stranded linear DNA as its genetic material. Its 
flexible tail is 150nm long and may contain tail fibres. Its genome is dsDNA of 48.5KB(Casjens 
and Hendrix, 2015).  λ  is a temperate phage which has two possible life cycles after infecting 
its E. coli host, both a lytic and lysogenic one(Clokie et al., 2011). A typical lytic cycle involves 
the multiplication and release of phage progeny into the extracellular space. To maintain this 
‘lysogenic’ state λ has evolved an elaborate pathway of site-specific recombination that inserts 
the viral chromosome into the chromosome of the host, using specific sites on the phage (attP) 
and bacterial (attB) chromosomes(Clokie et al., 2011). 
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7.2 Methods 
7.2.1 Disc Diffusion Method 
Discs impregnated with Colistin, Rifampicin, Erythromycin, Kanamycin and Vancomycinwere 
used in this study. Agar plates were prepared as described previously (section 2.11.1). Solutions 
of inhibiting reagents of appropriate concentrations (EGTA, 1.5mM; Bisindolylmaleimide-I, 
10µM; Imipramine, 25µM; Y27632, 1µM; D-pantethine, 1mM) were prepared and sterile paper 
discs were soaked in each reagent. An inhibitor disc was placed in the middle while an 
antibiotic disc was placedequi-distant to the inhibitor disc. These results were then graphically 
represented as in Section 7.3.1. 
 
7.2.2 Effect of OMV inhibitors on MIC of Colistin 
An E. coli suspension was prepared by inoculating a few colonies from an E. coli plate and 
mixing well with sterile distilled water. This was incubated overnight at 37°C. Müller Hinton 
Broth was prepared as stated earlier (section 2.9.2) on the day of the experiment.This 
experiment used 64µg/ml as the starting concentration. 100µl of Colistin was added to the first 
triplicate and mixed well. This then followed using the doubling dilution method whereby 100µl 
from each triplicate was transferred to the next set of triplicates until the concentration reached 
0.015µg/ml. A triplicate of control with no antibiotic added was also prepared. 20µl of the 
bacterial suspension was added to each well and mixed thoroughly (the total well volume being 
220µl). The remaining sets of wells of the plate followed the same pattern but had the inhibiting 
reagents (Figure 7.2). This was then incubated overnight at 37°C. The transparent wells were 
recorded for MIC values. The MIC values of antibiotic treated control wells were then 
compared to the wells treated with both inhibiting reagent and antibiotic. 
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Figure 7.2: MIC of Colistin. The 96-well microtitre well plates were arranged as shown with appropriate 
volumes of the antibiotic, inhibiting reagents and the bacterial suspension as described. Upon incubation, 
the wells were compared to the untreated control and transparent wells were considered for MIC values. 
 
7.2.3 Isolation and Propagation of Lambda Phage 
The phage kit, 200201/ Gigapack III Gold Packaging Extract, 4 Rxn from Agilent technologies 
was used as the source of lambda phage and E. coli VCS257. The isolation was carried out 
adhering to the manufacturer’s guidelines. Phage propagation was initiated by adding 5ml of 
SM buffer to the highly confluent phage plate as shown in Figure 7.8. It was left on the shaker 
for 2h at room temperature after which the SM buffer was pipetted off and spun at maximum 
speed (25,000g for 10min). The supernatant was either immediately used or stored at 4°C for 
future experiments.  
7.2.4 Effect of phage concentration on OMVRelease 
The isolated phage was used to prepare serial dilutions in SM buffer to examine the effect on 
OMV production.  An overnight culture of E. coli grown in LB broth to an OD of 0.5 was used 
in all experiments. 10µl of phage from each dilution was mixed with 200µl of E. coli suspension 
and incubated at 37°C for 1h. The OMV isolation was carried out as described in section 5.2.1.1. 
Phage concentration was calculated and expressed in Plaque Forming Units per ml (PFU/ml). 
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7.2.4.1 Effect of incubation time on OMV Release 
The isolated phage was used to prepare serial dilutions in SM buffer to examine the effect on 
OMV production.  An overnight culture of E.coli grown in LB broth to an OD of 0.5 was used 
in all experiments. 10µl of phage from each dilution was mixed with 200µl of E. coli suspension 
and incubated at 37°C for different durations (0, 5, 10, 15 and 20min). The OMV isolation and 
quantification were carried out as described previously (section 6.2.1). Phage concentration was 
calculated and expressed in Plaque Forming Units per ml (PFU/ml). 
7.2.4.2 Effect of PAD inhibition on OMV Release 
Chloramidine (Cl-amidine), a pharmacological inhibitor of PAD enzyme has been shown to 
affect EV synthesis and release (Fig 3.7). Its presence in E. coli (Section 6.3.4) was confirmed 
by immunoprecipitation and Western blotting. Therefore, it was interesting to examine its effect 
on OMV synthesis. An overnight culture of E.coli grown in LB broth was used in the 
experiment. The cells were washed at 4,000 g for 10min and seeded in triplicate in micro-
centrifuge tubes. 50µM of Cl-am was added separately into each tube and incubated for 24h at 
37°C in 5% CO2. OMV isolation was carried out according to section 6.2.1.The experiment was 
repeated thrice and the OMV count was determined using NTA analysis (Nanosight NS500). 
7.2.4.3 PAD Inhibition Enhances Phage Concentration 
The aim here was to determine the effect of pharmacological OMV inhibition on phage 
propagation. An overnight culture of E. coli grown in LB broth up to an OD of 0.5 was used. 
200µl of E. coli was incubated with 50µM of Cl-amidine for 60min which was then incubated 
with 10µl of 10-4 phage for 20min. 5ml of Top Agar was added to the mixture and poured on 
pre-warmed bottom agar plates. The plates were incubated overnight at 37°C in 5% CO2. The 
experiment was carried out in triplicate. Phage concentration was calculated and expressed in 
Plaque Forming Units per ml (PFU/ml). 
7.2.5 Effect of addition of OMVs on Phage Therapy 
With a view to identifying whether adding OMVs affects the phage concentration, the following 
experimental set-up was prepared: different concentrations of isolated OMVs were added to 
10µl of10-4 lambda phage and incubated for 60min at 37°C. Then 200µl of an overnight culture 
of E. coli was added to the phage-OMV mixture and further incubated for 20min at 37°C. 5ml 
of Top Agar was added to the mixture and poured on pre-warmed bottom agar plates. The plates 
were incubated overnight at 37°C in 5% CO2. The experiment was carried out in triplicate. 
Phage concentration was calculated and expressed in Plaque Forming Units per ml (PFU/ml). 
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7.2.6Transmission Electron Microscopy imaging of Lambda phage and phage-OMV 
Interaction 
10-3 of phage stock was used for TEM imaging of phage. 1.7µl of a 10-3dilution of phage stock 
(of titre 5.8×108 PFU/ml) was mixed with 3.6µl of a 10-1dilution of OMV stock (1.4×108 
OMVs/ml) and incubated for 30min at 37°C in 5% CO2. TEM was carried out as described 
previously (section 2.12).  
7.3 Results 
7.3.1 OMV inhibitors enhance the effect of antibiotic activity against E.coli 
The investigation into finding an effective inhibitor of OMV release from bacteria was 
important to examine their possible role in enhancing antibiotic activity. Initial data as presented 
inFigure 7.3 clearly shows the effect of OMV inhibitors on antibiotic activity. Rifampicin has 
shown to be the most responsive to inhibitors compared to other antibiotics. However, of the 
OMV inhibitors, GSK199 was effective against erythromycin, increasing its effectivity, 
measured as a percentage increase in the measured zone of inhibition on the lawn of E. coli by 
88.9 %( p=0.0025); rifampicin by 56.72% (p=0.0561) and colistin by 14.62% (p=0.2495). 
Bisin-I was active against rifampicin and kanamycin increasing their effectivity by 42.62% and 
17.9% respectively (p=0.0263 andp= 0.0122). PAD inhibition was superficially effective 
against all antibiotics used in the study. BB-Cl-amidine was the most potent PAD inhibitor 
which was mostly effective together with rifampicin. It increased the zone of inhibition 
by106.45% (p=0.0025).  Nonethelss, Cl-amidine was also effective across the study and was 
most effective in combination with erythromycin (35.6%, p=0.0572). Also, Bis-I and EGTA had 
quite similar effects with rifampicin with an overall increase of zone of inhibition by at least 40% 
with Bis-I (p=0.0263) and with EGTA being 100% (p=0.0005). EGTA increased the 
effectiveness of erythromycin by 50% (p=0.0093). The zone of inhibition as a result of 
Kanamycin activity wasincreased with bisin-I by 16.96% (p=0.0595), with Cl-amidine by 38.76% 
(p=0.0390) and with BB-Cl-amidine by65.62% (p=0.0186). Vancomycin had no activity against 
E. coli suggesting that it is only effective against Gram-positive bacterial species. Zhou and 
colleagues have clearly stated that E. coli is resistant to vancomycin as it cannot significantly 
penetrate outer membrane. However, the synergy between different antibiotics was used to 
monitor the improved effectiveness. The results indicated that the effect was insignificant on 
growth inhibition or cell killing (Zhou et al., 2015) which supports our thesis findings. 
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Figure7.3. UsingOMV inhibitors increase the antibiotic activity against E.coli.All antibiotics (Abs) 
except for vancomycin were shown to have significant increases in their zones of Inhibition. EGTA was 
effective against Erythromycin and Rifampicin increasing the measured zones as a measure of activity by 
50% (p=0.0093) and 100% (p=0.0005) respectively.GSK199, Cl-amidine and BB-Cl-amidine were all 
effective against all antibiotics tested. BB-Cl-amidine resulted in the highest inhibition of all. It increased 
the zones of inhibition by 37.5% (p=0.0351) for colistin, erythromycin by 90% (p=0.0006), rifampicin by 
106.45%(p=0.0025) and kanamycin by 65.18% (p=0.0186). However,the PAD2 inhibitor, AMF30a 
exerted an antagonist effect opposed to other PAD inhibitors with respect to all antibiotics except 
Rifampicin. Although not significant, the zone of inhibition was increased by 13.33% (p=0.0572). 
Bisindolylmaleimide-I was effective against rifampicin and kanamycin increasing their activity by at least 
44.3% (p=0.0263) and 16.96% (p=0.0595) respectively. Pantethine increased the zone of inhibition by 
75.47% (p=0.0034) with respect to erythromycin and by 43.11% in combination with rifampicin 
(p=0.0153). Kanamycin was the least affected antibiotic in the presence of OMV inhibitors. Cl-amidine 
was 38.76% (p=0.0390) effective and BB-Cl-amidine was 65.62% (p=0.0186) effective against 
Kanamycin. Vancomycin was not effective against Gram-negative bacterial colonies as it did not result in 
a zone of inhibition even in the presence of any of the used antibiotics alone. Importantly, there were no 
zones of inhibition seen in the plates which were only treated with the inhibitor discs which clearly shows 
that there is no sole effect exerted by the inhibitors on bacterial growth. The experiment was carried out 
two times and the data presented are mean ± SEM of the results. 
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7.3.2 Effect of OMV Inhibitors on MIC value of Colistin against E. coli 
The MIC value of Colistin against Gram-negative bacteria has been inconsistently reported in 
the literature so it was essential to investigate this further. The data presented in Figure 7.4 
reveals the effect of OMV inhibitors on the MIC of Colistin. It was interesting to see that all 
reagents used managed to decrease the MIC value of Colistin by more than 50%. BB-Cl-
amidine and Cl-amidine resulted in the lowest MIC values producing an 88% reduction in MIC 
(p=0.0001 and p=0.0002 respectively) while GSK199 lowered the MIC by 76% (p=0.0004). 
Though the MIC of Colistin in the presence of EGTA was higher compared to the others, this 
still resulted in a 52% reduction compared to the untreated control (p=0.0183).  
7.3.3 OMV inhibitors enhances the effect of antibiotic activity against S. aureus 
OMV inhibitors had a significant effect on Vancomycin with Cl-amidine being more potent 
with 42.67% increase in antibiotic effectivity (p=0.0354) (Figure 7.5). EGTA, GSK199 and 
Bisin-I increased the zone of inhibition by atleast 16% (p=0.0022). However, Kanamycin and 
colistin had the highest effect imposed by OMV inhibitors.  EGTA was effective against 
kanamycin which increased the zone of inhibition by 12.24% (p=0.0351) and Colistin by 10.96% 
(p=0.0296). However, EGTA did affect rifampicin as Bisin-I, which increased the effectiveness 
by 8.47% (p=0.1448). Bisin-I was also active against kanamycin increasing antibiotic effectivity 
by 19.42% (p=0.0166) and colistin by 19.35% (p=0.0351). GSK199 was also active against 
rifampicin, increasing the zone of inhibitionby 10.06% (p=0.0202). BB-Cl-amidine was also 
effective against erythromycin and kanamycin which managed to increase the zone of inhibition 
by 18.22%(p=0.0234) and 28.98% (p=0.0101) respectively. Cl-amidine was also active against 
rifampicin which increased the zone of inhibition by 6.43% (p=0.0239), kanamycin by 
20.81%(p=0.0055) and colistin by 21.53% (p=0.0444). Overall a significant effect of PAD 
inhibition was noted in antibiotic activity against S. aureus. 
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Figure7.4 OMV inhibitors reduce the MIC value of Colistin. All OMV inhibitors managed to lower 
the MIC value of Colistin by 50%. However, BB-Cl-amidine was the most potent which reduced the MIC 
by 91.59% (p=0.0002). Cl-amidine decreased MIC by 87.39% being the second most potent inhibitor 
against collistin. However, both GSK199 and EGTA were effective by 74.79% (p=0.0004) and 66.3% 
(p=0.0183) respectively in lowering MIC.  Although not significant, EGTA was 75% less effective than 
BB-Cl-amidine in reducing MIC (p=0.2065). GSK199 was less potent compared to BB-Cl-amidine by 25% 
(p=0.4879). Nevertheless there was no effect on MIC withCollistin in the presence of only the inhibitors 
which clearly shows that there is no sole effect exerted by the inhibitors on bacterial growth. The 
experiment was repeated three times and the data presented are mean ± SEM of the results. 
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Figure 7.5 Using OMV inhibitors increase the antibiotic activity against S.aureus. OMV inhibitors 
were active against all antibiotics used. However, Vancomycin, Rifampicin, Kanamycin and Colistin 
were shown to producea significant increase in their zones of Inhibition. Vancomycin was affected by 
Bisindolylmaleimide-I which increased its zone of inhibition by 16% (p=0.1181). GSK199 and Cl-
amidine were more potent against vancomycin which increased its effectiveness by at least 40% 
(p=0.0250 and p=0.1562). Cl-amidine was also effective against Rifampicin, Kanamycin and Colistin 
which also increased the zone of inhibition by 6.43% (p=0.1077), 20.81%(p=0.0055) and 21.53% 
(p=0.0444) respectively. GSK199 was also active against Rifampicin which increased the zone of 
inhibition by 10.06% (p=0.0202). BB-Cl-amidine was shown to increase the zone of inhibition by 18.22% 
(p=0.0234) against Erythromycin and by 28.98% (p=0.0101) against Kanamycin. EGTA and 
Bisindolylmaleimide-I were also potent against all antibiotics with Erythromycin being the exception. 
The PAD inhibitors were more effective in conjunction with antibacterial therapy against Gram positive 
bacterial species. There were no zones of inhibition seen in the plates which were only treated with the 
inhibitor discs which clearly shows that there is no sole effect exerted by the inhibitors on bacterial 
growth. The experiment was carried out three times and the data presented are mean ± SEM of the results. 
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Figure 7.6 OMV inhibitors reduce the MIC value of Vancomycin. All OMV inhibitors managed to 
lower the MIC value of Vancomycin by at least 50%. However, Bisindolylmaleimide-I (Bisin-I) and 
EGTA were the most effective reducing the MIC of vancomycin by 75% (p=0.0004 and p=0.0001 
respectively). GSK199 was the least effective in combination with vancomycin which only resulted in a 
25% decrease in MIC (p=0.0161). GSK199 was less effective compared to the most effective inhibitors 
by 80% (p=0.0079). Cl-amidine increased the effectiveness of vancomycin by at least 62.5% (p=0.0022). 
This was lower than that of the most potent inhibitors by 75% (p=0.0158). It was however more effective 
than GSK199 by 37% (p=0.0550). Nevertheless, there was no effect on MIC of Collistin in the presence 
of only the inhibitors which clearly shows that there is no sole effect exerted by the inhibitors on bacterial 
growth. The experiment was repeated three times and the data presented are mean ± SEM of the results. 
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7.3.4 Effect of OMV Inhibitors on MIC value of Vancomycin against S. aureus 
 
The MIC value of Vancomycin against S. aureus was inconsistently noted in the literature so it 
was essential to investigate this further. Figure 7.6 reveals the effect of OMV inhibitors on the 
MIC of Vancomycin. The reagents that were more effective in Figure 7.5 were used in this 
experiment. It was interesting to see that all reagents used managed to decrease the MIC value 
by at least 25%. Bisin-I and EGTA resulted in the lowest MIC value of 0.5µg/ml producing a 75% 
reduction (p<0.0001). PAD inhibitors together managed to reduce the MIC by 37.5% with Cl-
amidine being more effective resulting in a 50% reduction (p=0.0022) while GSK199 only 
lowered MIC by 25% (p=0.0161). The results suggest that these inhibitors can be used in future 
experiments.  
 
7.3.5 Propagation of Lambda phage 
 
Figure 7.7 Lambda phage propagated at 10-3concentration. This plate was used in phage propagation. 
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7.3.6 Effect of phage concentration on OMV Release 
It was very interesting to observe the effect of phage itself on the release of OMVs from its 
targeted cell, E. coli. It is very well established that the presence of a high concentration of 
phage promotes OMV release which in turn can have a decoy effect on phage activity (Shabbir 
et al., 2016, Reyes-Robles et al., 2018b, Kulkarni et al., 2015, Seed, 2015, Tabib-Salazar et al., 
2018, Górski et al., 2017). This is another type of defence mechanism adopted by bacteria in 
order to combat phage attack which may result in the building up of resistance towards phage 
therapy. The results obtained emphasise the importance in using low phage concentrations to 
actively sensitise the bacterial cells to phage therapy. Multiplicity of Infection (MOI) effectively 
indicates the concentration of infectious agents (phage in this case) that attack each bacterial cell 
during an infection. As the MOI decreases so does the OMV release As shown in Figure 7.8A 
and Figure 7.8B  the lowest phage titre of 4.4× 104 reduced the OMV count by 73.15% 
(p=0.0002) compared to the highest OMV concentration recorded in the study in the presence of 
a phage titre of 9.4×108. Compared to using the highest phage titre, a titre of 5×105 reduced the 
OMV concentration by 69% (p=<0.0001). There was a 54.23% decrease in OMV release when 
the MOI was decreasedfrom 6.27 to 0.05 (p=0.0055). The overall effect of decreased MOI from 
6.27 to its lowest of 0.0004 reduced the OMV count by 73.15%. Therefore a 10-4 phage dilution 
(5.8×108 PFU/ml)wasused as the standard in all experiments. 
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Figure 7.8 Effect of phage concentration on OMV release. A, Phage concentration has a significant 
effect on OMV release. As the phage concentration decreased so did the number of OMVs released. The 
OMV concentration was the lowest at the phage titre of 4.4× 104 PFU/ml. This was a reduction of 73.14% 
(p=0.0002) compared to the highest OMV concentration recorded in the study in the presence of a phage 
titre of 9.4×108 PFU/ml. The second lowest phage titre, 5×105PFU/ml reduced the OMV concentration by 
69% (p=<0.0001) compared to the highest phage titre. This was however 25.25% higher than the lowest 
OMV concentration (p=0.3107). B, At a MOI of 0.0004 the lowest OMV concentration released from 
bacteria was detected, which was a drastic reduction of 73% (p=0.0002) compared to the highest MOI of 
6.27. As the MOI of phage reduced so did the OMV concentration, showing a dose response of phage on 
OMV release. An MOI of 0.05 MOI reduced the OMV concentration by 54.25% (p=0.0055). However 
anMOI of 0.04 was shown to stimulate OMV release by 24% (p=0.6301).The MOI should be considered 
when investigating novel aspects of phage therapy. The experiment was repeated three times and the data 
presented are mean ± SEM of the results. 
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7.3.7 Effect of phage-OMV incubation time on the release of OMVs 
 
 
 
Figure 7.9 Effect of Incubation time on OMV release.The graph symbolises the significance of 
incubation time of phage and bacteria on OMV release. The concentration of OMVs increased steadily 
for 15min which was followed by a rapid decline. OMV concentration increased by 11.7 % in the first 5 
min (p=0.1365) which was further increased by 36.12% (p=0.0327). This was however rapidly decreased 
by 49.8% after 15min (p=0.0099) which was only 10.93% compared to the starting OMV concentration at 
5min (p=0.3331). The overall OMV reduction was calculated to be 43.6% (p=0.0073). The experiment 
was repeated three times and the data presented are mean ± SEM of the results.  
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There was a significant increase in OMV production (p=0.0073) within the first 15min of 
incubation by 11.72% (10 min) and 36.12% (15 min). However, there was a significant decrease 
in OMV release for incubation periods beyond that (20 min; p=0.0099). The concentration of 
OMVs released at 20 min was even lower than the starting concentration of OMVs by 
6.27 %( p=0.3331).  However previous experiments carried out in the field suggest that 15min 
incubation is optimal for E. coli-phage initial interaction. 
7.3.8 Pharmacological inhibition of PAD significantly improves therapeutic usage (in 
phage therapy) of Lambda Phage 
 
PAD catalysed citrullinated proteins are known to be present in E. coli (sections 6.3.4 and 
6.3.5). Figure 7.10A illustrates the effect of pharmacological inhibition of PAD via Cl-amidine 
as significantly reducing the number of OMVs released compared to untreated control by 48.06% 
after 1h incubation (p<0.0001). Moreover, the data presented in Figure 6.9B clearly shows that 
the presence of OMVs obstructs the (receptor-mediated) binding of phage to E. coli as the titre 
of free phage then able to infect E. coli in the subsequent plaque assay is dose-dependently 
diminished with increasing OMV concentration. Although it was not significant, addition of 10 
OMVs reduced the phage activity (measured as the phage titre) by 13.3 % (p=0.1987). In 
contrast, phage activity reduced by 97.92% after the addition of 103OMVs. This significant 
reduction (p=<0.0001) was however restored by 99.01% (p=<0.0001) when the OMV synthesis 
and release was inhibited.  Pharmacological inhibition of PAD by Cl-am has increased phage 
particles that are available to potentially cause bacterial lysis by 45.45% compared to Cl-am 
untreated E. coli and phage control (p=0.0052) and by 52.73% compared to addition of 10-fold 
OMVs (p=0.0002). Thus OMV inhibition would be expected to reduce the capacity of bacteria 
to use OMVs as decoys for infection with phage. Negative controls of samples without phage 
(just E. coli and OMVs) were used in the experiment to confirm that the plaques were only 
visible in the presence of phage and not as a result of the interaction of E. coli with introduced 
OMVs.  
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Figure 7.10 Effect of PAD inhibition on OMV release and its impact on Phage activity. Addition of 
OMVs significantly reduced the PFU in the samples (p=0.0010 in the presence of 103 OMVs). OMV 
‘absorption’ of phage was intimated by the significant increase in phage titre (PFU/ml) in Cl-amidine-
treated sample (p=0.0052). This was significantly higher by 42.85% (p=<0.0001) compared to addition of 
101 OMVs and 99% compared to the addition of 103OMVs (p=<0.0001). Additions of OMVs to E.coli 
samples were taken as negative control to confirm that changes were only observed in the presence of 
lambda phage.(*= significance compared to the control; *= significance addition of 103 OMVs compared 
to the Cl-am treated; *=significance addition of 101 OMVs compared to the Cl-am treated. The 
experiment was repeated three times and the data presented are mean ± SEM of the results.  
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7.3.9 Electron Microscopy Imaging confirms the likelihood of a phage-OMV Interaction 
during Bacterial Infections 
 
 
 
 
 
 
 
 
 
Figure 7.11 Negative stain TEM micrographs of OMVs after incubation with lambda phage.10-
3dilution of phage stock of titre 5.8×108 PFU/ml) was mixed with 10-1dilution of OMV stock (1.4×108 
OMVs/ml) and incubated for 30min at 37°C in 5% CO2. The particles were stained with 1% (w/v) uranyl 
acetate following incubation. A, ploydispersed population of OMVs were observed. B, an enlarged image 
of membrane bound   E. coli-OMV. C, lambda phage with icosahedral head, sheath, tail and fibres. .D, a 
clear  image of OMV-phage interaction. E,  phage attachment to a chain of OMVs. 
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200nm 
200 nm 
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Transmission electron microscopy was used to confirm OMV isolation by morphology and 
average size estimations. It was also used to visualize any lambda phage-OMV complexes. 
Figure 7.11A and Figure 7.11B show OMVs isolated from E. coli. The sample was clearly 
poly-dispersed with the majority of vesicles ranging in size from 20- 50nm while some were 
100-207nm in diameter. Figure 7.11C is a micrograph of lambda-phage with an icosahedral-
shaped head measuring approximately ranging in size from 27nm to 36.7nm in width, showing 
the contractile sheath (tail) ranging in length from 101nm to 260nm and the tail fibres ranging in 
length from 200-315nm. Many complexes between lambda and OMVs were visualised as in 
Figure 7.11D and Figure 7.11E. It was particularly interesting to identify the formation of 
chains of OMVs in complex samples (phage and OMVs) which were totally absent from 
samples of where only OMVs were present.  
 
 
 
Figure 7.12 Schematic representation of the effect Cl-am- mediated OMV inhibition on phage 
therapy. Synthesis of OMVs from E.coli cells promotes vesicle-receptor mediated interaction with phage 
particles arresting the bacterial-phage interaction. Pre-treatment of E.coli cells with Cl-am hinders OMV 
release. This promotes the phage-bacterial interaction leading to phage-mediated bacteriolysis.  
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7.4 Discussion 
This section has elucidated the importance of OMV inhibition on enhanced susceptibility of 
both Gram-positive and Gram-negative bacterial species to antibiotic therapy. Upon OMV 
inhibition, E. coli was more sensitive to erythromycin, rifampicin, colistin and kanamycin. 
There was no vancomycin activity on E. coli which confirms its limited effectiveness on Gram-
positive species. Colistin had a significant effect in this study (Figure7.1) clearly demonstrating 
that colistin activity is enhanced in the presence of certain inhibitors. This is further illustrated 
in Figure 7.4 where the inhibiting reagents have significantly decreased the MIC value of 
colistin which suggests that lower concentrations of the antibiotic can be used to treat infections 
with minimal damage to healthy cells. 
It has been shown that the presence of calcium decreases the effect of colistin mediated damage 
in Paenibacillus polymyxa which suggests that Ca2+ modulates a protective barrier against 
colistin(Wang et al., 2017). EGTA is a calcium chelator which can mop up the excess calcium 
present in the intercellular environment which acts synergistically with colistin to elicit a 
bactericidal effect. This together with its role in OMV inhibition enhances the antibiotic activity. 
Polymyxin B is a PKC inhibitor(Robinet et al., 2005).  
Although there is no evidence of Polymyxin E (colistin) being involved in PKC inhibition, the 
presence of PKC inhibitor, Bisin-I, is shown to cease OMV secretion. This might thereby 
decrease drug expulsion and increase bioavailability of colistin. Also, Vincent and colleagues 
have demonstrated that E. coli cells contain both a protein-tyrosine kinase and a 
phosphotyrosine-protein phosphatise (Whitmore and Lamont, 2012). So Bisin-I might be acting 
on these pathways and stop phosphorylation which is another mechanism by which E. coli 
undergoes apoptosis. Similarly, Imipramine, an inhibitor of A-SMase (Kosgodage et al., 2017)is 
directly involved in OMV inhibition as described in section 3.4. Thereforeimipramine is likely 
to improve the bacterial cell’s ability to retain the antibiotic within the bacterial cells 
augmenting its activity.  
Pharmacological inhibition of OMV release has not been communicated previously. However 
many groups have discussed the use of OMVs as drug delivery vehicles (Jain and Pillai, 2017, 
Gujrati et al., 2014, Wang et al., 2018, Gerritzen et al., 2017, Jan, 2017a, Ellis and Kuehn, 
2010) . The exact mechanism for packaging proteins and other reagents in OMVs has not been 
fully understood but Alves and colleagues have successfully managed to insert an enzyme, 
phosphotriesterase (PTE) in OMVs which enables its activity to be maintained when subjected 
to elevated temperatures, iterative freeze-thaw cycles and lyophilisation. This was designed by 
creating a synthetic linkage between PTE and a highly expressed transmembrane porin protein 
(OmpA) known to be abundant in OMVs (Alves et al., 2016a). Thesame group has shown that 
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bacterial OMVs can be used as nano-bioreactors in cancer therapy. A mutant E. coli strain that 
exhibits reduced endotoxicity toward human cells was engineered to generate OMVs displaying 
a human epidermal growth factor receptor 2 (HER2)-specific affibody in the membrane as a 
targeting ligand. Systemic injection of siRNA-packaged OMVs caused targeted gene silencing 
and induced highly significant tumour growth regression in an animal breast cancer model 
(Alves et al., 2016a). The effect of PAD inhibition on bacterial species has been discussed 
previously only on oral bacteria (Mangat et al., 2010). This has been only in the context of its 
correlation to rheumatoid arthritis (Montgomery et al., 2016) whereas there has been no 
reporting on PAD-related OMV inhibition in bacterial species let alone in E.coli or S.aureus. 
The work presented herein has clearly shown that PAD-mediated OMV inhibition has a 
significant effect on antibiotic activity, reducing MIC values specifically on colistin and 
vancomycin. Interestingly, this effect was reduced in S. aureus which suggests that there might 
be different mechanisms of OMV biogenesis and release involved. Additional experiments 
using different OMV inhibitors will be useful. However the PAD-mediated OMV inhibition 
remarkedly increased in S. aureus which suggests that Gram-positive species might be more 
sensitive to PAD enzyme. Looking forward, this needs to be examined in a range of Gram-
positive and Gram-negative species in order to reach a definite conclusion.  
 
This study has shownthat using OMV inhibitors strongly improves antibiotic activity.One might 
speculate that this could be due to minimising drug expulsion by bacterial cells and so 
increasing their capacitiy to retain antibiotic; this in turn allows a more effective bactericidal 
activity. Consequentlythis plays an important role in minimising antibiotic resistance as 
minimal doses of the antibiotic can be administered that can still provoke a bactericidal effect. 
Further work is needed to fully establish this phenomenon.  
 
Bacteriophage-OMV interaction has been widely expressed (Klimentova and Stulik, 2015, 
Shabbir et al., 2016, Manning and Kuehn, 2011, Jan, 2017b, Simmons et al., 2018) which in 
view of the capacity described in this thesis to modulate OMV release, made it a particularly 
interesting topic to further investigate. Identification of novel OMV inhibitors and their 
influence on improved antibacterial therapy set the background for the research undertaken in 
this chapter. It was also of interest to investigate the effect of phage itself on OMV synthesis 
and release. Figure 7.8 clearly demonstrated that the lower phage concentration resulted in a 
low level OMV release andFigure 7.9 depicted that a shorter incubation time increases the 
OMV concentration. These findings confirmed the optimal conditions recommended according 
to the literature. A 108 to 1010PFU/ml concentration of phage stock was used in the experiments 
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with an initial E.coli- phage interaction interaction time of 15min before plating up. This was 
then followed by 24h incubation at 37°C. However, countable phage particles were observed 
when the stock was diluted down to 10-5 to 10-7(Bonilla et al., 2016, Wang et al., 2006). 
Therefore, as the MOI decreases so does the OMV concentration. These findings are consistent 
with the research work on T4 and E.coli by Manning and co-workers (Manning and Kuehn, 
2011).  
OMVs released by bacteria elicit a subtle defensive effect that has been a challenge to develop 
successful therapy. Our previous research findings in the thesis evaluated the importance of 
OMV inhibition on improved antibiotic therapyin vitro. It has also been shown that the presence 
of OMVs decreases the virulence of phage allowing the bacterial cells to be resistant to such 
therapy leading to the possible therapeutic use of phage against bacterial infection. E. coli uses 
this defence mechanism to maximise the binding of phage particles to OMVs instead of the 
bacterial cells to maximise the survival in such conditions as shown in Figure 7.10 Addition of 
OMVs from 10-fold to 1000-fold reduced the MOI from 0.1 to 0.0001 significantly reduced 
which increased the chance of phage binding to OMVs by 85%. This in turn reduced the phage 
infection in bacterial cells drastically.  Further calculations revealed that approximately 24 
phage particles are mopped up by each OMV particle which decreases its infectivity. This 
phenomenon has also been demonstrated in other bacterial species in the presence of various 
bacteriophages including T7 and T4(Reyes-Robles et al., 2018b, Tzipilevich et al., 2017, 
Shabbir et al., 2016). Having seen the detrimental effect caused by OMVs and previous findings 
of OMV inhibition improving the antibiotic therapy in vitro, I was encouraged to investigate 
whether OMV inhibition similarly could stimulate the phage activity. The Pan-PAD inhibitor, 
Cl-amidine was used for OMV inhibition. The clear demonstration of the presence of PAD 
enzyme and citrullinated (deiminated) proteins in E.coli in previous chapters lead to the use of 
Cl-amidine in this section. As discussed previously, there was a significant improvement in 
phage infection in the presence of Cl-amidine. It considerablyreduced the number of OMVs 
available to bind to phage particles consequently increasing the chance and the rate of phage 
binding to E.coli.This strongly suggest  that OMV inhibition is the key to drive the maximum 
infection potential of lambda phage leading to successful phage therapy. These findings were 
confirmed via electron microscopy as shown in Figure 7.11. This was able to demonstrate the 
binding of lambda phage to OMVs which further confirmed our conclusion. TEM further 
signified the abundance of OMVs in the smaller size range of 20-50nm. In addition to the phage 
attachment to isolated OMVs, the TEM images in the study also revealed bacteriophage binding 
to multiple chains of OMVs as shown in (Figure 7.11 E). Similar chains of bacterial vesicles 
have been seen in Myxococcus xanthus TEM images as reported by a US research group 
(Berleman et al., 2016). Furthermore, Bohuszewicz and colleagues has also reported the 
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presence of similar structures in Shewanella oneidensis MR-1. These ‘nanowires’ were seen in 
atomic force microscopy images produced during the study(Bohuszewicz et al., 2016). S. 
oneidensis is a gram-negative, anaerobic species that is notable for metal iron reduction. 
Pirbadian and colleagues very interestingly has reported the presence of these chains of vesicles 
in vivo concluding that they offer an ‘extracellular electron transport pathway’ (Pirbadian et al., 
2014) linking the respiratory system of the microorganism to the external. Therefore, it can be 
concluded that these outer membrane protrusions closely associated with OMVs are functional 
energy distributors.Figure 7.12 is a schematic representation of how further research can aid in 
advancing OMV-mediated phage therapy. 
Furthermore previous research has highlighted that Arginine deiminase(ADI) present in certain 
bacterial species including the oral cavity microorganism, Porphyromonas 
gingivalis(P.gingivalis) inhibits the microorganism’s capacity for surface attachment(Cugini et 
al., 2013). This prompts the question whether inhibition of the enzyme would facilitate the 
binding of phage to E. coli in addition to mopping up the OMVs. Furthermore, a study reported 
that in P. gingivalis, PAD-mediated citrullination of a critical C-terminal arginine of the 
anaphylatoxin C5a disabled the protein function that resulted in reduced chemotaxis  of 
neutrophils and diminished calcium signalling in the pro-monocytic cell line U937 transfected 
with the C5a receptor (C5aR)(Bielecka et al., 2014). This phenomenon can be applied to E. coli 
as well in that PAD inhibition through Cl-amidine modulates different pathways to elicit a 
favourable response for phage attachment resulting in bacterial killing.  
 
Overall, the results presented in this chapter have presented the significance of OMV inhibition 
on effective antibiotic and phage therapy (Figure 7.12). This original research reveals for the 
first time the potential of pharmacological inhibition of OMV release on enhanced antibiotic 
sensitivity and effective phage therapy. Nevertheless, with further improvement this will be a 
valuable innovation against antibiotic resistance and enriched phage therapy. As a consequence, 
this phenomenon can be used to improve novel drug intervention and prognosis in bacterial 
infections.
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8.0 Discussion 
Over the past decade there has been a rapid interest in the association of extracellular vesicles 
(also known as EVs in the study) in various disease statuses. Scientists from different fields in 
biomedicine have been able to apply knowledge of the EV field in terms of EVs’ capacity for 
intercellular communication to explain the nature of disease biogenesis and progression. As a 
result, since the foundation of the International Society for Extracellular Vesicles (ISEV) 
(Araldi et al., 2012) there has been an immense drive, with several papers dedicated throughout 
the literature and in the Journal of Extracellular Vesicles to standardizing the isolation and 
characterization of EVs.This urgent need has enabled EV researchers to develop sophisticated 
isolation and quantitation techniques that have improved the outcome of such studies (Thѐry et 
al., 2018) 
Previous research has highlighted the role of EVs modulating intercellular communication 
which has been shown to be key to the progression ofseveral diseases, including infectious 
disease, autoimmune disease, cancer and neurodegenerative disease (Rodrigues et al., 2018, 
Turpin et al., 2016, Candelario and Steindler, 2014). Other diseases such as cardiovascular 
disease and diabetes have also attracted the attention of practioners to the EV field (van Niel et 
al., 2018). The great interest in EV-mediated intercellular communication has been due to the 
cargo that EVs are able to deliver. This includes various species of RNA such as miRNA, 
lncRNA as well as proteins and lipids that EVs are able to deliver to recipient cells.   Therefore, 
‘…the ‘language’ of EVs is by its nature combinatorial, multifaceted, and contextually complex’ 
(Maas et al., 2017). 
Through this interest in EVs in mediating and exacerbating disease and our increased 
understanding of their means of communicating such macromolecules to recipient cells EV 
researchers have naturally taken an interest in further applications of EV biology. This has taken 
the path of either modulating their production to for example ameliorate disease progression or 
of capitalizing on their lipid bilayer, vesicular nature with a lumen that may carry therapeutics, 
whether drugs of siRNA and the capacity to specifically engineer targeting moieties into their 
surface to develop their use as drug delivery vehicles.  EV-based targeted therapy has thus had a 
significant impact on clinically led investigations.  (van der Meel et al., 2014, Kim and Kim, 
2017, Armstrong and Stevens, 2018) and the prospect of EV modulation (removal of EVs from 
the system) has also showed recent promise (Karasu et al., 2018, Guo et al., 2018). Either way 
EV-led research has significantly contributed to the development of novel therapeutic 
interventions.  
A large focus of the work presented in this thesis has focussed on pharmacological elimination 
of EVs and the impact of so doing on reducing disease progression and improving prognosis 
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following successful treatment. Different cancer models have been used in this investigation 
along with different anti-cancer drugs to show the significance of EV inhibition. The study 
looked atthe effect of a range of pharmacological agents which according to the signaling 
pathways they were known to inhibit could be potentialEV inhibitors. Some were used 
previously in research but this has been the only study so far to have collectively presented the 
effect of these novel EV inhibitors in reducing EV biogenesis and pronouncedly sensitising the 
cancer cells to lower dosages of chemotherapeutic agents that have fallen out of favour because 
of too many adverse side-effects at the high concentrations that are needed to be effective or 
other chemotherapies where it is anyway desirable to reduce dosages while maintaining 
effectivity. In an extension to this theme, the work presented in this thesis has then applied this 
knowledge into identifying any possibilities of inhibition of OMV (Outer Membrane Vesicle) 
biogenesis in both Gram-positive and Gram-negative bacterial species. Somewhat surprisingly, 
this approach has proved successful, revealing a conserved mechanism of EV and OMV release, 
and as a consequence the capacity to modulate OMV biogenesis has been further applied to 
stimulating antibiotic sensitivity and phage-mediated bacterial clearance. Some of the successful 
discoveries throughout this research have been made available to the scientific community 
(Kosgodage et al., 2017, Kosgodage et al., 2018a, Kosgodage et al., 2018b, Kosgodage et al., 
2019). 
8.1 Identification of novel EV inhibitors and their effect on EV Biogenesis and Release 
The study was initiated by looking at a range of reagents in their capacity to inhibited EVrelease 
in prostate cancer cells, PC3. Some of these pharmacological agents have been described in the 
literature previously. However, there have been only a handful of studies in connection with 
EVs. A detailed investigation of the literature combined with preliminary empirical data derived 
in this thesis brought about a range of agents that were tested along with appropriate initial 
concentrations to be used. Also it was essential to carry out a pathway analysis of EV biogenesis 
and release to examine the role of each reagent used on overall EV inhibition. Both flow 
cytometry and nanoparticle tracking analysis was used to quantify the EVs which facilitated 
determining the effectiveness of each pharmacological reagent as a potential EV inhibitor.  
It was interesting to identify the most pathways which were most effective at inhibiting 
EVrelease because as the next stage of the study, pharmacological agents were then used in 
apoptosis studies, to see if they could promote chemotherapeutic-mediated cytotoxicity. Two 
pathways were considered initially, PKC-mediated signaling and the dimerization of 
pantothenic acid linked by disulphide cystamine which blocks PS externalization (a crucial 
event duringEV release). Both pathways were therefore targeted by their respective inhibitors, 
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Bisindolylmaleimide-I (Bisin-I) and D-pantethine and both were shown to indeed inhibit EV 
biogenesis.  
Similarly, the effect of protein citrullination (also termed deimination) has been widely studied 
both by our group and many researchers. It is associated with many disease models including 
rheumatoid arthritis (RA), cardiovascular disease, alzheimer’s and cancer (Fert-Bober et al., 
2015, Lange et al., 2017b, Wong and Wagner, 2018, Mohanan et al., 2012). The enzyme 
mediating this post-translational modification is peptidyl arginine deiminase or PAD (Lange et 
al., 2017a). The formation of the Neutrophil Extracellular Trap (NET) generally is part of the 
host defence mechanism (Kruger et al., 2015). However, NETosis together with PAD4 activity 
which produces citrullinated neoantigens that promote autoimmune diseases such as RA could 
cause injurious effect (Franck et al., 2018, Kenny et al., 2017). For this reason there has been a 
strong drive to inhibit PAD to thereby eliminate such adverse effects.  Our group has previously 
tested Cl-amidine, a pan-PAD inhibitor in association with EVs (Kholia et al., 2015). This 
further encouraged its use in the present study. Cl-amidine-mediated PAD inhibition was 
strongly involved in EV inhibition (Figures 3.7, 3.8, and 3.9). This suggests that PADs play a 
crucial role in EV biogenesis and release.  
It should be noted that pharmacological inhibition of other proposed pathways of EV biogenesis 
and release were also likely to be affected to some extent although not pronounced. D-
pantethine did affect the cell viability significantly which strongly suggested ruled it out in 
potential clinical use (Figure 3.7A). It was interesting to note the inhibitory effect of nicotine on 
EV release. A previous study also looked into the level of plasma microvesicles (MVs) in 
smokers and non-smokers and the effect of nicotine on MV release was also monitored (Grant 
et al., 2011). Whilst it was found that smokers (albeit this aspect of the study being restricted to 
a very small sample size) had reduced plasma MV levels compared to non-smokers, and that 
nicotine inhibited MV release from the promonocytic cell line, THP-1, more recent studies 
show that cigarette smoke extract stimulates exosome release in Airway Epithelial Cells (ACE) 
(Benedikter et al., 2017). This study however did not use nicotine but cigarette smoke extract 
which is a complex mixture of chemicals, and looked at exosome release alone. A similar study 
was carried out to determine the effect of tobacco smoke extract (TSE) on vesiculation in 
human macrophages derived from THP-1 cells. Macrophages are a key participant in 
extracellular matrix damage. The study concluded that exposure to TSE induced the release of 
proteolytically active microvesiclesfrom THP-1-macrophages (Li et al., 2013). The positive 
previously obtained effects observed for nicotine on EVinhibition encouraged its testing in 
apoptosis studies along with Bisin-I and Cl-amidine (Figure 3.10B and Figure 3.10C). 
Nicotine may possess different properties in different cell typesso it will be interesting to 
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examine the effect of pure nicotine used in this study on alveolar epithelial cells (AEC) to 
clarify any inconsistency found in the current results.   
8.2 Combinatory effect of Protein Kinase C and PAD inhibition together with Nicotine 
treatment augments the effectiveness of Chemotherapy 
Multi-drug resistance either intrinsic or acquired has been increasingly problematic in recent 
years(Salgia and Kulkarni, 2018, Housman et al., 2014, Baguley, 2010, Mansoori et al., 2017). 
Despite extensive research efforts in recent years, multi-drug resistance remains a major 
problem. The use of nanotechnology has fortunately given promise (Liu et al., 2016, Conde et 
al., 2013, Qi et al., 2017). This result of this research has prolonged the duration of drug-cell 
interaction and prevented the physiological damage during drug delivery to the target organ.   
However rapid genomic reshuffling in terms of mutations in cancer cells (and microorganisms) 
has meant that multiple strains of a disease have evolved. Various resistance mechanisms 
adopted have not only led to host defence mechanisms being weak, but progressive build-up of 
drug resistance has limited the success of targeted therapy (Moiseenko et al., 2017, Shah et al., 
2016, Friedman, 2016). 
The next section of the study focussed on an alternative to using nanotechnology to minimise if 
not overcome the magnitude of drug-resistance in anti-cancer therapy. Many researchers have 
used different methods to increase sensitivity of cancer cells to treatment and EV inhibition-
mediated sensitisation has been effective as was previously reported by the Inal lab (Jorfi et al., 
2015, Kholia et al., 2015) with respect to prostate cancer (PCa). This study aimed at using novel 
inhibitors both individually and in combination to increase drug sensitivity. This approach was 
tried in both PC3 cells (a PCa cell line) and MCF7 cells (a breast cancer cell line) in vitro. 
Nicotine and Cl-amidine was tested individually and in combination together with 5-FU in both 
PC3 and MCF7 cells. Apoptosis was drastically affected in the presence of inhibitors, more so 
than 5-FU alone. This suggested that EV inhibition had favourably sensitised the cancer cells to 
chemotherapy. This was further examined in the presence of Cl-amidine coupled with Bisin-I in 
PC3 cells. The outcome was similar to that observed previously. Essentially, Cl-amidine and 
Bisin-I-mediated EV inhibition was pronouncedly higher than the inhibition mediated by 
individual reagents on their own and significantly higher than 5-FU alone (Figures 4.2 to 4.8).  
Both Annexin V and VB-48 cell vitality assays showed increased cancer cell apoptosis in the 
presence of 5-FU and EV inhibitors. This further signifies the importance of EV inhibition in 
cell sensitisation to anti-cancer treatment.  
Addition of EVs carrying 5-FU to Bisin-I pre-treated cells (Figures 4.8 and 4.9) increased the % 
apoptosis considerably compared to that observed in the absence of pre-treatment. This further 
justified the importance of EV inhibition in effective therapy. However the apoptosis that 
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resulted from direct treatment with 5-FU was higher compared to that obtained from the 
addition of drug-loaded EVs. 
This strategy of limiting EV release during chemotherapy was then repeated with a second anti-
tumour drug, doxorubicin (DOX). Fluorescence microscopy, spectrophotometry and HPLC 
were used to observe the effect of pretreating cancer cells with Cl-amidine for the capacity to 
sensitisize cancer cells to chemotherapy. Collectively the results supported the hypothesis that 
EV inhibition increases anti-cancer drug effectiveness. Interestingly, nanosight analysis 
revealed that DOX alone increased the EV release markedly. This has been proven in the 
literature which is another valid reason to pharmacologically inhibit EV release in order for 
increased drug retention and effectiveness (Chulpanova et al., 2018, Sun et al., 2018, Sadovska 
et al., 2015). However on the same note, Cl-amidine pronouncedly inhibited EV release which 
once more confirmed previous findings. 
With a view to using EVs as drug delivery vehicles PC3 EVs were incubated with DOX for 4 
and 24h to generate DOX-EVs (that is EVs encapsulating DOX). PC3 cells were treated with 
these DOX-EVs 65% of which were shown to be DOX-positive (Fig. 4.13).This was confirmed 
by fluorescent microscopy (Fig. 4.15).  Cl-amidine pre-treatment facilitated the retention of 
DOX delivered by DOX-EVs (drug-EVs) in PC3 cells. By fluorescence microscopy increased 
DOX fluorescence was also observed after Cl-amidine inhibition of EV release suggesting 
increased retention of drug in the PC3 cells. This further confirmed the importance of EV 
inhibition on drug efficacy. This was then supported by HPLC data (Figure4.16). An increase 
of 51% drug internalisation was noticed following Cl-amidine pre-treatment compared to its 
absence (Figure 4.17). Fluorescent spectroscopy data also supported this observation. DOX 
intensity and absorption was increased in Cl-amidine pre-treated cells compared to the absence 
of pre-treatment (Figures 4.18 and 4.19) further highlighting the significance of EV inhibition 
on minimising drug expulsion.  
The experimental data to this point emphasised the importance of EV inhibition on increasing 
drug efficacy. Release of EVs from tumour cells minimises the period of drug retention and 
reduces the concentration of drug in the cells thereby reducing the ability of the drug to induce 
apoptosis. This has thus encouraged the use of increased dosages of anti-cancer treatment which 
has deleteriously affected the patient prognosis. Pharmacological EV inhibition not only 
increases the drug retention capacity but also encourages the use of minimum dose of drug 
which can increase the level of tolerance of chemotherapy in patients. Not many studies have 
concentrated on this but successful research has been undertaken that supports the current 
findings (Ivanov, 2014, Kosgodage et al., 2017, Datta et al., 2018). The research findings by 
Datta and co-workers., looked into inhibitors of exosome biogenesis and release in PC3 cells 
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through immunoblot analysis of protein markers of the endosomal sorting complex required for 
transport (ESCRT)-dependent and ESCRT-independent pathways(Datta et al., 2018). Koch and 
colleagues have also established that chemical depletion of ATP-transporter A3 (ABCA3) 
inhibited the release of exosomes. Therefore, pre-treatment of B cell lymphoma cells with 
ABCA3 inhibitor, Indomethacine augmented the retention of both doxorubicin and pixantrone 
increasing its cytostatic efficacy (Koch et al., 2016) 
8.3 CBD-mediated EV inhibition: A novel implication of its Activity 
Cannabidiol(CBD) is  a naturally occurring cannabinoid constituent of cannabis(Atakan, 2012). 
The prescription drug of cannabidiol, Epidiolex is known to prevent the breakdown of a 
chemical in the brain reducing psychotic symptoms (Devinsky et al., 2014, Maroon and Bost, 
2018, Zuardi et al., 2012, Iffland and Grotenhermen, 2017). It is therefore effective against 
anxiety, bipolar disorder, seizures, multiple sclerosis, Parkinson's disease, and schizophrenia 
(McGuire et al., 2018, Stampanoni Bassi et al., 2017, Tambaro and Bortolato, 2012).  This study 
further elaborates its potential use as an EV inhibitor for the first time. CBD activity was been 
tested in multiple cancer cell lines including, PC3, MDA-MB-231, HEPG2, LN18 and LN229 
in which CBD has consistently affected the EV profiles differently but had a significant effect 
on exosome release across all cell lines. This effect was also more apparent than Cl-amidine 
treatment in some instances.  
Using a combination therapy of CBD and Cl-amidine resulted in different effects on the various 
EV subsets and varied between the three cancer cell lines. Combinatory treatment was more 
effective on some subsets than Cl-amidine alone, as was observed on exosome release in PC3 
cells and on MV release in HEPG2 cells.  Interestingly, in MDA-MB-231 cells, Cl-amidine 
counteracted the increased CBD-mediated release observed for the total EVs when used in 
combination. Previously, Cl-amidine has been shown to act on MV biogenesis via increased 
cytoskeletal actin deimination and nuclear PAD translocation, indicative for changes in histone 
deimination (Lange, 2016, Dreyton et al., 2014, Witalison et al., 2015, Kholia et al., 2015). A 
recent study proposed that CBD may act in part through modulation of mitochondrial 
metabolism as described (Kosgodage et al., 2018a) 
Previously, CBD has been shown to enhance effects of TMZ (Torres et al., 2011). In this study 
we also have used TMZ in conjunction with CBD to study the effect of CBD-mediated EV 
inhibition on glioma treatment. CBD treatment did not express any favourable activity on 
glioma cell line, LN29. TMZ, anti-glioma therapy itself inhibited EV release whereas CBD 
resulted in hyper-vesiculation. In contrast, LN18 (the TMZ-resistant cell line) (Würstle et al., 
2017)exhibited opposing activity in the presence of both TMZ and CBD. Nonetheless, both cell 
lines varied in the proportional amounts of total EVs, exosomes and MVs, released under 
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standard conditions (Figure 7.8). LN229 resulted in a significant release of vesicles in all 
subpopulations compared to LN18.  
Further work on miRNA profiling of these vesicle subtypes will have to be carried out to ensure 
whether LN229 vesicles contain protective miRNAs which would then support the observations 
made so far. The results presented in this section achieved the aim of enhancing anti-cancer 
therapy and minimising drug resistance. TMZ-resistant LN18 responded to CBD treatment 
favourably which means its resistance was overcome. The effects of CBD on EVs, described 
here, may explain some of the beneficial effects that have been observed for GBM in response 
to CBD treatment in combination with TMZ (Ivanov, 2014). 
As with previously suggested EV inhibitors, CBD has enhanced the effectivity of chemotherapy 
in cell cultures, which could lead to treatment using lower doses of chemotherapeutic drugs, 
thus minimising side-effects and result in equally effective inhibition of tumour growth in vivo.  
 
8.4 OMV isolation and the identification of PAD- mediated citrullination/deimination inE. 
coli 
The technology for isolation of OMVs and that is used to characterize them has slightly lagged 
behind that used on EVs from eukaryotic cells(Dauros Singorenko et al., 2017). Initially two 
techniques of OMV isolation were adopted in this study; ultracentrifugation was by far the 
preferred method as it met the requirements of high yield and rapid isolation which was applied 
throughout the chapters (Figures 5.3.1 and 5.3.2).  
In the next part of the project PAD-mediated citrullination in E. coli was investigated. In 
bacteria, PAD has been reported as a protein that is exclusively expressed in P. gingivalis 
(Scher and Abramson, 2013, Gabarrini et al., 2015, Gully et al., 2014b). The findings presented 
in this section firmly substantiated the presence of citrullinated proteins in E. coli through 
immunoprecipitation and Mass spectrometry analysis. Though PAD association with P. 
gingivalis has been looked at previously (Jenning et al., 2017, Xibille-Friedmann et al., 2014), 
my study was the first to investigate the presence of PAD in E. coli.. 
The phylogenetic relationship between E.PAD and Homo sapiens (H. sapiens) was first 
identified in this study which revealed that E.PAD is closely associated with H. sapiens PAD2. 
This was further confirmed by MAP analysis (Figure 5.3.3).  Citrullinated proteins resulted 
from PAD2, PAD3, PAD4 and F95 mediated catalysis were identified in E.coli and E. coli-
OMV isolates.  Western blotting resulted in bands in the size range of 37-50 and 75-76 and 20 
kDa for pan-deimination antibody (F95). PAD was detected at an expected band of 37-50 kDa 
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with PAD4 being very prominent. PAD2 and PAD3 were less expressed. Identification of 
citrullinated proteins in OMV isolates confirmed lateral transfer of proteins in vesicles. This 
vesicle-mediated horizontal gene transfer (Fulsundar et al., 2014a, Biller et al., 2014, Hasegawa 
et al., 2015) was noticed in previous research that has increased the chance of bacterial survival. 
The outcome of IP The outcome of IP further confirmed the findings. E.PAD proteins are 
predicted to have a size of   49 kDa which was noticed in the blot following IP. This establishes 
the prominent separation and detection of E. coli PAD-mediated protein citrullination.  
Mass spectrometry following IP further revealed the unique citrullinated proteins identified in 
the samples. This identified Threonine-tRNA ligase for the first time in OMVs. String analysis 
shows interactive partners(Figure 5.3.6 B). 30S ribosomal protein S4 (rpsD) and S15 (rpsO) 
were present in all deiminated samples including those obrtained from OMVs. This has been 
previously reported as a substrate of PAD4-mediated citrullination in HEK 293T (Guo et al., 
2011). This confirms its presence in both F95 and PAD4 E. coli IP samples. All commonly 
expressed proteins including chaperone protein, ribonuclease, outer membrane lipoprotein, 50S 
ribosomal protein L22 and flagellin are believed to be either substrates or products of protein 
deimination (Magnadóttir et al., 2018).    
OMV inhibition assays were performed on both Gram-positive and Gram-negative bacteria. 
Interestingly, PAD4 inhibitor, GSK199 was an effective PAD inhibitor (Figure 5.3.8 and 5.3.9).  
The presence of a prominent band corresponding to anti-PAD4 activity strongly confirmed the 
effectiveness of GSK199 in OMV inhibition, as this seems thus to be related to a PAD4-like 
activity. Interestingly, total deiminated proteins were captured by anti-F95 in both E. coli and 
OMV samples.  
The strongest OMV inhibition in E. coli was in the presence of Imipramine whereas EGTA was 
the weakest. Nevertheless all other inhibitors influenced OMV inhibition differently.  In 
contrast to the reagent activity seen in Gram-negative bacterial-OMVs, inhibition in Gram-
positive bacterial was enhanced by EGTA. Both Bisin-I and EGTA showed significant 
inhibition.  
PAD inhibitors were more effective in inhibiting E. coli-OMVs production than S. aureus-
OMVs, GSK199 being the most potent inhibitor, but all PAD inhibitors showed a strong 
capacity to reduce OMV biogenesis. However this was not true with Gram positive-OMVs, the 
PAD-mediated OMV release not being affected by PAD-inhibitors. Overall the inhibition of 
OMV release was below 40% in the presence of pan-PAD inhibitors, suggesting that they are 
less effective in Gram-positive species than Gram-negative.  
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There has been no similar previous research undertaken on this subject. Therefore this study of 
OMV inhibition in both Gram-positive and Gram-negative species is the first to combine OMV 
modulation with improvement of antibiotic sensitivity and phage therapy, and identifying a 
novel PAD-specific pathway of OMV release. 
8.5 OMV inhibition enhances Gram-positive and Gram-negative bacterial Antibiotic 
Sensitivity and increases Susceptibility to Bacteriophage Therapy 
Upon OMV inhibition, E.coli was more sensitive to erythromycin, rifampicin and colistin but 
did not show any effect in the presence of kanamycin. There was no vancomycin activity on 
E.coli which confirmed its limited effectiveness on Gram-positive species. Susceptibility to 
colistin was significantly affected by OMV inhibition (Figure 6.2). This encouraged the use of 
lower concentrations of the antibiotic to treat infections with minimal damage to healthy host 
cells. There was however a distinct difference between the species. 
This work has clearly shown that PAD-mediated OMV inhibition has a significant effect on 
antibiotic activity resulting in reduced MIC values specifically when using colistin on E.coli and 
vancomycin on S.aureus. Interestingly, this effect was reduced in S.aureus suggesting that there 
might be different mechanisms of OMV biogenesis and release involved. This however is in 
line with previous results obtained on PAD-mediated OMV inhibition. PAD inhibitors were 
more potent in inhibiting OMV release by E. coli compared to S. aureus. A maximum inhibition 
of 60% was recorded in the presence of GSK199 in E. coli which was far less in S. aureus being 
only 22.49%. Similarly Cl-amidine exerted a 30% maximum inhibition on E.coli OMVs but 
was only 12.5% in S. aureus. The least effect was in the presence of AMF30a, PAD2 inhibitor. 
Only 3.39% inhibition was observed in S. aureus. This was at least 20% less compared to the 
effect on E. coli OMVs. BB-Cl-amidine was 51.23% effective in E. coli but only decreased the 
OMV release in S. aureus by 7.64%. These results strongly indicate that PAD effect is minimal 
in S. aureus compared to E. coli. 
As discussed previously, where inhibition of EV release enhanced anti-cancer drug sensitivity, 
the results presented in this thesis have similarly shown an enhanced antibiotic activity. Much of 
the evidence surrounding the work to increase drug sensitivity by inhibiting EV release in 
cancer cells pointed to the inhibition resulting in retention of drug within cells. The hypothesis 
that a similar mechanism may operate in prokaryotes with regard inhibition of OMV release and 
possible antibiotic retention (resulting in reduced levels of antibiotic being equally effective); 
however, will need more empirical data be able to make a judgement.   
Bacteriophage-OMV interaction has been widely described in the field (Kharina et al., 2015, 
Reyes-Robles et al., 2018a, Klimentová and Stulík, 2015). These researchers have quite 
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logically expressed the OMV intereaction with bacteria as a potential barrier to phage infection 
and therefore an impediment to effective phage therapy. Just as for anti-cancer drugs stimulating 
EV release, data presented here shows phage itself to stimulate OMV release (Figure 7.3).This 
work showed that the lower phage concentrations resulted in a low OMV release and that 
shorter incubation time resulted in increasing levels of OMV release (Figure 7.4).  It has 
previously been shown that OMVs decrease the virulence of phage allowing the bacterial cells 
to be resistant to such therapy (Tzipilevich et al., 2017, Ellis and Kuehn, 2010, Schwechheimer 
and Kuehn, 2015, Klimentova and Stulik, 2015) 
My data presented also showed that increased addition of (externally isolated) OMVs to E. coli 
reduced the phage infection significantly. These findings are consistent with the research work 
on T4 and E. coli (Manning and Kuehn, 2011). Manning and colleagues have also looked at the 
effect of OMVs on T4 virulence. The remaining irreversible phage concentration was 
determined following chloroform pre-treatment. The results suggested that inactivation of T4 
phage occurred very quickly following addition of OMVs. 80% reduction of free phage was 
observed within 5min of co-incubation with OMVs which also can be used to support our 
findings of shorter incubation time resulting in increased levels of OMVs. It further confirmed 
that phage-OMV binding is not only instant but also irreversible (Manning and Kuehn, 2011). 
Further research has shown OMVs comprise a natural defence mechanism used by bacteria to 
prevent phage attack (Manning and Kuehn, 2011, Kuehn and Kesty, 2005, Altindis et al., 2014, 
Schwechheimer and Kuehn, 2013, Kharina et al., 2015). Much of the research of this thesis has 
tried to dissect EV and OMV biogenesis and through this to find pharmacological inhibitors of 
EV and OMV release in eukaryotic and prokaryotic cell respectively. This ability to modulate 
OMV release was then used uniquely in the data presented in this thesis to use an approach to 
modulate OMV release with a view to removing the protection they afford bacteria from 
infection with phage and therefore to enhance the efficacy of phage therapy. To begin with the 
pan-PAD inhibitor, Cl-amidine was used for OMV inhibition. This resulted in a significant 
improvement in phage infection in the presence of Cl-amidine. A significant reduction of 
OMVs released and therefore present in the immediate environment of the bacteria suggested 
that there was a significantly decreased chance of OMVs successfully acting as decoys to 
infection and a a greater chance for phage tail fibers to adhere to bacterial receptors resulting in 
infection and then lysis.  This strongly suggests that OMV inhibition is the key to drive the 
maximum infection potential of lambda phage leading to successful phage therapy. These 
findings were further reinforced by electron microscopy as shown in (Figure 7.7) which shows 
the binding of lambda phage to OMVs. 
Previous  research showed Arginine deiminase(ADI) inhibiting the surface attachment in 
P.gingivalis (Cugini et al., 2013). This prompts the question as to whether inhibition of the 
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enzyme could facilitate the binding of phage to the E.coli bacterium in addition to stopping 
OMV release. Intriguingly the finding by Cugini et al that PAD inhibition in bacteria prevented 
attachment may be due to OMVs themselves facilitating the attachment process. Thus inhibiting 
OMV release would result in decreased attachment to host. This would be akin to the finding 
from the groups of Inal and Ramirez who showed attachment of Giardia intestinalis to intestinal 
epithelial cells (Evans-Osses et al., 2017)and more appropriately results using different bacteria 
showing OMVs to be involved in attachment to host cells (MacDonald and Kuehn, 2012).  
The hypothesis still remains unconfirmed but this thesis has begun to collate data supporting the 
role of OMV modulation and the associated improvements in antibiotic therapy and possibly 
phage therapy. Thereforeit will be interesting to see whether similar improvements of activity as 
a result of OMV inhibition are seen in other bacteria-bacteriophage complexes to improve the 
therapeutic use of Cl-amidine. OMV inhibition using other suggested novel inhibitors in the 
study will be important also to further confirm the exisiting data.  
As part of further studies it would be useful to visualise the phage-OMV interaction by means 
of fluorescent microscopy using membrane staining. Using a PAD gene knock-out model of E. 
coli would also make a useful control to confirm the effect of Cl-amidine. Looking further 
ahead it would also be interesting to test the OMV inhibition  in a murine model of E. coli 
infection in order toshow its applicability in vivo in terms of improving both antibiotic and 
phage therapies. . It would also be important to visualise phage attachment in Gram-positive 
bacteria once more by electron microscopy. Overall these strategies will open new avenues to 
improve current antibacterial therapy and minimise therapeutic resistance. 
8.6 Summary and Concluding Remarks 
Extracellular vesicles (EVs) are important mediators of intercellular communication. They have 
been widely accepted as playing a key role in disease progression and used in many therapeutic 
strategies. This thesis has focused on a small aspect of the importance of these key players in 
developing novel therapies primarily in cancer. This has been achieved successfully in vitro 
using a variety of cancer cell-lines, numerous potential EV inhibitors and a range of different 
anti-cancer drugs as as evidenced by the increased sensitisation of cells to therapy and 
interestingly an alternative to minimise multi-drug resistance.  
An unexplained role of Cannabidiol is revealed for the first time in this study. Its use as a 
potential EV inhibitor was clearly established through utilisation of multiple cancer cell lines. It 
was fascinating to report the diverse function of CBD on EVs released in different cancers. This 
has not only made the reader aware of a novel role of CBD but has encouraged other researchers 
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to test its potency in anti-cancer effectivity. Interestingly CBD had a pronounced effect on the 
TMZ-resistant, LN18 cells encouraging its use to overcome drug resistance.  
The final focus was bacterial outer membrane vesicles (OMVs). Their isolation, characterisation 
and quantification are well detailed in the study. The thesis, for the first time has demonstrated 
OMV inhibition with respect to both Gram-positive (S.aureus) and Gram-negative bacteria 
(E.coli) using various reagents. It has also highlighted the presence of PAD in E.coli for the first 
time through detecting the presence of citrullinated proteins via immunoprecipitation, Western 
blotting and mass spectrometry analysis. The investigator has also presented the different modes 
of OMV inhibition by using a range of reagents. The reader is then able to appreciate the 
implication of OMV inhibition in increasing antibiotic sensitivity and bacteriophage therapy for 
the first time. This observation has been confirmed using a range of antibiotics and lambda 
phage. Electron microscopy imaging has added value to depict the significance of OMV 
inhibition on enhanced phage therapy.  
The findings of the study have clearly shown selective pharmacological inhibition with respect 
to EVs and OMVs (Figure 7.13). However most of the reagents used have been effective in 
inhibiting both type of vesicles.  There is a higher lipid composition in Gram-negative cell 
membrane compared to Gram-positive cell membranes, meaning that lipid soluble regaents 
more easily penetrate E.coli compared to S.aureus. This phenomenon also can be applied to the 
greater effect of inhibitors on EVs and Gram-negative OMVs compared to that of Gram-
positive.Some inhibitors were only tested against EVs. CBD and nicotine possess antibacterial 
properties as outlined previously. However, there is no research undertaken in relation to its 
application in OMVs. Therefore, it will be interesting to test this hypothesis. Previous research 
has revealed the use of the second pan-PAD inhibitor BB-Cl-amidine (Jang et al., 2017), PAD2 
specific inhibitor AMF30a (Muth et al., 2017) and PAD4 specific inhibitor GSK199 (Slade et 
al., 2015).  Therefore, in this study these inhibitors were used against bacterial OMVs.  
It was also interesting to observe the effect of inhibitors on different types of vesicle. PAD 
inhibition was more potent in EV inhibition as Cl-amidine was more effective against PC3-cell 
derived EVs and as shown earlier in the study in MCF-7 cell derived EVs (Table 5). Non-PAD 
inhibition was more successful in Gram-positive OMV inhibition compared to Gram-negative, 
EGTA was more potent in Gram-positive but was significantly less in Gram-negative OMV 
inhibition. However, Bisin-I did not elicit a major oppossing response in release of  MVs from 
Gram-positive or Gram-negative bacteria. Furthermore, PAD4 inhibitor, GSK199 was more 
effective against both bacterial OMVs compared to PAD2-mediated inhibiton via AMF30a. 
Hydrophobicity of the reagents as described in Table 1 could have played a significant role in 
cell penetration hence the differential effect on EV and OMV release. A recent review has 
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demonstrated the presence of different types of vesicles released from both Gram-negative and 
Gram-positive bacteria. (Toyofuku et al., 2019). The compsition of cell membrane plays a major 
role in vesiculation. Presence of a thickend peptidoglycan cell wall in Gram-positive restricts 
the penetration of most of the drugs into the cells which suggests the need of an alternative 
receptor-mediated transport system (Liu et al., 2018). However, the high lipid content of the 
Gram-negative cell membrane with a thin layer of peptidoglycan increases membrane fluidity 
thus facilitating OMV release (Roier etal., 2016). It also makes it easier for the lipid soluble 
drugs to penetrate the bacterial cell easily to elicit a favourable response which is also apparent 
from our results.  
The majority of the inhibitors were investigated against PC3 cells. A diverse group of cancer 
cells were used in the CBD study which made it a successful comparative study. This finding 
should now be used with regards to the effect of different inhibitors of EV release from cancer 
cells. 
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Table 5. Comparative analysis of the effect of different inhibitors on EV and OMV release. PAD 
inhibition was more potent in EV inhibiton compared to OMV inhibition. However, PAD-specific 
inhibition was noted in OMVs with PAD4-mediated OMV inhibition being successful. Non-PAD 
inhibition was effective against Gram-positive OMV inhibiton and EV inhibition compared to Gram-
negative OMV inhibition.  
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Figure 7.13.  Identification of common inhibitiors of EVs and OMVs. Venn diagram illustrates that 
most of the potential inhibitors used in the study were capable of inhibiting all type of vesicles. PAD 
inhibitors, BB-Cl-amidine, GSK199 and AMF30a were only tested in bacteria. However, Y27632, 
Imipramine and Pantethine were only potent against EVs and Gram-negative bacteria. This may be due to 
the low lipid content of the Gram- positive cell membrane which then need a different transporter system 
for cell penetration. Furthermore, CBD and nicotine were only tested against EVs. 
 
This thesis therefore presents a collection of potential novel therapeutic strategies developed 
through both EV inhibition in carcinogenesis and Outer Membrane Vesicle inhibition in 
bacterial infections.  
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9.0 Appendix 
9.1        Complete Proteomic Analysis of E.coli and E.coli-derived OMVs 
   number of unique 
peptides 
 MS2 intensities     
   Sample 
1 
Sample 
2 
Sample 
3 
Sample 
1 
Sample 
2 
Sample 3   
UniPr
ot ID 
 Protein 
name (short) 
Gene 
name 
E.coli 
F95 
E.coliPA
D4 
OMV 
F95 
E.coli 
F95 
E.coliPA
D4 
OM
V 
F95 
 best_ 
protei
n 
score 
 
sum
_ 
scor
e 
 
sa
m
pl
es  
Q8X9
B6 
Biotin 
carboxylase  
accC 1   8219.04   49.8 49.8 1 
P0A9
Q6 
Acetyl-
coenzyme A 
carboxylase 
carboxyl 
transferase 
subunit beta  
accD 3 3  10170.15 21748.64
9 
 130.77 224.
59 
2 
Q0TF
D0 
Acetyl-
coenzyme A 
carboxylase 
carboxyl 
transferase 
subunit beta  
accD  2   156916.3
05 
 99.12 99.1
2 
1 
P0A9
G7 
Isocitrate 
lyase  
aceA 2 1  207418.3 302355.5
2 
 88.61 126.
09 
2 
P0AF
G8 
Pyruvate 
dehydrogenas
e E1 
component  
aceE 8 9  144390.2 211469.8
21 
 323.68 608.
51 
2 
P0695
9 
Dihydrolipoyl
lysine-residue 
acetyltransfer
ase 
component of 
pyruvate 
dehydrogenas
e complex  
aceF 8 6  583182.8 1471690.
61 
 285.02 547.
58 
2 
P0A6
A5 
Acetate 
kinase  
ackA  2   79145.63
8 
 70.42 70.4
2 
1 
P3668
3 
Aconitate 
hydratase B  
acnB 1 1  47979.66 60431.90
4 
 207.76 340.
93 
2 
B7MT
M4 
Acyl carrier 
protein  
acpP 1   54078.05   23.71 23.7
1 
1 
P0AE
07 
Multidrug 
efflux pump 
subunit AcrA  
acrA  1   115575.9
99 
 45.61 45.6
1 
1 
P3122
4 
Multidrug 
efflux pump 
subunit AcrB  
acrB 1 1  91864.08 27081.85
2 
 69.46 94.2
2 
2 
P2418 Multidrug acrE 1   58880.44   35.04 35.0 1 
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0 export protein 
AcrE 
4 
Q8X5
T5 
Acetyl-
coenzyme A 
synthetase  
acs 1   56659.86   36.17 36.1
7 
1 
P0A9
Q8 
Aldehyde-
alcohol 
dehydrogenas
e  
adhE  1   16626.90
4 
 542.93 542.
93 
1 
P0AE
10 
Alkyl 
hydroperoxid
e reductase 
subunit C  
ahpC 1 4  64627.09 570140.1
4 
 158.76 314.
22 
2 
Q8X3
W8 
Alanine--
tRNA ligase  
alaS 1 3  12755.68 14569.64
1 
 79.57 119.
11 
2 
P0080
5 
L-
asparaginase 
2  
ansB 1 1  15888.17 28337.13  38.03 71.0
3 
2 
P0A9
Q3 
Aerobic 
respiration 
control 
protein ArcA  
arcA  2   19035.19  60.23 60.2
3 
1 
B7MR
48 
Acetylornithi
ne 
deacetylase  
argE  1   107868.8
1 
 45.19 45.1
9 
1 
Q8X5
W4 
Phospho-2-
dehdro-3-
deoxyheptona
te aldolase, 
Trp-sensitive 
aroH 1   4800.6   25.69 25.6
9 
1 
Q8XD
S0 
Aspartate 
ammonia-
lyase  
aspA 9 3  41866.05 22582.04
3 
 392.45
36715 
476.
7536
7 
2 
P0050
9 
Aspartate 
aminotransfer
ase  
aspC  1   40123.23
5 
 36.89 36.8
9 
1 
B7L6
M2 
Succinylornit
hine 
transaminase  
astC 16 10  217900.4 366167.8
65 
 475.7 838.
54 
2 
B7US
C9 
Succinylornit
hine 
transaminase  
astC 13 9  290787.6 167965.7
04 
 345.62 603.
61 
2 
B7M
VM7 
Succinylornit
hine 
transaminase  
astC 12 8  753161.3 1573119.
98 
 368.09 676.
8 
2 
A7ZM
L6 
Succinylornit
hine 
transaminase  
astC  3   232079.3
16 
 73.58 73.5
8 
1 
A8A0
U0 
Succinylornit
hine 
transaminase  
astC  2   28021.86
9 
 73.51 73.5
1 
1 
Q8X5
98 
Succinylornit
hine 
transaminase  
astC 1 1  2839.005 16188.23
2 
 363.03 656.
42 
2 
B7N2
H3 
ATP synthase 
subunit alpha  
atpA 7 5  17275.58 25477.84
4 
 278.97 428.
67 
2 
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B7N2
H0 
ATP synthase 
epsilon chain  
atpC  1   50390.40
3 
 40.92 40.9
2 
1 
A8A6
J5 
ATP synthase 
subunit beta  
atpD 3 8  242535.7 1784489.
81 
 242.64 303.
31 
2 
B7N2
H1 
ATP synthase 
subunit beta  
atpD 4 5  393488.4 1393864.
1 
 266.67 441.
04 
2 
B7N2
H2 
ATP synthase 
gamma chain  
atpG 1 1  25752.43 52398.21
6 
 40.52 73.4
2 
2 
P0A9
H4 
Inducible 
lysine 
decarboxylas
e 
cadA  2   716567.2
5 
 78.26 78.2
6 
1 
P7663
2 
CRISPR 
system 
Cascade 
subunit 
CASB 
casB 1   48439.74   37.18 37.1
8 
1 
B7MP
T2 
Curved DNA 
binding 
protein 
cbpA  3   6123.157
6 
 90.68 90.6
8 
1 
P0AB
M9 
Cytochrome 
c-type 
biognesis 
protein 
CcmH 
ccmH 1 2  5425.614 6263.335  41.12 72.1
9 
2 
P0A9
66 
Chemotaxis 
protein CheW  
cheW  1   6079.74  40.65 40.6
5 
1 
P6328
5 
Chaperone 
protein ClpB  
clpB 1 1 1 5169079 5833442.
7 
30537.
26 
227.63 430.
06 
3 
P0AC
K0 
cAMP-
activated 
global 
transcriptiona
l regulator 
CRP  
crp 4 9  93378.67 298240.1
94 
 479.3 689.
38 
2 
P6978
4 
Glucose-
specific 
phosphotransf
erase enzyme 
IIA 
component  
crr 3 4  242379.4 408741.3
9 
 157.56 296.
21 
2 
P0A9
Y8 
Cold shock-
like protein 
CspC  
cspC  1   14612.86
4 
 25.76 25.7
6 
1 
P0AB
J2 
Cytochrome 
bo(3) 
ubiquinol 
oxidase 
subunit 2  
cyoA 1   33604.2   43.07 43.0
7 
1 
B7N1
F1 
Siroheme 
synthase 
cysG  1   231691.8
45 
 20.21 20.2
1 
1 
P0AE
B4 
D-alanyl-D-
alanine 
carboxypepti
dase DacA  
dacA 11 12  1993153 3989363.
58 
 565.99 1057
.64 
2 
B7M
NN7 
4-hydroxy-
tetrahydrodipi
dapB 2 2  88421.6 472167.7
8 
 88.45 123.
88 
2 
202 
 
colinate 
reductase  
Q8X8
Y7 
2,3,4,5-
tetrahydropyr
idine-2,6-
dicarboxylate 
N-
succinyltransf
erase  
dapD 1 1  44638.34 435885.2
28 
 29.79 50.8
8 
2 
P0AE
E0 
DNA-
cytosine 
methyltransfe
rase  
dcm 1   3012.168   25.22 25.2
2 
1 
P0AB
N7 
Anaerobic 
C4-
dicarboxylate 
transporter 
DcuA  
dcuA 1 1  14725.33 37571.09
1 
 94.06 157.
92 
2 
B7MT
C9 
Phosphopento
mutase  
deoB 2   4098.075   40.28 40.2
8 
1 
P0AB
S3 
RNA 
polymerase-
binding 
transcription 
factor DksA  
dksA  1   8272.797  22.76 22.7
6 
1 
B7M
NM2 
Chaperone 
protein DnaJ  
dnaJ 1 1  5226.309 40686.87  43.92 75.7
3 
2 
P0A6
Z0 
Chaperone 
protein DnaK  
dnaK 1 1  204589.7 98262.38  386.58 718.
01 
2 
P0AE
G0 
Dipeptide 
transport 
system 
permease 
protein DppB 
dppB  1   7462.026  21.12 21.1
2 
1 
B7M
QR6 
DNA 
protection 
during 
starvation 
protein  
dps 1 5  49293.94 397406.8
14 
 179.03 324.
33 
2 
Q8FJ
M0 
DNA 
protection 
during 
starvation 
protein  
dps  2   51561.81
6 
 65.43 65.4
3 
1 
B7MZ
75 
Enolase  eno 1 1  73150.26 113597.7
2 
 358.57 709.
6736
7 
2 
P0A9
W4 
Energy-
dependent 
translational 
throttle 
protein EttA  
ettA 1 1  61002.77 67219.11  47.22 77.9
2 
2 
P0A9
54 
3-oxoacyl-
[acyl-carrier-
protein] 
synthase 1  
fabB 1   7902.669   47.06 47.0
6 
1 
P0AE
K2 
3-oxoacyl-
[acyl-carrier-
protein] 
reductase 
FabG  
fabG  1   4225.648  56.61 56.6
1 
1 
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P0AE
K5 
Enoyl-[acyl-
carrier-
protein] 
reductase 
[NADH] FabI  
fabI 1 2  4621.212 64691.11
5 
 96.9 154.
53 
2 
P0AB
72 
Fructose-
bisphosphate 
aldolase class 
2  
fbaA 1 5  2382.267 17559.62
7 
 165.26
12477 
187.
7712
5 
2 
P5959
0 
Chaperone 
protein FimC  
fimC 1   42662.38   31.55 31.5
5 
1 
P0A9
L3 
FKBP-type 
22 kDa 
peptidyl-
prolyl cis-
trans 
isomerase  
fklB 1 1  26969.75 59181.50
7 
 28.96 52.2
7 
2 
P0494
9 
Flagellin  fliC 10 14 2 704598.6 1146224.
24 
9488.7
24 
653.24 1305 3 
Q1R9
R9 
GTP 
cyclohydrolas
e 1  
folE 3 2  589202.6 741671.7
4 
 123.62 236.
04 
2 
P0036
3 
Fumarate 
reductase 
flavoprotein 
subunit  
frdA 1 1  3390.246 4483.52  57.26 99.8
9 
2 
B7MP
32 
Ribosomal 
recycling 
factor 
frr  1   2181.198  36.06 36.0
6 
1 
Q8X9
L0 
ATP-
dependent 
zinc 
metalloprotea
se FtsH  
ftsH  6   1159639.
11 
 151.09 151.
09 
1 
P0A9
A8 
Cell division 
protein FtsZ  
ftsZ 1 1  16559.87 16662.99
9 
 68.18 89.3
8 
2 
Q8X4
P8 
Fumarate 
hydratase 
class I, 
aerobic  
fumA 3 4  407340.7 604730.9
73 
 114.04 216.
36 
2 
P1440
7 
Fumarate 
hydratase 
class I, 
anaerobic  
fumB 2   15232.67   78.27 78.2
7 
1 
P0A9
B1 
Ferric uptake 
regulation 
protein  
fur 22 19  1534314 1421004.
09 
 732.46
36715 
1459
.517
3 
2 
B7N0
X6 
Elongation 
factor G  
fusA 7 9  483355.8 1142360.
97 
 356.45 637.
69 
2 
B7ND
U8 
Elongation 
factor G  
fusA 1   57190.14   316.36
36715 
316.
3636
7 
1 
P2552
6 
Succinate-
semialdehyde 
dehydrogenas
e [NADP(+)] 
GabD  
gabD  1   136760.4
23 
 32.28 32.2
8 
1 
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P5822
8 
Glutamate 
decarboxylas
e alpha  
gadA 8 8  57333 94579.33
5 
 312.35 577.
22 
2 
P6991
1 
Glutamate 
decarboxylas
e beta  
gadB  3   387378.1
17 
 72.46 72.4
6 
1 
Q8FH
G5 
Glutamate 
decarboxylas
e beta  
gadB  1   23077.82
6 
 72.69 72.6
9 
1 
P0A9
B3 
Glyceraldehy
de-3-
phosphate 
dehydrogenas
e  
gapA 11 10  566896.6 570950.7
54 
 448.05 766.
15 
2 
P0A9
B6 
Putative 
glyceraldehyd
e-3-phosphate 
dehydrogenas
e C  
gapC  1   17560.10
2 
 35.4 35.4 1 
P0A9
S6 
Glycerol 
dehydrogenas
e  
gldA 2   220449.1   441.19 441.
19 
1 
B7N1
76 
Glycogen 
synthase  
glgA 7 9  102277.9 262501.7
19 
 355.81 706.
33 
2 
Q1R5
J7 
Glycogen 
synthase  
glgA 6 6  518282.8 978486.7
05 
 292.77 577.
97 
2 
Q8XE
G2 
Glutamine--
fructose-6-
phosphate 
aminotransfer
ase 
[isomerizing]  
glmS 1 4  40677.99 187964.5
43 
 536.14 1035
.05 
2 
A7ZP
K7 
Glutamate--
tRNA ligase  
gltX  1   7927.44  33.96 33.9
6 
1 
B7M
YI0 
Serine 
hydroxymeth
yltransferase  
glyA 5 4  28752.94 35118.91  199.01
36715 
329.
1173
4 
2 
B7N1
L1 
Glycine--
tRNA ligase 
beta subunit  
glyS  2   23005.61
58 
 87.76 87.7
6 
1 
Q8XD
88 
Guanylate 
kinase 
gmk 1   30770.63   21.72 21.7
2 
1 
B7MP
N9 
2,3-
bisphosphogl
ycerate-
dependent 
phosphoglyce
rate mutase  
gpmA 1   43889.44   23.86 23.8
6 
1 
B7M
YL2 
Autonomous 
glycyl radical 
cofactor  
grcA 3 4  327409.2 1445352.
32 
 234.73 383.
83 
2 
B7MI
R4 
Autonomous 
glycyl radical 
cofactor  
grcA 3 4  224635.4 1189183.
3 
 188.81 290.
95 
2 
Q0T9
P8 
60 kDa 
chaperonin  
groL 9 9  33034.06 61275.83
2 
 477.38 831.
31 
2 
205 
 
A1AJ
51 
60 kDa 
chaperonin 1  
groL1 15 12  317080.7 180363.6
75 
 504.5 883.
25 
2 
Q19N
J4 
60 kDa 
chaperonin 2  
groL2 6 7  703376.3 1227065.
95 
 256.99 503.
59 
2 
Q1R3
B7 
10 kDa 
chaperonin  
groS 4 2  46761.72 60904.69
8 
 131.21
36715 
212.
6436
7 
2 
B7M
YA6 
Protein GrpE  grpE  1   5408.954  51.76 51.7
6 
1 
P0AC
59 
Glutaredoxin-
2  
grxB 2 2  253146.2 637131.5
6 
 89.14 151.
4 
2 
P0AD
G8 
Inosine-5'-
monophospha
te 
dehydrogenas
e  
guaB  1   5275.682  27.22 27.2
2 
1 
Q8X4
S5 
Arabinose 5-
phosphate 
isomerase 
GutQ  
gutQ  4   486219.4
05 
 120.37 120.
37 
1 
P0AE
T3 
Acid stress 
chaperone 
HdeB  
hdeB  1   25340.94  94.64 94.6
4 
1 
P3213
1 
Oxygen-
independent 
coproporphyr
inogen III 
oxidase 
hemN  1   244051.1
79 
 28.32 28.3
2 
1 
P0AC
B9 
Protein 
HemY  
hemY 3 3  45377.47 215596.8
08 
 155.4 241.
68 
2 
P0AB
C5 
Modulator of 
FtsH protease 
HflC  
hflC  5   66849.55
8 
 189.23 189.
23 
1 
P0AB
C8 
Protein HflK  hflK 5 8  550602.2 1654879.
03 
 420.85 598.
43 
2 
B7MS
J0 
RNA-binding 
protein Hfq  
hfq 4   256916.9   132.47 132.
47 
1 
P0AC
E8 
HIT-like 
protein HinT  
hinT 5 4  48687.09 47522.30
1 
 231.05 376.
53 
2 
B7N1
S3 
ADP-L-
glycero-D-
manno-
heptose-6-
epimerase  
hldD 1 1  5405.202 3741.466  40.58 70.5
8 
2 
P0AC
G0 
DNA-binding 
protein H-NS  
hns 3 4  40401.71 50673.61
2 
 129.48 240.
95 
2 
P0895
7 
Type I 
restriction 
enzyme 
EcoKI M 
protein 
hsdM  1   61548.18  29.4 29.4 1 
B7N2
S2 
ATP-
dependent 
protease 
ATPase 
subunit HslU  
hslU  2   398702.7
26 
 52.01 52.0
1 
1 
206 
 
P0A6
Z5 
Chaperone 
protein HtpG  
htpG 2 3  4380.75 17582.38
9 
 160.1 209.
12 
2 
P0AC
F2 
DNA-binding 
protein HU-
alpha  
hupA 2 4  18452.03 96330.11
97 
 174.13 238.
87 
2 
P0AC
F6 
DNA-binding 
protein HU-
beta  
hupB  1   38401.36  33.07 33.0
7 
1 
P0AA
N4 
Hydrogenase 
isoenzymes 
nickel 
incorporation 
protein HypB  
hypB 1   4406.638   50.65 50.6
5 
1 
B7MZ
27 
D-
phenylhydant
oinase  
hyuA  1   8175.753
6 
 31.92 31.9
2 
1 
P0A9
W7 
Acid stress 
protein IbaG  
ibaG 3 2  16776.79 35776.44
5 
 79.18 132.
6 
2 
B7N1
Z1 
Small heat 
shock protein 
IbpA  
ibpA 2 2  9821.772 9303.624  95.58 180.
83 
2 
B7N2
D2 
Small heat 
shock protein 
IbpB  
ibpB 3 1  66906.29 123676.5
93 
 125.75 204.
2 
2 
P0820
0 
Isocitrate 
dehydrogenas
e [NADP]  
icd 6 1  601762.5 44659.42  188.54 360.
72 
2 
B7M
NN1 
Isoleucine--
tRNA ligase 
ileS  1   2933.824  40.26 40.2
6 
1 
Q1R6
H0 
Translation 
initiation 
factor IF-2  
infB 1 1  9979.556 10560.88
4 
 51.63 82.9
7 
2 
A7ZU
G1 
Catalase-
peroxidase  
katG  1   39981.33
7 
 23.71 23.7
1 
1 
P0AB
78 
2-amino-3-
ketobutyrate 
coenzyme A 
ligase  
kbl 1 1  4434.879 18208.60
8 
 43.85 73.4
1 
2 
P2186
5 
Sensor 
protein KdpD  
kdpD  1   2085.633  23.1 23.1 1 
B7MT
Z9 
2-dehydro-3-
deoxyphosph
ooctonate 
aldolase  
kdsA  1   75229  48.97 48.9
7 
1 
B7M
NQ3 
Glutathione-
regulated 
potassium-
efflux system 
ancillary 
protein KefF  
kefF 1 1  17840.59 19691.29  27.65 52.4
5 
2 
P0A9
P2 
Dihydrolipoyl 
dehydrogenas
e  
lpdA 7 6  98884.65 119226.6
62 
 335.04 575.
84 
2 
P0AB
39 
Penicillin-
binding 
protein 
lpoB 1   7220.348   31.18 31.1
8 
1 
207 
 
activator 
LpoB  
P6977
8 
Major outer 
membrane 
lipoprotein  
lpp 6 3  90253.11 163080.8
7 
 149.27 296.
16 
2 
P0AC
J2 
Leucine-
responsive 
regulatory 
protein  
lrp 1 2  4064.236 6108.736
6 
 49.11 74.9 2 
B7M
YZ0 
S-
ribosylhomoc
ysteine lyase  
luxS 4 6  306210.9 1515951.
92 
 189.99 276.
87 
2 
B7LE
A1 
S-
ribosylhomoc
ysteine lyase  
luxS 1 2  5577.112 11211.97
2 
 64.82 104.
2 
2 
E0IWI
3 
Diaminopime
late 
decarboxylas
e  
lysA 1   4361.5   23.39 23.3
9 
1 
P0A8
N3 
Lysine--
tRNA ligase  
lysS  1   13274.05
5 
 46.3 46.3 1 
P0A8
N5 
Lysine--
tRNA ligase, 
heat inducible  
lysU  7   321997.3
71 
 300.12
36715 
300.
1236
7 
1 
P7655
8 
NADP-
dependent 
malic enzyme  
maeB  1   2393.892
1 
 26.6 26.6 1 
P6979
9 
PTS system 
mannose-
specific 
EIIAB 
component  
manX 2   94232.46   56.71 56.7
1 
1 
P6980
7 
Mannose 
permease IID 
component  
manZ  1   10940.91
9 
 20.23 20.2
3 
1 
B6I1V
4 
Malate 
dehydrogenas
e  
mdh 4 4  832640.7 1788561.
48 
 218.67 418.
82 
2 
Q0TC
N0 
Malate 
dehydrogenas
e  
mdh 4 2  91096.26 32903.83
2 
 218.38 268.
83 
2 
P3735
3 
2-
succinylbenz
oate--CoA 
ligase 
menE 1   9193.93   21.81 21.8
1 
1 
P7778
1 
1,4-
dihydroxy-2-
naphthoyl-
CoA 
hydrolase  
menI 1   2642.538   76.78 76.7
8 
1 
P0AB
B9 
Magnesium -
transporting 
ATPase, P-
type 1 
mgtA  1   3954.304  22.84 22.8
4 
1 
P0AE
Z5 
Septum site-
determining 
protein MinD  
minD  1   27457.73
7 
 21.78 21.7
8 
1 
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P6338
8 
Probable 
phospholipid 
import ATP-
binding 
protein MIaF 
mlaF 1   4800.6   25.69 25.6
9 
1 
P5474
6 
Mannosylgly
cerate 
hydrolase 
mngB  1   14874.10
5 
 20.93 20.9
3 
1 
B7M
QN7 
Cyclic 
pyranopterin 
monophospha
te synthase 
accessory 
protein  
moaC 6 6  740836.5 1327054.
6 
 199.75 375.
05 
2 
A7ZY
39 
Cyclic 
pyranopterin 
monophospha
te synthase 
accessory 
protein  
moaC  3   17231.85  67.03 67.0
3 
1 
P3212
5 
Molybdopteri
n-guanine 
dinucleotide 
biosynthesis 
adapter 
protein  
mobB 2 1  11182.77 4190.38  83.18 111.
7 
2 
P0039
3 
NADH 
dehydrogenas
e  
ndh  1   4306.996  84.07 84.0
7 
1 
B7M
YF2 
Nucleoside 
diphosphate 
kinase  
ndk 2 3  97655.26 149204.5  56.35 102.
73 
2 
P0A7
64 
Nucleoside 
diphosphate 
kinase  
ndk 2 1  11030.94 12477.58
8 
 50.72 98.3
9 
2 
B7N1
R9 
Nickel-
responsive 
regulator  
nikR 1 1  20081.3 64273.8  111.15 184.
42 
2 
B7UL
33 
Nickel-
responsive 
regulator  
nikR 1   64264.6   20.94 20.9
4 
1 
B7M
XG5 
NADH-
quinone 
oxidoreductas
e subunit C/D  
nuoC  1   2487.342  28.53 28.5
3 
1 
P0AF
D2 
NADH-
quinone 
oxidoreductas
e subunit E  
nuoE 2 2  17505.05 53040.80
1 
 101.62 151.
15 
2 
P3197
9 
NADH-
quinone 
oxidoreductas
e subunit F 
nuoF 1   4427.308   22.73 22.7
3 
1 
Q8XC
X2 
NADH-
quinone 
oxidoreductas
e subunit G  
nuoG 5 4  29390.6 39332.47
4 
 121.38 234.
64 
2 
P0AF
F8 
Transcription 
termination/a
nusA  1   10447.77
27 
 41.89 41.8
9 
1 
209 
 
ntitermination 
protein NusA  
B7M
QD1 
N utilization 
substance 
protein B 
homolog  
nusB  1   4264.065  40.42 40.4
2 
1 
P0A9
11 
Outer 
membrane 
protein A  
ompA 26 28  376301.4 639014.0
18 
 1045.1 1989
.78 
2 
P0AA
18 
Transcription
al regulatory 
protein 
OmpR  
ompR 1 1  12755.68 4925.856  39.54 68.0
6 
2 
P0C0
L2 
Peroxiredoxin 
OsmC  
osmC 1 4  33791.23 721805.4
86 
 124.32 151.
09 
2 
P0AD
B2 
Osmotically-
inducible 
lipoprotein E  
osmE 1 1  4085.12 6470.59  35.25 56.3
8 
2 
P0AF
H9 
Osmotically-
inducible 
protein Y  
osmY 3 3  152214.8 403707.3
6 
 92.33 181.
49 
2 
P1531
9 
Chaperone 
protein PapD  
papD 1   1638.998   21.41 21.4
1 
1 
B7N2
Q7 
ATP-
dependent 6-
phosphofruct
okinase 
isozyme 1  
pfkA  2   57552.04  62.75 62.7
5 
1 
P0699
9 
ATP-
dependent 6-
phosphofruct
okinase 
isozyme 2  
pfkB 1   9622.43   51.16 51.1
6 
1 
P0937
3 
Formate 
acetyltransfer
ase 1  
pflB 15 9  297271.4 444181.2
42 
 441.75 768.
88 
2 
A8A4
66 
Phosphoglyce
rate kinase  
pgk 2 4  177327.3 1082788.
4 
 168.13 251.
23 
2 
Q8XD
03 
Phosphoglyce
rate kinase  
pgk 1 1  52794.29 58935.94  217.31 399.
66 
2 
B7UJ
59 
Polyribonucle
otide 
nucleotidyltra
nsferase  
pnp  2   5914.682  70.94 70.9
4 
1 
B7N0
U9 
Polyribonucle
otide 
nucleotidyltra
nsferase  
pnp 1 1  10006.96 14293.99
5 
 53.96 84.0
4 
2 
P0700
1 
NAD(P) 
transhydroge
nase subunit 
alpha  
pntA 1 1  59337.06 149039.4
2 
 50.79 89.6
8 
2 
P2353
8 
Phosphoenolp
yruvate 
synthase  
ppsA 2 4  79410.2 414087.3
87 
 187.44 254.
12 
2 
P0A7
19 
Ribose-
phosphate 
prs 1 1  106292.1 118090.9
98 
 189.19 329.
79 
2 
210 
 
pyrophospho
kinase  
P0A9
M8 
Phosphate 
acetyltransfer
ase  
pta 10 5  722931.5 1153871.
86 
 310.28
36715 
478.
9073
4 
2 
P0AA
06 
Phosphocarri
er protein 
HPr  
ptsH 2 3  271328 997502.4
15 
 114.33 193.
82 
2 
P0883
9 
Phosphoenolp
yruvate-
protein 
phosphotransf
erase  
ptsI 2 2  40895.88 139961.4
89 
 72.25 125.
33 
2 
B7MS
J5 
Adenylosucci
nate 
synthetase  
purA 2 2  23459.6 47643.37
2 
 120.77 169.
5 
2 
B1LN
C6 
Phosphoribos
ylaminoimida
zole-
succinocarbo
xamide 
synthase  
purC  2   129627.7
71 
 44.28 44.2
8 
1 
P3705
1 
Formyltetrah
ydrofolate 
deformylase  
purU 5 9  35994.79 84004.29
2 
 333.37 490.
54 
2 
P0A4
40 
Formyltetrah
ydrofolate 
deformylase  
purU 2 1  423342.5 120189.2  357.91 687.
55 
2 
P0954
6 
Bifunctional 
protein PutA  
putA 1   5358.864   36.88 36.8
8 
1 
P2159
9 
Pyruvate 
kinase II  
pykA 4 8  13954.18 39846.89
54 
 310.88 477.
44 
2 
P0AD
61 
Pyruvate 
kinase I  
pykF 1 3  30297.19 188820.2
79 
 144.84 176.
54 
2 
B7MZ
76 
CTP synthase  pyrG  2   17162.51
6 
 59.39 59.3
9 
1 
P0AA
55 
Protein 
QmcA  
qmcA 1 1  5092.593 9497.072  55.01 89.9
9 
2 
P0AD
51 
Ribosome-
associated 
inhibitor A  
raiA  1   158439.9
36 
 51.87 51.8
7 
1 
B7N0
J8 
RNase 
adapter 
protein RapZ  
rapZ 2 3  4366.437 12991.35
6 
 98.58 130.
87 
2 
P0292
5 
D-ribose-
binding 
periplasmic 
protein  
rbsB 5 4 1 48977.3 178441.5
92 
6973.6
66 
270.86 529.
27 
3 
P6941
2 
Outer 
membrane 
lipoprotein 
RcsF  
rcsF  1   18626.17
2 
 50.583
6715 
50.5
8367
1 
1 
B7M
YJ9 
Protein RecA  recA  1   1959.172  31.75 31.7
5 
1 
B7MR
01 
ATP-
dependent 
rhlB  2   27936.01
5 
 39.3 39.3 1 
211 
 
RNA helicase 
RhlB  
P2588
8 
ATP-
dependent 
RNA helicase 
RhlE  
rhlE 1   2791.438   22.3 22.3 1 
P0AG
32 
Transcription 
termination 
factor Rho  
rho  1   6039.511  70.05 70.0
5 
1 
B7N0
J6 
3,4-
dihydroxy-2-
butanone 4-
phosphate 
synthase  
ribB 2 3  14414.36 31662.65
1 
 96.48 160.
97 
2 
P2553
9 
Riboflavin 
biosynthesis 
protein RibD  
ribD  1   75194.03
9 
 52.6 52.6 1 
B7M
QD0 
6,7-dimethyl-
8-
ribityllumazin
e synthase  
ribH  2   101818.6
8 
 44.91 44.9
1 
1 
P3699
9 
23S rRNA 
(guanine(745)
-N(1))-
methyltransfe
rase  
rlmA  1   47156.00
5 
 30.57 30.5
7 
1 
P2151
3 
Ribonuclease 
E  
rne 11 7 1 2351234 578948.9
91 
8574.8
55 
369.58 688.
48 
3 
Q1R5
U9 
50S 
ribosomal 
protein L1  
rplA 2 5  58648.11 929533.7
3 
 207.32 260.
82 
2 
Q1R6
07 
50S 
ribosomal 
protein L2  
rplB 6 6  4875830 3958421.
57 
 294.04 526.
89 
2 
Q1R6
02 
50S 
ribosomal 
protein L3  
rplC 3   69461.01   254.77 254.
77 
1 
Q1R6
04 
50S 
ribosomal 
protein L4  
rplD 1 3  23396.57 78412.14
3 
 128.55 179.
68 
2 
Q1R6
20 
50S 
ribosomal 
protein L5  
rplE 1 1  30716.26 270075.5
19 
 120.7 179.
8 
2 
Q1R6
24 
50S 
ribosomal 
protein L6  
rplF 3 1  62367.3 23478.82
9 
 386.53 698.
42 
2 
Q1R3
57 
50S 
ribosomal 
protein L9  
rplI 7 7  22189.18 41732.75  264.24 502.
53 
2 
Q1R5
V0 
50S 
ribosomal 
protein L10  
rplJ  5   478658.5
86 
 218.99 218.
99 
1 
Q1R5
U7 
50S 
ribosomal 
protein L11  
rplK 1 2  14745.52 46332.55
2 
 109.61 180.
71 
2 
Q1R5
V1 
50S 
ribosomal 
rplL 2 4  107919.6 458967.5
53 
 152.57 249.
89 
2 
212 
 
protein 
L7/L12  
Q1R6
A9 
50S 
ribosomal 
protein L13  
rplM  4   99364.50
58 
 135.62 135.
62 
1 
Q1R6
17 
50S 
ribosomal 
protein L14  
rplN 2 6  208567.2 1085357.
31 
 214.15 285.
09 
2 
Q1R6
30 
50S 
ribosomal 
protein L15  
rplO 1 1  212270 268996.1
64 
 218.58 360.
08 
2 
P0241
3 
50S 
ribosomal 
protein L15  
rplO 1 1  43104.39 27467.12
92 
 204.44 364.
3 
2 
Q1R6
13 
50S 
ribosomal 
protein L16  
rplP  3   475139.7
2 
 95.53 95.5
3 
1 
Q1R6
38 
50S 
ribosomal 
protein L17  
rplQ 4   126430.3   128.85 128.
85 
1 
Q1R6
26 
50S 
ribosomal 
protein L18  
rplR  1   6570.726  36.49 36.4
9 
1 
Q1R8
B9 
50S 
ribosomal 
protein L19  
rplS 1 2  5878.179 21250.93
8 
 93.26 150.
51 
2 
Q1RB
79 
50S 
ribosomal 
protein L20  
rplT 4 1  214207.4 318728.6
55 
 107.93 158.
75 
2 
Q1R6
F0 
50S 
ribosomal 
protein L21  
rplU 2 3  9478.912 36519.67
8 
 115.09 164.
92 
2 
Q1R6
10 
50s ribosomal 
protein L22 
rplV 1 1 1 204453.3 137499.1
89 
4362.4
65 
36.38 92.9
9 
3 
Q1R6
19 
50S 
ribosomal 
protein L24  
rplX 3   6484.408   75.48 75.4
8 
1 
B5Y
WX8 
50S 
ribosomal 
protein L25  
rplY 1 2  14513.39 330060.1
42 
 51.12 74.6
3 
2 
B6I18
4 
50S 
ribosomal 
protein L25  
rplY  2   56617.96
2 
 57.85 57.8
5 
1 
B1LK
T4 
50S 
ribosomal 
protein L25  
rplY  1   16522.59
6 
 35.9 35.9 1 
Q1R4
V5 
50S 
ribosomal 
protein L28  
rpmB  1   35076.15  46.58 46.5
8 
1 
Q1R6
29 
50S 
ribosomal 
protein L30  
rpmD 1   12062.56   35.02 35.0
2 
1 
P0C20
3 
50S 
ribosomal 
protein L31  
rpmE 1   143944.3   59.18 59.1
8 
1 
213 
 
Q1R6
32 
50S 
ribosomal 
protein L36 1  
rpmJ1 1 2  10101.77 31294.47
8 
 75.35 122.
43 
2 
P0A7
Z6 
DNA-
directed RNA 
polymerase 
subunit alpha  
rpoA 4 5  19232.49 37768.53
5 
 162.06 294.
31 
2 
B7MR
B3 
DNA-
directed RNA 
polymerase 
subunit beta  
rpoB 4 5  35417.39 125498.5
29 
 301.95 478.
14 
2 
Q0TA
78 
DNA-
directed RNA 
polymerase 
subunit beta  
rpoB  2   102175.2
02 
 72.91 72.9
1 
1 
P0A8
T8 
DNA-
directed RNA 
polymerase 
subunit beta'  
rpoC 9 7  1629679 1231105.
03 
 420.05
36715 
764.
3836
7 
2 
P0057
9 
RNA 
polymerase 
sigma factor 
RpoD 
rpoD  1   10242.74
3 
 29.54 29.5
4 
1 
P0AG
67 
30S 
ribosomal 
protein S1  
rpsA 5 8  42099.26 168448.6
71 
 218.14 340.
19 
2 
Q1RG
21 
30S 
ribosomal 
protein S2  
rpsB 4 4  69125.29 573877.0
41 
 140.09 238.
28 
2 
B6HZ
E3 
30S 
ribosomal 
protein S2  
rpsB  2   226034.9
49 
 68.17 68.1
7 
1 
Q1R6
12 
30S 
ribosomal 
protein S3  
rpsC 1 5  87762.57 1603406.
07 
 241.14 313.
52 
2 
Q1R6
36 
30S 
ribosomal 
protein S4  
rpsD 6 6 2 22718.9 44378.06
8 
3554.3
63 
289.35 633.
87 
3 
Q1R6
27 
30S 
ribosomal 
protein S5  
rpsE 1 2  72767.1 245384.2
4 
 258.8 420.
06 
2 
B7NG
D4 
30S 
ribosomal 
protein S6  
rpsF  2   151007.3
88 
 61.19 61.1
9 
1 
Q1R3
60 
30S 
ribosomal 
protein S6  
rpsF 1 1  185516.8 139620.3
27 
 63.22 115.
45 
2 
Q1R5
U2 
30S 
ribosomal 
protein S7  
rpsG 1 1  1411.526 3590.718  54.67 86.2
1 
2 
Q1R6
B0 
30S 
ribosomal 
protein S9  
rpsI 3 3  265882.3 591593.9
8 
 111.82 198.
68 
2 
Q1R6
01 
30S 
ribosomal 
protein S10  
rpsJ 6 7  312588 465910.7
58 
 272.01 515.
7 
2 
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Q1R6
35 
30s ribosoaml 
protein S11 
rpsK 5 2  210614.4 26547.39
6 
 154.58 259.
4 
2 
Q1R5
U1 
30S 
ribosomal 
protein S12  
rpsL 3 3  98482.35 286514.0
72 
 145.38 258.
77 
2 
C4ZU
J7 
30S 
ribosomal 
protein S12  
rpsL  2   396280.7
2 
 110.55 110.
55 
1 
Q1R6
33 
30S 
ribosomal 
protein S13  
rpsM 6 6  435893.5 578486.8
8 
 273.87 506.
3 
2 
B5YS
55 
30S 
ribosomal 
protein S15  
rpsO 2 4  5450.814 34470.26
9 
 193.1 249.
31 
2 
Q1R6
H3 
30S 
ribosomal 
protein S15  
rpsO 1 1 3 128707.1 61762.03
5 
67181.
14 
585.62 1235
.71 
3 
Q1R6
16 
30s ribosomal 
protein S17 
rpsQ  1   153927.8
37 
 26.14 26.1
4 
1 
Q1R3
58 
30S 
ribosomal 
protein S18  
rpsR  3   312269.4
2 
 103.87 103.
87 
1 
Q1RG
H9 
30S 
ribosomal 
protein S20  
rpsT  1   1914.052  33.08 33.0
8 
1 
B7MR
18 
Regulator of 
ribonuclease 
activity A  
rraA  1   2528.569  30.34 30.3
4 
1 
B7MR
C1 
Regulator of 
sigma D  
rsd  6   23401.74
9 
 247.53 247.
53 
1 
P0AA
45 
Ribosomal 
small subunit 
pseudouridine 
synthase A  
rsuA  4   50727.44
4 
 162.27 162.
27 
1 
P0AC
43 
Succinate 
dehydrogenas
e flavoprotein 
subunit  
sdhA 21 19  663065.2 851727.6
16 
 922.35 1772
.5 
2 
P0701
4 
Succinate 
dehydrogenas
e iron-sulfur 
subunit  
sdhB  3   48650.99
2 
 157.85 157.
85 
1 
B7N2
55 
Protein-
export protein 
SecB  
secB 3   136512.2   77.043
6715 
77.0
4367
1 
1 
P0AG
91 
Protein 
translocase 
subunit SecD  
secD 1 1  5589.2 9121.068  37.34 69.9
8 
2 
B7M
QL5 
tRNA 2-
selenouridine 
synthase 
selU 1   62528.36   25.69 25.6
9 
1 
B7MR
V6 
Serine--tRNA 
ligase  
serS 2   16844.89   55.11 55.1
1 
1 
P0AE
U9 
Chaperone 
protein Skp  
skp 1 1  57159.63 73421.10
3 
 45.52 86.0
5 
2 
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P3719
4 
Outer 
membrane 
protein slp  
slp 2 2  248008.1 308136.7
47 
 104.47 171.
6 
2 
P0A9
06 
Outer 
membrane 
lipoprotein 
SlyB  
slyB 11 15 2 289573.7 555800.0
37 
10565.
21 
632.79 1231
.97 
3 
P0A9
L1 
FKBP-type 
peptidyl-
prolyl cis-
trans 
isomerase 
SlyD  
slyD 15 12  1605919 1829200.
46 
 706.17 1285
.23 
2 
B7M
YQ8 
SsrA-binding 
protein  
smpB  1   68079.71
1 
 46.1 46.1 1 
P0A9
52 
Spermidine 
N(1)-
acetyltransfer
ase  
speG  1   5172.028  27.37 27.3
7 
1 
P0AG
E2 
Single-
stranded 
DNA-binding 
protein  
ssb 3 1  192743.9 22773.38
7 
 97.95 118.
6 
2 
P0AF
G3 
2-
oxoglutarate 
dehydrogenas
e E1 
component  
sucA 9 8  78159.13 287168.1
84 
 474.24
36715 
863.
5173
4 
2 
P0AF
G6 
Dihydrolipoyl
lysine-residue 
succinyltransf
erase 
component of 
2-
oxoglutarate 
dehydrogenas
e complex  
sucB 5 2  62720.66 36309.38
5 
 314.43 512.
98 
2 
B7M5
P1 
Succinyl-
CoA ligase 
[ADP-
forming] 
subunit beta  
sucC 6 5  70603.15 55332.06
06 
 177.37 340.
56 
2 
P0A8
38 
Succinyl-
CoA ligase 
[ADP-
forming] 
subunit beta  
sucC 8 3  423587.9 282917.6
49 
 220.89 338.
86 
2 
P0AG
F1 
Succinyl-
CoA ligase 
[ADP-
forming] 
subunit alpha  
sucD 5 6  238748.5 463724.7
66 
 245.74 380.
9 
2 
P0A8
69 
Transaldolase 
A  
talA 1 2  42937.29 189704.0
88 
 33.12 57.5
5 
2 
P0A8
71 
Transaldolase 
B  
talB 1 3  55140.49 154683.5
79 
 94.81 125.
1 
2 
P0701
8 
Methyl-
accepting 
chemotaxis 
protein IV  
tap  1   6429.138  32.23 32.2
3 
1 
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P0701
7 
Methyl-
accepting 
chemotaxis 
protein II  
tar 5 4  323323.2 698197.9
2 
 181.69 343.
65 
2 
P0AG
F8 
L-threonine 
dehydratase 
catabolic 
TdcB  
tdcB  1   5570.586  27.34 27.3
4 
1 
P4263
2 
PFL-like 
enzyme TdcE  
tdcE  3   29499.43
4 
 66.01 66.0
1 
1 
P0AG
L3 
Putative 
reactive 
intermediate 
deaminase 
TdcF  
tdcF  3   161745.9  80.57 80.5
7 
1 
B7N1
S0 
L-threonine 
3-
dehydrogenas
e  
tdh  1   2487.342  40.47 40.4
7 
1 
B7M
VJ7 
Threonine--
tRNA ligase  
thrS 12 10  257338.9 406729.2
42 
 441.53 739.
29 
2 
B7L6J
2 
Threonine--
tRNA ligase  
thrS 9 6 1 2097880 886276.7
22 
8718.5
52 
371.78 776.
46 
3 
B7M
QF2 
Trigger factor  tig 5   81192.55   192.72 192.
72 
1 
B7N2
12 
Tryptophanas
e  
tnaA 3 3  18024.02 68734.85
2 
 151.78 260.
69 
2 
P0AD
I2 
Transposon 
Tn3 resolvase  
tnpR  1   120169.9
8 
 34.19 34.1
9 
1 
B7MP
N1 
Protein TolB  tolB  1   66870.90
69 
 39.78 39.7
8 
1 
P0A8
60 
Triosephosph
ate isomerase  
tpiA  1   6734.41  81.48 81.4
8 
1 
P0A8
64 
Thiol 
peroxidase  
tpx  1   10666.86
6 
 40.75 40.7
5 
1 
P0A8I
6 
tRNA 
(guanine-
N(7)-)-
methyltransfe
rase  
trmB 1 1  114660.7 72873.14  75.86 101.
53 
2 
B7MP
30 
Elongation 
factor Ts  
tsf 4 1  319680.8 127523.2
35 
 112.82 148.
22 
2 
P0294
2 
Methyl-
accepting 
chemotaxis 
protein I  
tsr 2 1  194745.1 56974.30
2 
 55.32 87.9
6 
2 
A7ZU
J2 
Elongation 
factor Tu 2  
tuf2 1 1  424640.6 130264.3
35 
 476.59
36715 
865.
9136
7 
2 
P0A6
N3 
Elongation 
factor Tu  
tufA 2 2  177541.5 176742.5
2 
 791.64 1446
.99 
2 
Q8XB
J4 
Oxidoreducta
se UcpA  
ucpA 2 2  85930.05 1001172.
69 
 51.74 87.8
5 
2 
P1275 Uridine udp 1 3  29970.24 253864.4  96.26 147. 2 
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8 phosphorylas
e  
01 93 
B7M
YC5 
Uracil 
phosphoribos
yltransferase  
upp 1 1  2043.835 3884.974  32.64 59.4
3 
2 
P0A4
P7 
Universal 
stress protein 
F  
uspF  1   20765.02
2 
 29.85 29.8
5 
1 
P3790
3 
Universal 
stress protein 
F  
uspF 1   1600.2   49.11 49.1
1 
1 
Q8XB
T3 
Universal 
stress protein 
G  
uspG  2   36115.02  159.67 159.
67 
1 
P0AD
Z9 
UPF0092 
membrane 
protein YajC  
yajC  1   50079.04
2 
 125.06 125.
06 
1 
P0AF
P6 
GTP 
cyclohydrolas
e 1 type 2 
homolog  
ybgI 10 9  787612.7 826435.9
53 
 325.46 647.
3036
7 
2 
P7581
8 
Uncharacteriz
ed lipoprotein 
YbjP  
ybjP  1   27057.31
9 
 42.47 42.4
7 
1 
B7M
QX0 
UPF0145 
protein YbjQ  
ybjQ 2 2  115091.8 326669.6
79 
 89.79 158.
16 
2 
P0AB
16 
Uncharacteriz
ed protein 
YccJ  
yccJ  1   29737.46  38.15 38.1
5 
1 
B7MT
N8 
UPF0227 
protein YcfP  
ycfP 7 6  58229.52 76340.89
5 
 205.6 393.
28 
2 
B7NK
H1 
UPF0227 
protein YcfP  
ycfP 5   11941.04   166.86 166.
86 
1 
P3180
8 
Uncharacteriz
ed 
oxidoreductas
e YciK  
yciK 1 1  10328.12 9005.072  36.52 58.3
6 
2 
P7610
0 
Uncharacteris
ed 
acetyltransfer
ase YdcK 
YdcK 1   1356.867   23.21 23.2
1 
1 
P6446
5 
Putative 
selenoprotein 
YdfZ  
ydfZ 1   32119.58   32.34 32.3
4 
1 
P6717
6 
Probable 
transcriptiona
l regulatory 
protein YebC  
yebC  1   3822.203  40.72 40.7
2 
1 
Q8X7
I0 
UPF0339 
protein YegP  
yegP  3   6121.679  87.63 87.6
3 
1 
P0AD
34 
UPF0381 
protein YfcZ  
yfcZ 2 2  97730.7 442109.5
35 
 96.17 148.
97 
2 
P0AD
E7 
Uncharacteriz
ed protein 
YgaU  
ygaU 1   6774.944   68.03 68.0
3 
1 
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P6580
9 
Uncharacteriz
ed protein 
YgeY  
ygeY 3 1  173427 124008.8
85 
 87.29 114.
69 
2 
Q8XD
75 
Uncharacteriz
ed protein 
YgfK  
ygfK 1 2  37926.08 190107.2
2 
 213.72 286.
6 
2 
P0AD
T7 
Putative acid-
-amine ligase 
YgiC  
ygiC  1   5411.331  22.39 22.3
9 
1 
P0AD
U3 
Probable 
quinol 
monooxygena
se YgiN  
ygiN 2 3  152988 480285.3
51 
 105.23 139.
93 
2 
P0AD
W5 
Putative 
cytochrome d 
ubiquinol 
oxidase 
subunit 3  
yhcB 2 3  33406.26 99323.44  156.48 255.
76 
2 
P2863
8 
DNA adenine 
methyltransfe
rase YhdJ 
yhdJ  1   64097.77
5 
 28.02 28.0
2 
1 
P6820
7 
UPF0337 
protein YjbJ  
yjbJ  1   62127.08  41.28 41.2
8 
1 
P0AF
94 
2-
iminobutanoa
te/2-
iminopropano
ate deaminase  
yjgF  2   22467.87
6 
 105.18 105.
18 
1 
P3934
2 
Uncharacteriz
ed protein 
YjgR  
yjgR 1   1600.2   25.69 25.6
9 
1 
P6458
3 
Uncharacteris
ed protein 
YqjD 
yqjD 4 5  279435.2 306374.8
86 
 122.44 221.
75 
2 
P6458
8 
Transcription
al regulator 
YqjI  
yqjI 3 5  6270881 7515577.
86 
 183.32 318.
68 
2 
P6459
8 
Uncharacteriz
ed protein 
YraP  
yraP  1   13732.64
1 
 24.47 24.4
7 
1 
P0A9
W9 
Protein YrdA  yrdA  1   77292.98
8 
 53.34 53.3
4 
1 
Q8X4
B4 
NAD(P)H 
dehydrogenas
e (quinone)  
Z1423/
Z1504 
2 1  6858.729 2050.472  59.56 105.
18 
2 
B7N2
R9 
Cell division 
protein ZapB  
zapB 1   55250.33   39.4 39.4 1 
P0AA
B0 
Zinc 
resistance-
associated 
protein  
zraP 2 5  3052.526 36955.68
1 
 167.33 199.
78 
2 
Table 4: Total proteomics data of E.coli and E. coli-derived OMVs. Sample 1, E.coli-F95; sample 2, 
E. coli-PAD4; sample 3, E.coli-OMV 
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9.1.2   Complete proteomic Analysis of unique E.coli-OMV proteins 
 
   number of 
unique peptides 
 MS2 
intensiti
e-s 
     
UniProt 
ID 
 Protein 
name (short) 
Gene 
name 
E.coli 
F95 
E.coli
PAD4 
OMV 
F95 
E.coli 
F95 
E.coli
PAD4 
OMV 
F95 
Bestpr
otein 
score 
 
Sum 
scor
e 
 
s
a
m
p
l
e
  
Q1R6H3 30S 
ribosomal 
protein S15  
rpsO 1 1 3 128707 61762.
035 
67181.
1 
585.62 1235
.71 
3 
P04949 Flagellin  fliC 10 14 2 704599 11462
24.2 
9488.7
2 
653.24 1305 3 
P0A906 Outer 
membrane 
lipoprotein 
SlyB  
slyB 11 15 2 289574 55580
0.04 
10565.
2 
632.79 1231
.97 
3 
Q1R636 30S 
ribosomal 
protein S4  
rpsD 6 6 2 22718.9 44378.
068 
3554.3
6 
289.35 633.
87 
3 
B7L6J2 Threonine--
tRNA ligase  
thrS 9 6 1 2097880 88627
6.72 
8718.5
5 
371.78 776.
46 
3 
P21513 Ribonuclease 
E  
rne 11 7 1 2351234 57894
8.99 
8574.8
6 
369.58 688.
48 
3 
P02925 D-ribose-
binding 
periplasmic 
protein  
rbsB 5 4 1 48977.3 17844
1.59 
6973.6
7 
270.86 529.
27 
3 
P63285 Chaperone 
protein ClpB  
clpB 1 1 1 5169079 58334
42.7 
30537.
3 
227.63 430.
06 
3 
Q1R610 50S 
ribosomal 
proten L22 
rplV 1 1 1 204453 13749
9.19 
4362.4
7 
36.38 92.9
9 
3 
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Table 6: Total proteomics data of proteins isolated from E.coli and E.coli -derived OMVs.Sample 1, 
E.coli-F95; sample 2, E.coli-PAD4; sample 3, E.coli-OMV 
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9.2 Materials 
9.2.1      Reagents & Solutions 
 
Annexin V- apoptosis kit    Thermofisher  
BCA protein assay kit     Thermofisher 
Bisindolymaleimide I     Sigma-Aldrich 
BSA (Bovine serumalbumin)    Sigma-Aldrich 
BzATP       Sigma-Aldrich 
Calpeptin      Sigma-Aldrich 
Canabidiol      G W Pharma 
Catch and Release v2.0 IP kit    Millipore 
Chloramidine      A gift fromProf. Thompson  
Cytochalacin D      Sigma-Aldrich 
Colistin       Sigma-Aldrich 
DAPI Vecta Shield mounting medium    Sigma-Aldrich 
Doxorubicin    Sigma- Aldrich 
DMSO        Fisher Scientific 
D-pantethine       Sigma-Aldrich  
DPBS       Sigma-Aldrich 
EGTA       Sigma-Aldrich 
Erythromycin      Sigma-Aldrich 
5-Fluorouracil      Sigma-Aldrich 
Guava ViaCount reagent    Guava Technologies,UK 
HALT Protease Cocktail    Sigma-Aldrich 
HEPES       Sigma-Aldrich 
Imipramine      Sigma-Aldrich  
Kanamycin      Sigma-Aldrich 
Laemmli sample buffer      BioRad 
Müller Hinton Agar     Sigma-Aldrich 
Müller HintonBroth     Sigma-Aldrich 
Nicotine      The Alchemists Cupboard 
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Paraformaldehyde     Sigma-Aldrich 
Penicillin / Streptomycin     Sigma-Aldrich 
Pkh26 cell labelling kit     Sigma-Aldrich 
Propidium iodide     Sigma-Aldrich 
Protein molecular weight marker    BioRad 
Rifampicin      Sigma-Aldrich 
RPMI       Sigma-Aldrich 
Running buffer      BioRad 
RIPA buffer      Sigma-Aldrich 
SDS (Sodium dodecyl sulphate)    Sigma-Aldrich 
TEMED      Sigma-Aldrich 
TGX- ready gels     BioRad 
Transfer Buffer      BioRad 
Tris base      Sigma-Aldrich 
Triton X-100 Trypsin/EDTA solution    Sigma-Aldrich 
Trypsin/EDTA solution     Sigma-Aldrich 
Tween 20      Sigma-Aldrich 
Y27632      Sigma-Aldrich 
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9.2.2 Equipment 
 
Beckman L8-70M Ultracentrifuge   Beckman 
Cell culture flasks (75 cm2, 25cm2)   Fisher Scientific 
Centrifuge 5804 R     Eppendorf   
Centrifuge 5810 R     Eppendorf 
ECL system      Amersham, UK 
Eppendorf tubes (1.5ml)    Fisher Scientific 
Fluorescence microscope (1X81)   OlympusCorporation, Germany 
FLUOstar Omega plate reader    BMG Labtech, UK 
Guava EasyCyte flow cytometer   Guava Technologies UK 
Incubator Heraeus CO2-Auto-Zero   Thermo Electron Corporation 
NanoSightLM10     School of Pharmacy, UCL 
NanoSight NS500     St. George’s University 
NucleoCounter® NC-3000™     Chemometec 
Microcentrifuge 5417R     Eppendorf 
Microplate (12-well)     Fisher Scientific   
Microplate (24-well)     Fisher Scientific 
Microplate (96-well)     Fisher Scientific 
Nikon Inverted Microscope, TS100   Nikon Eclipse, Japan 
Semi-dry transfer system    BioRad 
Suction filtration apparatus    Kind provided 
UVP Chemiluminescence    UVP BioDoc-IT™ System, U.K 
Viva flow Kindly provided (Dr. P. Matewele) 
9.2.3 Antibodies 
Anti-Annexin V     ImmunoTools 
Anti-PAD2, Anti-PAD3, Anti-PAD4   BioRad 
Mouse anti-IgG FITC     ImmunoTools 
CD9-FITC, CD29-FITC, CD71-FITC, CD58-FITC  ImmunoTools 
F95       BioRad 
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9.3 Experimental Solutions 
9.3.1 Mammalian cell freeze medium 
 
90%   cell growth medium 
10%  DMSO 
9.3.2 RIPA Lysis Buffer pH 7.4 
 
1ml  RIPA buffer 
1:100   HALT protease inhibitor 
9.4.1  Sample Buffer (10x) 
 
2x  laemmli sample buffer  
5%   beta mercaptoethanol 
9.4.2  Running Buffer 
 
30.0 g   Tris base 
144.0 g  glycine 
10.0 g of SDS  
1000 ml of H2O.-pH- 8.3 dilute to 1X before using 
 
9.4.3 TBS buffer (10x) 
To prepare 1000ml: 
60.6 g   Tris 
87.6 g   NaCl 
1M   HCl 
Deionized water 
 
9.4.4 Blocking buffer 
5% BSA  
TBS-T (1x TBS-T with 0.01% tween 20) 
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9.4.5  Transfer Buffer (10X) 
 
15.2 g   Tris (free base)  
72.1 g   Glycine  
5.0 g   SDS  
Ultra pure water to 500 ml 
 
9.4.6 Transfer Buffer (1X) 
 
50 ml   10X Transfer Buffer  
100 ml  Methanol  
350 ml  Distilled water  (Make fresh for each use)
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